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ABSTRACT OF DISSERTATION 
 
 
 
 
METHODS DEVELOPMENT AND APPLICATION OF TWO-DIMENSIONAL GEL 
ELECTROPHORESIS AND MASS SPECTROMETRY IN PROTEOMICS 
 
 
The development of a highly sensitive ruthenium-based fluorescent staining solution is 
described in this dissertation. The in-house synthesized ruthenium complex (RuMS) 
containing both sulfonated and non-sulfonated ligand has detection limit of 1 ng of 
protein that is better than colloidal coomassie, silver and ruthenium complex containing 
all sulfonated ligands (RuBPS). RuMS stain has 100-fold dynamic range and does not 
interfere with subsequent mass spectral identification of proteins. The capability of in-
house synthesis of the staining solution makes it a viable cost-effective alternative to the 
expensive commercially available fluorescent stain, Sypro Ruby. The low detection limit, 
broad linear dynamic range and compatibility with mass spectrometry, make the 
development of this stain a worthwhile pursuit. The staining solution was utilized in 
subsequent applications of two-dimensional gel electrophoresis (2-DE) technology.  
 
Proteomics methodology utilizing 2-DE and mass spectrometry was applied to 
investigate the effect of malathion on the proteome of human neuroblastoma cells. 
Results indicated that out of 122 proteins that were identified from the neuroblastoma 
proteome, sixteen proteins were down-regulated while five proteins were significantly 
up-regulated after treatment with malathion. Significant down-regulation of calcium 
modulators like calmodulin and calgizarrin and other key chaperones makes the 
malathion-treated cells highly prone to oxidative stress. With increased awareness in 
pesticide related adverse effects, identification of altered proteins in malathion-treated 
human neuroblastoma cells is a critical finding.  
 
Proteomics is a major area of research in the identification of biomarkers for diseases. A 
novel immunoprecipitation method developed in this work allowed for successful 
isolation and identification of albumin-interactome in cerebrospinal fluid (CSF) that is 
usually under-represented in standard CSF analysis using 2-DE. A key finding is the 
differential expression of various isoforms of proteins in CSF albumin-interactome from 
Alzheimer’s disease (AD) subjects. The data implicate the acidic isoform of 
prostaglandin D2 synthase (PGDS2) as a potential biomarker for AD. An understanding 
                                                                            
of the differential expression of these protein isoforms in AD will provide insight into the 
etiology of the disease and this can have far-reaching implication on drug development 
leading to the cure or even preventation of the disease.     
 
 
KEYWORDS: proteomics, 2-DE, mass spectrometry, OP toxicity and Alzheimer’s 
disease      
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CHAPTER ONE 
 
INTRODUCTION 
 
Successful completion of the Human Genome Project led to the surprising finding that 
there are far fewer genes in the human genome that actually code for proteins than there 
are proteins in the human proteome. This discrepancy implied that gene analysis alone is 
not sufficient to understand the complexity of life. The rapidly growing field of 
proteomics that involves the global analysis of proteins was initiated to enable better 
understanding of proteins- the functional entities of life. Marked improvements in various 
proteomics tools are essential for continued exploitation of this technology in various 
fields of research.  
 
Proteomics is the subject of this dissertation. This work has been organized into three 
main data chapters. Two techniques that were employed in this work are two-dimensional 
gel electrophoresis and mass spectrometry. Development of a sensitive staining solution 
that is a key component of proteomics technology utilizing two-dimensional gel 
electrophoresis is discussed in this dissertation. The technology was applied in two 
different areas of research namely environmental toxicology and biomarker discovery.    
 
A FLUORESCENT RUTHENIUM COMPLEX FOR STAINING PROTEINS 
SEPARATED BY SDS-PAGE  
 
1.1 Study Goal 
 
The goal of this project is to synthesize a ruthenium chelate, optimize the solvent 
composition so that the stain can be used to detect proteins separated by gel 
electrophoresis with better sensitivity than RuBPS and can be used as a cost-effective 
alternative to Sypro Ruby. 
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1.2 Study Hypothesis 
 
The hypothesis is that ruthenium complex with both sulfonated and non-sulfonated 
ligands will provide better sensitivity than the RuBPS complex that contains all 
sulfonated ligands and the development of the stain in-house will prove to be cost-
effective. 
 
1.3 Study Rational 
 
Commonly employed staining solutions to visualize proteins in polyacrylamide gels have 
inherent disadvantages associated with them like low linear dynamic response for silver 
stain and low detection limits for Coomassie blue. Improved techniques for the detection 
of proteins in 2-DE gels involve staining with fluorescent dyes, such as Sypro Ruby. 
Sypro Ruby is a ruthenium-based dye that has detection limit of approximately 1-2 ng of 
protein and about three orders of magnitude of linear dynamic range of quantification.  
 
An alternative to Sypro Ruby staining based on ruthenium (II) tris (bathophenanthroline 
disulfonate) (RuBPS) has been developed by Rabilloud et al. We synthesized RuBPS in 
our lab following the published Rabilloud protocol to stain proteins. It was observed that 
RuBPS stain, an all-sulfonated ligand-containing complex had poor sensitivity compared 
to Sypro Ruby and could detect only about 5 ng of protein on the gel. This prompted us 
to explore the possibility of having both sulfonated and non-sulfonated ligands attached 
to the ruthenium complex. We predict that the presence of both sulfonated and non-
sulfonated ligands attached to ruthenium chelate in an appropriate solvent may result in 
an additive, synergistic interaction of the different ligands of dye molecules with the 
proteins and in turn improve sensitivity. Since the dye can be synthesized in-house it 
provides for a cost-effective means to stain proteins.  
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1.4 Specific Aims 
 
The specific aims are to synthesize and optimize the formulation of a ruthenium complex 
containing both sulfonated and non-sulfonated ligands, to achieve maximum sensitivity 
in detecting proteins in gels. 
 
PROTEOMIC INVESTIGATION OF MALATHION-INDUCED DIFFERENTIAL 
PROTEIN EXPRESSION IN HUMAN NEUROBLASTOMA CELLS 
 
2.1 Study Goal 
 
The goal is to investigate the effect of malathion on the proteome of human 
neuroblastoma cells using 2-DE and mass spectrometry. 
 
2.2 Study Hypothesis 
 
The hypothesis is that treatment of human neuroblastoma cells with malathion, a safe 
organophosphate insecticide, does not cause significant alteration in levels of protein. 
 
2.3 Study Rational 
 
An increasing body of literature suggests that developmental exposure to the 
organophosphate chlorpyrifos results in biochemical and behavioral abnormalities in 
young animals. It was also reported that chlorpyrifos could cause developmental 
neurotoxicity in exposed young children. Malathion, on the other hand, is a more benign 
organophosphate and is being used in huge quantities to eradicate pests in both 
agriculture and the household. There is general lack of data in literature on the effects of 
pesticide exposure at the protein level. This study was initiated to conduct a proteomic 
investigation on the effect of pesticides and we predict that malathion, a safer 
organophosphate, compared to other potent organophosphates like chlorpyrifos, does not 
cause significant alteration in levels of protein. 
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2.4 Specific Aim 
 
The specific aim is to study the effect of malathion, if any, on protein expression in 
human neuroblastoma using proteomic tools namely 2-DE and mass spectrometry.  
 
COMPARISON OF ALBUMIN-INTERACTOME IN VENTRICULAR 
CEREBROSPINAL FLUID BETWEEN ALZHEIMER’S DISEASE SUBJECTS 
AND NORMAL SUBJECTS  
 
3.1 Study Goal 
 
The primary goal of this project is to identify biomarkers for Alzheimer’s disease by 
comparing the albumin-interactome in CSF between Alzheimer’s disease subjects and 
normal subjects. 
 
3.2 Study Hypothesis 
 
The hypothesis is that alterations in levels of proteins that constitute the CSF albumin-
interactome will provide insight into Alzheimer’s disease pathology. 
 
  3.3 Study Rational 
 
CSF is an ideal target to identify protein biomarkers for diseases like Alzheimer’s disease 
(AD) that affect the brain. Two-dimensional gel electrophoresis (2-DE) appears 
particularly well-suited for such analyses since it has the ability to resolve the complex 
protein mixture into individual protein spots in a polyacrylamide gel. However, a major 
challenge associated with the analysis of CSF by 2-DE is the very large dynamic range of 
CSF protein expression. The CSF proteome consists mostly of albumin, transferrin, 
immunoglobulins and these represent greater than 70% of the total protein in CSF. One 
way to overcome the dynamic range problem is to remove the most abundant proteins 
albumin and immunoglobulins using commercially available depletion kits. However, 
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there is increasing evidence that depletion of these most abundant proteins could lead to 
concomitant removal of other small proteins and peptides that might be interacting with 
the high abundant proteins. This would mean loss of valuable information about these 
potential biomarkers for the disease. The increased awareness that small proteins and 
peptides interact with the most abundant proteins like albumin led us to selectively isolate 
and identify the CSF albumin-interactome using immunoprecipitation technique.  
 
3.4 Specific Aim 
 
There are two specific aims in pursuit of this goal. The first specific aim is to isolate the 
albumin-interactome by immunoprecipitation and identify the protein components that 
constitute the albumin-interactome, using mass spectrometry. 
    
The second specific aim is to compare the albumin-interactome in CSF between AD and 
control subjects to identify biomarkers for AD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                          6  
CHAPTER TWO 
 
BACKGROUND  
 
Main technologies utilized in the preparation of this work are 2-DE and mass 
spectrometry and this chapter provides background information and literature review on 
these two techniques. Statistical treatment of data is also briefly discussed here.   
 
2.1 TWO-DIMENSIONAL GEL ELECTROPHORESIS (2-DE) 
 
Two-dimensional gel electrophoresis (2-DE) is a powerful and widely used method for 
the analysis of complex mixture of proteins like biological fluids, cell extracts, tissue 
samples etc. This technique was first introduced by O’Farrell [1], Klose [2] and Scheele 
[3] in 1975 to map proteins from Escherichia coli, mouse and guinea pig respectively. 2-
DE separates proteins by exploiting two properties of proteins in orthogonal directions. In 
the first dimension called the isoelectric focusing step, proteins are separated based on 
their isoelectric point (pI). In the second dimension step, sodium dodecyl sulfate – 
polyacrylamide gel electrophoresis (SDS-PAGE) proteins are separated based on their 
molecular weight (Mr). Development of immobilized pH gradient (IPG) strips coupled 
with pre-cast polyacrylamide gels and introduction of new sensitive fluorescent stains 
have greatly improved the capacity, sensitivity and reproducibility of 2-DE.  
 
In the original technique, carrier ampholytes were used to form a pH gradient under the 
influence of electric field and the first dimension isoelectric focusing was performed in 
carrier ampholyte containing polyacrylamide tube gels. In the current method developed 
by Gorg et al. [4, 5] the carrier ampholyte-generated pH gradient is replaced with IPG 
strips. This change overcomes limitations like reproducibility, handling and resolution of 
carrier ampholyte generated pH gradient gels. After 2-DE separation, proteins separated 
on a polyacrylamide gel are subjected to “in-gel” proteolytic digestion. The resulting 
peptides are analyzed by either matrix assisted laser desorption ionization (MALDI) or 
liquid chromatography tandem mass spectrometry (LC-MS/MS) and the mass spectrum is 
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searched against protein database for identification. The major steps involved in the 
proteomics approach utilizing 2-DE are sample preparation, protein separation by 
isoelectric focusing, equilibration with SDS buffer, separation by SDS-PAGE, protein 
detection using sensitive staining solution, analysis and quantification using image 
analysis software, spot excision and in-gel enzymatic digestion and finally identification 
using mass spectrometry (Figure 2.1). Each step in 2-DE will be discussed in detail in the 
following sections. 
 
• Sample preparation 
 
Appropriate sample preparation is absolutely essential for good 2-DE results. The method 
of sample preparation depends on the aim of the research. Various factors such as 
solubility, size, charge and isoelectric point (pI) of proteins of interest play critical role. 
Sample preparation/solubilization is important in reducing the complexity of a protein 
mixture. There is a wide range of solubilization cocktails available to researchers but it 
should be kept in mind that the sample to be loaded on a 2-DE must be of low ionic 
strength denaturing buffer that maintains the native charge of the protein and keeps them 
soluble. 
 
An effective sample preparation procedure should be able to achieve the following: 
 
1. Solubilize the proteins including hydrophobic proteins: denature the proteins 
to break the non-covalent interactions and break disulfide bonds.  
2. Prevent protein aggregation but keep the proteins in solution. 
3. Prevent post-extraction modifications like degradation or chemical 
modifications of the proteins.  
4. Remove IEF interfering species like nucleic acids and salts. In 2-DE, proteins 
are the analyte and hence anything other than proteins are contaminants, some 
of which that can affect IEF must be completely removed. 
5. Provide proteins of interest at a detectable level which might require removal 
of abundant proteins especially when handling biological fluids 
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Figure 2.1 2-DE approach in bottom-up proteomics 
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• Rationale for Solubilization 
 
Forces such as disulfide bonds and non-covalent interactions hold proteins together. The 
non-covalent forces are mainly ionic bonds, hydrogen bonds and hydrophobic 
interactions. The hydrophobic interaction is because of the presence of water and the side 
chains of apolar amino acids like leucine, valine, isoleucine, phenylalanine, tryptophan 
and tyrosine pack together and form “hydrophobic core” of the protein due to the 
thermodynamically unfavorable exposure to water molecules. Therefore, a good 
solubilization buffer should break the ionic bonds, hydrogen bonds, hydrophobic 
interactions and disulfide bonds under IEF-compatible conditions i.e. very low salts and 
other charged molecules. Rabilloud describes a detailed review on solubilization of 
proteins for electrophoresis [6]. 
 
Solubilization of proteins is usually achieved by the use of chaotropic agents, detergents, 
reducing agents, buffers and ampholytes. Structures of common reagents used are given 
in figure 2.2.  
 
Chaotropic agent: Chaotropic compounds are chemicals that disrupt hydrogen bonding 
between and within proteins. They prevent protein aggregation and formation of 
secondary structure that can alter protein mobility. Neutral urea in concentration of 8M is 
usually used as a chaotrope in 2-DE that completely unfolds the protein to random coil 
and exposes the ionizable groups. However, care must be taken not to heat urea-
containing solutions above 37°C as urea hydrolyses and carbamylation of protein occurs. 
Neither must the temperature of the solution go below 4°C since urea precipitates at this 
temperature. Thiourea is also sometimes used in addition to urea to increase the solubility 
of otherwise difficult-to-solubilize proteins like membrane proteins [7].  
 
Detergent: In addition to the chaotropic agent, a detergent is also added to facilitate 
protein solubility. There are a number of cationic, anionic and zwitterionic compounds 
that can be used as detergents. For IEF, zwitterionic or non-ionic detergent is the best to 
use, as it is uncharged. The detergent aids in protein solubilization and prevents its 
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aggregation by disrupting the hydrophobic interactions. Originally the nonionic detergent 
Triton X-100 was used [1, 2] but subsequently it was shown that the zwitterionic 
detergent CHAPS was more effective. Detergents are usually used in concentrations upto 
4% [8]. The anionic detergent SDS can be used as it is a very effective protein solubilizer 
but because of the charge and the ability to form associations with proteins it can affect 
IEF. The negative effect of SDS on IEF can be minimized by the addition of another 
detergent in combination with SDS and keeping the detergent to SDS ratio about 8:1 [9]. 
New detergents like SB 3-10 and ASB-14 that have great potential are being used in 
proteomics studies [10].  
 
Reducing agent: Reducing agents are used in sample preparation to break the disulfide 
bond between cysteine residues between and within proteins. Compounds used as 
reducing agents in 2-DE are either sulfydryl or phosphine reducing agents. Examples of 
sulfydryl containing compounds are dithiothrietol (DTT) and β-mercaptoethanol (βME). 
Examples of phosphine reductants include tributylphosphine (TBP) and tris-
carboxyethylphosphine (TCEP). The phosphine containing reductants are more effective 
than the sulfydryl compounds and can be used in lower concentrations. Following 
reduction of disulfide bonds, the free –SH groups are protected by alkylation using 
iodoacetamide. This prevents oxidative crosslinking of –SH groups.  
  
Carrier ampholytes and buffer: Carrier ampholytes are small, amphoteric substances 
that have great buffering capacity at their pI. They are added in sample solubilization 
buffer to enhance protein solubility. They prevent protein aggregation due to charge-
charge interaction. They are used typically in concentrations of <0.2% (w/v) in the 
sample buffer. Since they carry current, high concentrations of carrier ampholytes slow 
down IEF till they are focused at their pI and hence limit the voltage.  
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Figure 2.2 Structures of common reagents used in 2-DE sample buffer 
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• FIRST DIMENSION – ISOELECTRIC FOCUSING (IEF) 
 
The first dimension in 2-DE separation is the isoelectric focusing. IEF is an 
electrophoretic method that separates proteins according to their isoelectric point (pI). 
Proteins are amphoteric biomolecules carrying both negative and positive charges on the 
same molecule. The isoelectric point of a protein is the pH at which the protein carriers 
no net charge. Proteins are positively charged at a pH below their isoelectric point and are 
negatively charged at a pH above their pI. For IEF separation, pH gradient is essential 
and mixture of proteins is separated in the pH gradient as they move under the influence 
of an electric field. A protein that is positively charged will move towards the cathode 
until it reaches a pH at which it carries a net zero charge (pH equal to its pI) and does not 
migrate further as it does not see the electric field at this point (Figure 2.3). If for some 
reason the protein diffuses from its pI point, it is immediately focused back to position. 
This is the focusing effect of IEF. The degree of resolution is determined by the pH 
gradient and voltage applied. Typically IEF is performed at high voltages. IEF carried out 
under denaturing conditions gives the best resolution, as the proteins are all completely 
denatured and exists in only one conformation.  
 
The original method of IEF depended on pH gradient formed by carrier ampholytes in 
polyacrylamide tube gels [1, 2]. The carrier ampholytes comprise of small amphoteric 
molecules with pIs spanning a specific pH range. When voltage is applied, the carrier 
ampholyte with the most negative charge will move towards the anode, the molecule with 
the most positive charge will move towards the cathode and a pH gradient is established. 
However, the major disadvantage of a pH gradient formed by carrier ampholytes is the 
drift in the pH. These molecules are unstable and suffer batch-to-batch reproducibility. 
The polyacrylamide tube gels have low mechanical stability and also suffer from batch-
to-batch differences. 
 
 
 
 
 
                                                                          13  
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Isoelectric focusing. A mixture of proteins resolved on a pH 3-10 IPG strip 
according to their pIs 
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Gorg et al. developed another method to form pH gradient polyacrylamide gels[4, 5, 11]. 
An immobilized pH gradient polyacrylamide gel strip was developed by covalently 
incorporating a gradient of acidic and basic buffering groups into the polyacrylamide gel 
at the time of its polymerization. The buffers are called acrylamido buffers that are well-
defined molecules with a single acidic or basic buffering group linked to an acrylamide 
monomer. The immobilized pH gradients are formed using two solutions, one containing 
a relatively acidic mixture of acrylamido buffers and other containing basic mixture. The 
concentrations of the various solutions define the pH range. During polymerization the 
acrylamido portion of the buffer co-polymerizes with the acrylamide and bisacrylamide 
monomers to form a polyacrylamide gel. The gel is cast onto a plastic backing for easy 
handling and is usually dried which can be rehydrated with the sample.  
 
Low voltage is applied sometimes to aid the sample rehydration, a process called active 
rehydration that is carried out typically for 12 hours (overnight). IPG strips are a marked 
improvement over tube gels in the following aspects: 
 
• The first dimension separation is more reproducible because the covalently 
fixed gradient cannot drift 
• The plastic backing provides easy handling 
• With the IPG technology desired pH range can be developed  
• The IPG strips have greater loading capacity for protein [11] 
• The protein sample can be introduced into the IPG strip during rehydration 
[12] 
 
Samples can be loaded onto an IPG strip either during rehydration or after rehydration of 
the IPG strip via sample cups.  
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Sample loading during rehydration of the IPG strip is the most common method and has 
multitude of advantages such as: 
 
• Large quantities of proteins can be loaded [12] 
• Because the sample is not applied at one single place like when using sample 
cup, this method eliminates precipitation of proteins  
 
The rehydration buffer also called sample buffer contains urea, DTT, CHAPS, IPG buffer 
and bromophenol blue (dye). The sample is dissolved in the rehydration buffer and added 
to the sample tray. The IPG strip is placed over the sample and is allowed to rehydrate for 
about 12 hours (or overnight). A low voltage is applied to facilitate the entry of protein 
into the gel during rehydration. A layer of mineral oil is added above the IPG strip mainly 
to minimize sample evaporation and urea crystallization. After the IPG strip is rehydrated 
with the sample, IEF can be performed. IEF is usually carried out at high voltages up to 
4000 V. A typical IEF protocol generally proceeds through a series of voltage steps that 
begin at a low value. The initial low voltage is to separate the salt (which is collected by 
the paper wicks placed at either ends of the IPG strip) from the sample. The voltage is 
gradually increased to a final desired focusing voltage that is held for several hours. 
Many factors affect the time required for focusing. Optimization of the protocol is 
essential to achieve good separation. After focusing, the IPG strips are equilibrated with 
buffers containing DTT and iodoacetamide. The equilibration is to saturate the IPG strip 
with the SDS, reduce and alkylate any disulfide bonds.  
 
The equilibration solution has several components in it. A solution of 50 mM tris, pH 8.8 
maintains the IPG strip pH in a range appropriate for the second dimension separation 
and 6M urea and 30% glycerol reduces electroendosmosis by increasing the viscosity of 
the buffer and helps in the transfer of proteins from the first to the second dimension. 
DTT in the solution preserves reduced state of the denatured proteins while ioacetamide 
alkylates the reduced disulfide bonds and residual DTT to prevent point streaking seen 
especially in silver stained gels. 
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SDS in the equilibration buffer denatures proteins and forms negatively charged protein-
SDS complexes, which facilitates separation in the second dimension based on molecular 
weight. After equilibration of IPG strips, they are ready for the second dimension 
separation. 
 
• SECOND DIMENSION- SODIUM DODECYL SULFATE- 
POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
 
The separation of biomolecules in an electric field is called electrophoresis. The method 
of protein separation by electrophoresis employs polyacrylamide gel as a support medium 
and SDS as the denaturant and hence called SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE). SDS is an anionic detergent that denatures proteins by wrapping around 
their peptide backbone in a ratio of approximately 1.4 SDS to 1 protein. The bound SDS 
masks the charge of the protein itself giving it a net negative charge. The proteins are 
totally unfolded and carry a net negative charge and separation is based on molecular 
weight of the protein. The most commonly used buffer system is the tris-glycine system 
described by Laemmli [13].    
 
Polyacrylamide gel: Polyacrylamide gel is the polymerization product of the monomer 
acrylamide and a crosslinking comonomer, most commonly bisacrylamide. The 
polymerization is started and propagated via a free radical reaction. The chemical 
N,N,N',N'-tetramethylethylenediamine (TEMED) causes ammonium per sulfate (APS) to 
produce sulfate radical. The radicals react with the acrylamide and bisacrylamide leading 
to polymerization. Single percentage acrylamide gels provide good resolution of proteins 
that fall within a narrow molecular weight range. However, gradient polyacrylamide gels 
give excellent resolution of wide range of molecular weight and the decrease in pore size 
allows for sharper protein spots. The percentage of total acrylamide monomer is referred 
to as %T and this value determines the pore size of the gel. The greater the %T, the 
smaller is the pore size of the gel. In gradient gels, percentage of acrylamide increases 
from top to bottom of the gel while the pore size decreases, allowing smaller proteins to 
travel more towards the bottom of the gel resulting in better separation.  
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2.2 MASS SPECTROMETRY 
 
An essential tool in addition to the protein separation technology, for proteomics, is mass 
spectrometry (MS). MS is an ubiquitous analytical tool in a number of fields including 
chemistry, biochemistry, pharmacy and medicine. The history of MS dates back to 1897 
when Sir J.J. Thomson of the Cavendish laboratory at the Cambridge University, while 
studying electrical discharges in gases discovered the electron. He then went on to build 
the first ever known mass spectrometer in the first decade of the 20th century for the 
measurement of mass to charge ratio (m/z) of ions [14]. In this instrument, ions from 
discharge tubes were passed through both electrical and magnetic fields, by virtue of 
which they take parabolic trajectories. The ions were then detected on a fluorescent 
screen or photographic plate. Since then, MS has changed tremendously and is still 
undergoing improvements. 
 
The basic principle of mass spectrometry is to generate ions of the analyte by suitable 
method, to separate the ions by their m/z values and to detect them quantitatively and 
qualitatively by their respective m/z value and abundance. A mass spectrometer consists 
of an ion source, a mass analyzer and a detector, which are operated under high vacuum 
(schematic shown in figure 2.4). Ions are separated in a mass analyzer on the basis of m/z 
and can be manipulated by electric or magnetic fields to direct ions to a detector in a m/z 
dependent manner. A mass spectrum is the two dimensional representation of the signal 
intensity versus the m/z. The intensity of the peaks (signals) directly reflects the 
abundance of ionic species of that respective m/z. The mass-to-charge ratio, m/z, is 
dimensionless as it is a ratio between the mass number of the ion and the number of 
charge on it. 
 
Instrumentation 
 
Basic types of mass analyzers are given in Table 2.1. MS instrumentation has undergone 
tremendous change since its introduction in 1946 by Stephens [15]. Highly sensitive, 
robust instruments have been developed that can reliably analyze proteins. The two mass 
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analyzers that were used for the preparation of this dissertation namely, ion trap and time-
of-flight are discussed below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 General scheme of a mass spectrometer 
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Table 2.1 Types of different mass analyzers 
 
 
TYPE 
 
 
Acronym 
 
Principle 
 
 
Time-of-flight 
 
 
 
TOF 
 
pulsed ion beam dispersed in time 
and separated by time of flight 
  
 
 
Magnetic sector 
 
 
 
B 
 
Continuous ion beam is deflected 
in magnetic and separated based 
on the momentum 
  
 
 
Quadrupole 
 
 
 
Q 
 
Continuous ion beam in Rf 
quadrupole field, separated on the 
basis of stable trajectories 
 
 
 
Quadrupole ion trap 
 
 
 
 
QIT 
 
Ions trapped in the 3D trap under 
the influence of Rf field and 
separated based on stable 
trajectories 
 
 
 
Fourier transform ion cyclotron 
 
 
 
FT-ICR 
 
Ions are trapped and separated by 
cyclotron frequency in a magnetic 
field 
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• QUADRUPOLE ION TRAP (QIT) 
 
Introduction 
 
The origin of ion trap goes back to the work of Paul and Steinwedel [16, 17] that was 
recognized by the presentation of shared 1989 Nobel Prize in Physics to Wolfgang Paul. 
QIT also known as 3D trap consists of an arrangement of three hyperbolic electrodes- a 
ring electrode and two end caps (Figure 2.5). In the normal mode of use, the end caps are 
connected to earth potential (grounded) while a radiofrequency (RF) fundamental 
potential (driving potential) typically 1 MHz is applied to the ring electrode. By virtue of 
the driving potential, ions are held stable within the ion trap. By gradually increasing the 
amplitude of the driving potential, ions become more energetic and their trajectories 
become unstable along the axis of symmetry (z axis) of the trap. As a result, the ions in 
order of increasing m/z value are ejected from the trap through holes in one of the end-
cap and are detected by the channeltron electron multiplier. The resulting signal 
represents a mass spectrum. This mode of operation is called mass-selective ejection. The 
working principle of the 3D trap is based on creating stable trajectories for ions of a 
certain m/z or m/z range while removing unwanted ions by colliding them with the walls 
or by axial ejection from the trap due to their unstable trajectories.  
 
Theory of the “perfect” Quadrupole ion trap 
 
The theory of quadrupole ion trap is best explained by equations that govern both the 
electric field in the trap and the motion of ions inside. The potential φx,y,z developed 
within the trap on applying both RF and DC (direct current) potential to the ring electrode 
is given by 
                             ( ) ( )
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U is maximum DC potential and V the maximum RF potential 
Ω is the angular frequency of the RF potential 
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r is the internal radius of the ring electrode  
2z is the distance between the end-cap electrodes (for perfect quadrupole field r2 = 
2z2 however a different relation was shown to work better) and 
t is the time 
 
The motion of ions in a quadrupole field is described mathematically by solutions to the 
Mathieu equation, which has the general form 
 
( ) 02cos22
2
=−+ uqa
d
ud
uu ξξ
 
   where, 
 u = x, y and z directions 
 ξ = Ωt/2  
 
The trapping parameters a and q which are fundamental for the operation of the ion trap 
is derived as 
22
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The form of an ion trajectory in the r-z plane has the general appearance of a Lissajous 
curve composed of two fundamental frequency components ωr.0 and ωz.0 of the secular 
motion with a super imposed micromotion of frequency Ω/2π Hz. The graphical 
representation of stable solutions to the Mathieu equation is called the stability diagram 
(Figure 2.6). Ions can be stored in the trap provided they are stable in both r and z 
direction. The βz = 1 line intersects the qz axis at q=0.908, this is the ejection limit of the 
ion from the trap. The parameter β appears in the solution to the Mathieu equation and 
defines the secular frequency of oscillation of the ion. When the values of U and V are 
held constant and the driving frequency Ω is reduced, the values of both az and qz will 
increase and at one point the (az, qz) coordinate of the ion will cross the boundary and the 
trajectory will become unstable. Keeping the frequency Ω constant and increasing the V 
can achieve a similar effect. 
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Figure 2.5 Typical quadrupole iontrap comprising of the two endcap electrode and the 
ring electrode at the center 
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Figure 2.6 Mathieu stability diagram for quadrupole ion trap (QIT). 
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In most ion traps, end-caps are grounded and a RF potential is applied to the ring 
electrode. By gradually increasing the RF amplitude, the motion of ions become 
progressively more energetic and they eventually develop unstable trajectories in the 
order of increasing m/z. When qz reaches the value of qeject = 0.908 along the az = 0 line, 
the ion motion remains stable in the radial plane while the axial component of the 
trajectory becomes unstable so that ions are ejected from the trap. This method of ion 
ejection is referred to as mass selective axial instability [18]. Trapped ions of a given m/z 
oscillate at a frequency known as the secular frequency that is proportional to the angular 
frequency of the applied RF. Stafford et al. discovered that a helium damping gas of ~1 
mTorr within the trap greatly improved both the sensitivity and the mass resolution of the 
instrument [19]. The light helium (He) atoms collide with heavier ions; this reduces their 
kinetic energy, and they migrate to the center of the trap. Consequently, when being 
ejected ions tend to start from essentially the same position along the axis of the trap 
hence improved resolution and with minimum radial dispersion forming a tightly focused 
ion beam that cleanly passes through holes in the end-cap electrode, resulting in greater 
sensitivity.  
 
Stretched geometry 
 
The performance of the quadrupole ion trap is affected by imperfections in the 
quadrupolar electric fields used to trap ions. For a perfect quadrupole field, the geometry 
of the ion trap should be such that r2 = 2z2. However, the commercial ion traps have a 
“stretched geometry” in which the shapes of the endcap and the ring electrode are 
retained but the distance between them is extended by about 11%. This was shown to 
increase the signal intensity and improve resolution. The trapping parameters are now 
calculated using the actual r and z as follows: 
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Mass Range extension 
 
By rearranging the equation for the trapping parameters, we get  
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where qej is 0.908 and Vmax is the maximum value for the RF potential. In order to 
increase the m/z value for a given Vmax, we can either reduce r and/ or Ω or reduce the q 
value. The most efficient way to accomplish mass range extension is by resonant ion 
ejection. Resonant ejection requires cooling of ions towards the center of the trap with the 
help of Helium buffer gas. Resonance excitation is brought about by matching the 
frequency of the supplementary potential applied to the endcap electrodes to the secular 
frequency of the ion. The ion will absorb the energy from the applied field and the 
trajectory will increase linearly towards the endcap until the ion becomes unstable and is 
ejected.   
 
Instrument and Its Operation 
 
LCQ Classic: 
The instrument used for the analysis/identification of proteins is the Thermo Electron 
Corporation LCQ Classic (San Jose, CA). The ions will be pre-formed by solution phase 
chemistry before the analyte reaches the probe. This is accomplished by adding a proton 
donor such as formic acid to the mobile phase. A potential of + 4kV is applied at the 
heated capillary. By virtue of the potential, positive ions move towards the tip and a 
Taylor cone is formed. The Taylor cone emits very small charged droplets, which are 
desolvated by a combination of nitrogen gas (nebulizer) and heated capillary. The 
charged gas phase ion molecules are steered into the ion trap. There are two octapoles in 
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the LCQ Classic. The main purpose of these octapoles is to transmit ions from the exit of 
the skimmer to the ion trap and allow any remaining neutrals or opposite charge ions to 
be lost in vacuum. Ions are transmitted as a beam by the first octapole which then passes 
through the inter octapole lens and are refocused into the trap by the second octapole. The 
inter octapole lens has a tunable charge that is opposite to the ions of interest so that they 
are accelerated towards the second octapole. The second octapole has a even higher 
voltage so that the ions finally enter the ion trap. The RF frequency of the octapole is 
typically around 2400 Hz, which focuses ions into a beam. The octapoles act only as lens 
focusing ions and in no way take part in the mass selection. Once the ions enter the ion 
trap, it is here that they are selected and scanned-out to be detected.  
 
There are four basic steps involved in an ion trap operation. These include collection, 
isolation, excitation and ejection of ions. During a full scan event which is the simplest, 
all ions regardless of mass are collected inside the trap and ejected resulting in a 
spectrum, that displays the ion count of each mass. RF is applied to the ring electrode to 
collect all ions. The endcap electrodes are held at ground. The RF frequency applied at 
the ring electrode in a LCQ Classic is 760 kHz. Due to this RF, the ions oscillate towards 
and away from the center of the trap along the radial axis. Due to the oscillating RF 
frequency, the trapped ions never hit the electrodes and thus are maintained inside the 
trap. The use of buffer gas greatly improved sensitivity and resolution of low mass ions. 
By cooling ions by collision with He gas, the kinetic energy of the ions entering the trap 
is reduced and their trajectories collapse to the center of the trap. With each collision 
some of the kinetic energy is converted to vibrational energy and heat, both of which 
quickly dissipate. The net result is loss of kinetic energy without much change in the 
vibrational energy to cause fragmentation. Thus ions cooled down in the center of the 
trap can be scanned out resulting in increased sensitivity and resolution.  
 
The theory of ion trap has been discussed earlier in a previous section. In an LCQ, the 
above equations are even simpler. The r and z are dimensions of the ion trap which will 
remain constant for a trap, Ω the angular frequency of the drive potential is 760 kHz and 
the DC component U is zero, so rearranging the above q equation 
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The only variable that affects an ion’s stability is the q value, the ion’s m/e and the RF 
amplitude (V). All ions trapped inside an ion trap will have an a value of zero and a q 
value that extends from 0 to 0.908 (q=0.908 is called the edge of stability) depending 
upon their mass. At given RF amplitude, the q value is inversely proportional to the mass 
of the ion, meaning smaller ions will have larger q value than heavier ions. In LCQ, RF 
amplitude is ramped from a low voltage to high voltage and in this process the q value of 
the ions will increase. When an ion of particular mass reaches the qz value of 0.908, its 
trajectory will become unstable in the z direction (axial) and it is scanned out of the hole 
in the endcap into the detector (Figure 2.7).  
 
 
Ramp RF amplitude and ions leave the trap in the order of increasing mass 
 Figure 2.7 Mass selective instability scan 
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becomes 0.908 and that is close to the exit hole will eject out of the trap immediately 
while other ions of the same mass that continue to have stable trajectories and stay within 
the trap, will have chaotic motion from collisions with other ions and He atoms. This will 
affect the resolution. To prevent this, a RF potential is applied at the endcaps, which is 
exactly 180° out of phase from another. So, when the entrance endcap is of positive 
polarity, the positive ions are repelled from it and attracted towards the exit endcap as it 
qz axis 
0.908 
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has negative polarity. However, in less than a second, the polarity of the endcaps 
interchange and the ions are again repelled form the exit endcap. In this way, the ions are 
oscillating in the trap back and forth in a group. Hence, when the q value of a particular 
mass of ion is reached, the same mass ions are ejected as a group and this increases 
resolution. This type of ejection is called resonance ejection. The frequency of RF 
applied to the endcap in the LCQ classic is about 320 kHz. This however reduces the q 
value to 0.83.  
 
Tandem Mass Spectrometry 
 
For a full scan, all ions that enter the ion trap are ejected and detected and a full MS scan 
spectrum is obtained. In the case of tandem mass spectrometry (MS/MS), the ions are all 
collected inside the trap and the ion of interested mass is specifically isolated from the 
other ions of different masses. Ejecting the other ions with different m/z values isolates 
ions of m/z of interest. This is accomplished by applying a resonant frequency equal to 
the secular frequency with which the ions oscillate and by doing so their trajectories are 
made unstable and they exit the trap. Now the isolated precursor ion has to fragment to 
give product ions for MS/MS. This is done by excitation. Excitation of precursor ion is 
accomplished by applying a RF voltage at the endcap. This voltage that is very small in 
amplitude causes the fragmentation of the precursor ion along with collision with He 
buffer gas. RF voltage applied to the endcap to bring about fragmentation is called tickle 
voltage. Before the precursor ion is excited it must be cooled to a lower q value, so that 
most of the fragment ions remain inside the trap (Remember, the q value is inversely 
proportional to the mass of the ion. If the precursor ion fragmented at a large q value then 
the fragment ions which are low in mass than the precursor ion will have greater q values 
and will be ejected out of the trap). So, in order to trap small fragment ions it is essential 
to cool down the precursor to a lower q value (not 0.83). The fragment ions will not 
resonate at the same frequency as the precursor ion (frequency is mass dependent) and 
hence will cool down due to collision with the He atoms down to the center of the trap. 
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The final step in both full scan and MS/MS is ejection in which ions are scanned out of 
the trap and to the detector in order of small mass to large mass. Ramping the ring 
electrode RF amplitude to increase the q value of all ions in the trap and scan them out 
from small to large mass – mass selective scanning performs ejection. At the same time, 
RF is applied to the endcap that makes the ions of same mass oscillate as a group and 
they scan out at the same time – resonance ejection.  
 
Detection system comprises of the conversion dynode and electron multiplier. The 
conversion dynode is held at a very high voltage of about -15kV (for positive ions) and 
the ions exiting the trap are accelerated towards the conversion dynode because of the 
high negative potential. The ion strikes the dynode and secondary particles like electrons 
are emitted towards the electron multiplier. The electron multiplier increases the electron 
current for each ion. When a secondary particle strikes at the cathode, several electrons 
are given off, these electrons strike the inner walls of the cathode to give off more 
electrons, and thus signal is amplified. These electrons are detected by the anode and 
signal is digitized.    
 
Time-of-flight (TOF) mass analyzer 
 
Introduction 
 
Stephens described the construction of a time-of-flight mass spectrometer in the year 
1946 [15]. The principle of TOF is ions of different m/z are dispersed in time during their 
flight along the field-free drift path of known length. In other words, population of ions 
with different m/z but constant kinetic energy will have different velocities while moving 
in a field-free region of constant length. Provided the ions start at the same time or at 
least within a short time interval, the lighter ions will arrive earlier at the detector than the 
heavier ions. This however demands that ions emerge from a pulsed source. This 
separation-in-time technique is different from the separation-in-space of traditional 
magnetic sectors and quadrupole scanning instruments. The first commercial TOF 
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instrument was by Bendix in 1950. These were designed for gas-chromatography mass 
spectrometry (GC-MS). The main advantages of a TOF instrument are: 
 
1. in theory, m/z is unlimited 
2. from a single ionizing event, the mass spectrum is obtained within a very short 
period of time 
3. highly sensitive 
4. recent improvements in the TOF instrumentation allows for tandem mass 
experiments 
 
Principle of TOF Instruments   
 
1. Velocity of ions 
 
The electric charge q of an ion of mass m is equal to the number of charge z times the 
electron charge e 
 
Thus, 
ezq =  
(Note: For singly charged ions q = z) 
 
Force EqF =  
But F = ma where a is acceleration 
Therefore,  
maEq =  
m
Eqa =  
dt
dua =  
dt
m
Equ ∫=  
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We know that the potential energy of ions is converted to their kinetic energy, 
2
2
1 mvqE =  
where E is electric field strength and v is drift velocity 
Therefore, 
2
1
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Eqv  
 
Drift time 
v
Dt D=  where D is length of the drift tube 
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Eq
mDt D         Equation (2) 
 
 
Observed time-of-flight TOF = dDa tttt +++0  
 
where, 
t0 is time after which the ions starts to accelerate 
ta time the ion actually accelerates 
tD time in the drift tube when it moves with constant velocity and  
td is the response time of the detection system 
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Mass Resolution 
 
In MS, mass resolution is usually given by m/Δm where Δm is the difference in mass. In 
TOFMS, since it is separation-in-time domain and from Equation 2   
m is proportional to t2 
 
2Atm =  
Therefore,                                      At
dt
dm 2=  
⎟
⎠
⎞
⎜
⎝
⎛=
t
dt
dt
dm 2  
Thus, 
t
t
m
m
Δ
=
Δ
 
               where, 
Δt is the full width at half maximum height of the peak (FWHM) 
 
Linear Time-of-flight 
 
A schematic of a linear TOF instrument is shown in figure 2.8. The analyte is in a sample 
holder or “target” on which a pulsed laser is focused. An acceleration voltage is applied 
between this target and an electrode that is grounded. Due to the potential applied, ions 
that are formed and desorbed during the laser pulse are extracted and accelerated into the 
flight tube. They drift down a field-free region and hit the detector at the end. This kind 
of instrument in which ions travel in a straight line from the point of formation/desorption 
to detection is called a linear TOF. 
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Figure 2.8 A schematic of a linear TOF instrument. Two ions of different mass ARE 
shown in figure as blue and red filled circles. D is the length of the flight tube and E is 
the electric field applied to accelerate the ions.  
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The ions theoretically posses similar kinetic energy at the point of desorption and as they 
drift in the flight tube, they are separated by their masses. The lighter ions travel faster 
than the heavier ones. However in practice, the pulse is not felt by all ions to the same 
intensity and a kinetic energy distribution for each discrete m/z exists. This lowers the 
resolution by creating a time-of-flight distribution for each m/z [20]. Effects of initial 
time, space and kinetic energy distribution on mass resolution is shown in linear TOF are 
shown in figure 2.9.  
 
Solution to the energy distribution problem 
 
A technique called time-lag focusing or delayed extraction was introduced by Wiley and 
McLaren [21] to overcome the energy distribution. Ionization can be confined to a small 
distance and extraction of ions carried out with a delay in time. They devised an 
instrument with a pulsed two-grid ion source to compensate for the spatial distribution. In 
1966, Mamyrin and coworkers proposed the use of “reflectron” (ReTOF), wherein the 
more energetic ions follow a longer trajectory to overcome the temporal spread due to 
difference in initial velocity [22]. The reflectron, essentially a mirror, consists of a 
decelerating and reflecting field (Figure 2.10). For ions of the same m/z entering such a 
field, those with higher kinetic energy (and velocity) will penetrate the decelerating field 
further than ions with lower kinetic energy. Therefore the faster ions will spend more 
time within the reflecting field, and ‘catch up’ with lower energy ions further down the 
flight path. By adjusting the reflectron voltages it is possible to achieve a time-focusing 
plane. In this ideal case, the resolution of the peaks in the mass spectrum will only be 
dependent on the time-width of ion formation. The angle of ion entry into the reflectron is 
set at slightly away from 90° and the ions take a different path after being reflected. This 
allows the detector to be placed in a path not along the axis of the ion entry from the 
source. The reflector increases the flight path and hence the dispersion in time-of-flight, 
the effect is negligible when compared to the capability of the reflectron to compensate 
for the initial energy difference. The other time-widening parameters that can affect 
resolution are temporal and spatial distribution (figure 2.9) and metastable ion formation. 
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Figure 2.9 Effect of initial time, space and kinetic energy distributions in linear TOF 
 
 
 
   
 
Figure 2.10 Schematic of the ReTOF 
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Temporal distribution: 
 
The differences in time of ion formation and limitations of the detection system 
contribute to the temporal distribution. The ions formed at different times with the same 
kinetic energy will travel the field-free region maintaining a constant difference in time. 
 
The resolution is given by  
t
t
m
m
Δ
=
Δ
 
 
As dt is constant, the mass resolution can be improved by increasing the flight time by 
either decreasing the accelerating potential or my increasing the length of the flight tube. 
By applying the potential after a delay, all ions experience the accelerating voltage at 
about the same time and dt is reduced. 
 
Spatial distribution 
 
When same mass ions are formed at the same time with the same kinetic energy but at 
different locations, the ions formed at the rear of the source will experience larger 
potential gradient than the ions formed close to the extraction grid. Ions at the rear will 
enter the flight tube later but will reach the detector faster than ions formed close to the 
grid because of the higher velocities. The extraction field can be adjusted such that the 
ions arrive at a space focus plane in the drift region at the same time. The space focus 
plane is independent of mass hence ions of different mass arrive at the plane at different 
times. Delayed extraction can also reduce the spatial distribution. 
 
Fragmentation and Mass Resolution 
 
Fragmentation occurs due to excess of internal energy in the ion during the ionization 
process. In MS, fragmentation can provide a wealth of information on the identity of the 
compound. If the compound is an organic molecule it provides information on the 
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functionality and if it is a protein the information can be used to deduce sequence 
information. The different types of fragmentation are shown in figure 2.11.  
 
 
 
 
 
 
 
 
 
Figure 2.11 Different types of fragmentation that can occur in TOF. Red filled circle is 
parent ion while black filled circle is fragment from the parent ion. 
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Prompt fragmentation: If the molecule fragments at the source due to the ionization 
impact, it is called prompt fragmentation. The fragment ions have same velocity but since 
they have different mass they arrive at the detector at different times.  
 
Metastable fragmentation: If the fragmentation occurs in the acceleration region, then the 
ions reach the detector at times between the molecular ion and its fragment resulting in 
poor resolution. The ions cause tailing of the molecular ion peak and increased 
background noise.  
 
Post-source fragmentation/decay: Any fragmentation is undesirable when the goal is to 
identify molecular ion. However, with MALDI the fragmentation can be used to get 
sequence information and is like a tandem MS/MS. Ions which fragment in the field-free 
region of the drift tube, retain essentially the same velocity as intact ions This 
fragmentation is called post-source decay (PSD) and is a result of the laser irradiation and 
collision with other molecules (e.g. residual gas). The reflector will separate precursor 
and metastable decay ions by their difference in kinetic energy. PSD can be employed to 
obtain sequence information from peptides.    
 
2.3 IONIZATION TECHNIQUES 
 
Ionization techniques are critical for converting molecules into ions that can be analyzed 
by mass spectrometry. The challenge with biomolecules is to convert the zwitterionic 
molecules into gas-phase ions without fragmenting. However, there has been incredible 
progress in the ionization techniques that now successful biological mass spectrometry 
can be carried out. Two ionization techniques employed in the work towards this 
dissertation are discussed below.    
 
Electrospray 
 
Electrospray is essentially a transport process wherein ions in solution are transferred to 
gas phase. The application of ES as a source of gas phase ions for mass spectrometric 
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studies was first proposed by Dole [23] in 1968 but the work was very focused on 
polymers and was not explored any further. The groundbreaking application of ES was 
the ionization of biomolecules and their subsequent analysis by mass spectrometry, a 
work done by Yamashita and Fenn [24, 25] and John Fenn won the 2002 Nobel Prize in 
chemistry for his work on Electrospray-Mass Spectrometry (ESMS). The overall process 
of ES involves production of charged droplets at the capillary tip, shrinkage of the drop 
by solvent evaporation and subsequent disintegration to form a small drop with a charge 
on it and transfer into gas phase (Figure 2.12). 
 
A solution of the analyte is passed through a capillary tube to which a potential of about 4 
kV is applied. The counter electrode is a plate with an orifice leading to the mass 
analyzer. Since the capillary has a fine tip, the electric field is very high. The typical 
solution in the capillary is a polar solvent in which the analyte is soluble. When potential 
is applied, the positive and negative ions in solution will move under the influence of the 
electric field and in this case the positive ions will move towards the tip of the capillary 
i.e. towards the meniscus of the solution. Bombarding against the walls of the capillary 
neutralizes the negative ions. The positive ions at the very tip repel each other and this 
causes the meniscus to expand and a cone is formed called the Taylor cone[26] and if the 
potential is high enough, the cone expands and a fine jet of ions can be sprayed from the 
capillary tip. Drops of ions are drifted towards the counter electrode and in this process 
solvent evaporation occurs and the drop shrinks. As the drop reduces in size, it splits into 
smaller droplets and finally gas phase charged analyte molecules are formed which drift 
into the mass analyzer through the holes in the counter electrode.  
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Figure 2.12 Ion formation in Electrospray 
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There are two theories for the formation of charged analyte molecules from the Taylor 
cone – Charge residue model (CRM) and Ion evaporation model (IEM) (Figure 2.13). 
Each of these theories are discussed briefly below. 
 
Charge Residue Model 
 
This mechanism was proposed by Dole [23] depends on the formation of extremely small 
droplets which should contain only one ion. Solvent evaporation at atmospheric pressure 
from such a droplet will lead to a gas phase ion. As the drop shrinks, the columbic energy 
exceeds the surface tension of the drop (Rayleigh limit) at which point fission occurs and 
the droplet is ripped apart. This fission process continues until small charged ion is 
formed.  
 
Ion Evaporation Model 
 
Iribane and Thomson proposed a new mechanism for the production of gas phase ions 
from charged droplets [27, 28]. Their theory describes that the radii of the droplets 
decrease to a given size (solvent evaporates) and direct ion emission takes place from the 
droplets due to columbic repulsion. A detailed explanation on ESMS analysis of proteins 
will be discussed in the following section. 
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Figure 2.13 Diagram of two theories for the formation of charged analyte molecules 
from the Taylor cone 
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Matrix assisted laser desorption ionization (MALDI) 
 
Early 1960s was the advent of laser desorption ionization (LDI), which involves the 
irradiation of low-mass organic molecules with a high intensity laser to form ions that can 
be mass analyzed. Laser desorption, however, could not ionize large biomolecules. 
Matrix assisted laser desorption ionization (MALDI) was developed by Karas and 
Hillenkamp in the late 1980s [29] and is one of the two “soft ionization” techniques that 
was capable of ionizing proteins. The other soft ionization technique is the Electrospray 
(ES) that was discussed earlier. Koichi Tanaka received the Nobel Prize for Chemistry in 
2002 [30], for his developments in the field of MALDI [31].   
 
Principle: 
 
MALDI involves the use of matrix to successfully ionize proteins. The analyte is mixed 
thoroughly with a small organic substance. The organic substance has strong absorbance 
at the laser wavelength that causes the co-crystallization of both matrix and analyte. The 
incorporation of analyte molecules in the lattice of the matrix crystal is the pre-condition 
for the laser desorption/ionization process. The crystallized surface of the sample is then 
exposed to laser (typically nitrogen laser 337 nm-UV wavelength) under high vacuum 
(Figure 2.14). This causes the evaporation of analyte molecules into gas phase. The target 
on which the sample is crystallized is floated at about 20 kV. Depending upon the 
polarity of ions, they are accelerated towards the mass analyzer, which is usually the 
TOF. The mechanism of ionization is still is topic of debate and is not very clear.  
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Figure 2.14 Matrix assisted laser desorption ionization (MALDI) 
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Lasers:  
 
A number of laser wavelengths can be used ranging from ultraviolet (UV) to infrared 
(IR). UV lasers are emitting pulses of 3-10 ns duration while those of IR are in the range 
of 6-200 ns. UV lasers include Nd-YAG laser (yttrium-aluminum-garnet crystals doped 
with neodymium) at wavelengths of 335 nm (tripled frequency) or 266 (four-fold 
frequency) and nitrogen laser operating at a wavelength of 337 nm. IR lasers include Er-
YAG laser (yttrium-aluminum-garnet doped with erbium) that work at wavelengths 294 
μm.  
 
Matrix: 
 
The matrix is usually a small aromatic organic compound that can absorb energy at the 
laser wavelength. For the analysis of proteins, α-cyano-4-hydroxycinnamic acid (HCCA), 
dihydroxy benzoic acid (DHB) and sinapinic acid (SA) are the most used matrices. The 
structures of these matrices are shown in figure 2.15. 
 
A good matrix must have the following properties: 
 
• Have high extinction coefficient at the laser wavelength so that it can absorb 
the laser energy  
• Be miscible with the analyte so that the analyte can co-crystallize with it 
• Be stable in vacuum – should not sublime 
• Have proper functional group to provide proton and hence act as a proton 
donor for the analyte 
• Should be easily crystallized 
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There are a number of ways to “spot” the sample on a target (sample holder). These are 
all variations of the basic dried-droplet method which was introduced by Hillenkamp and 
Karas in 1988 [32] where the matrix is simply added to the sample on the target, mixed 
by pipetting up and down and allowed to air dry. The non-volatile substances may be 
washed away, but this method tolerates salts better than the other spotting techniques. 
The second common method is the Overlay method, which involves the use of a fast 
evaporation to form the first layer of crystals. Then a layer of mixture of analyte and 
matrix is applied and allowed to dry. The third method is the sandwich method; here the 
analyte is sandwiched between two layers of matrix. 
 
Vacuum:  
 
Vacuum system is an integral part of any mass spectrometer. The reason for maintaining 
vacuum in a mass spectrometer is the “mean free path”. The mean free path is defined as 
the average distance between molecules before they collide with each other. It is given by 
the mathematical formula 
 
Mean free path = 5 * 10-3 Torr cm / P torr  
 
At atmospheric pressure (7.6 x 102 torr), the mean free path will be 2 x10-6 inches, which 
is 500 nm. At this distance, there will be lot of collisions and the ions do not accelerate 
but travel with a constant velocity. The collisions could also bring about ion/ion reactions 
which are not desired. Hence the mean free path should be kept to a maximum and this 
can be achieved by decreasing the pressure in the system.   
 
2.4 WESTERN BLOTTING 
 
Blotting is the transfer of biomolecules separated on a gel onto a membrane like 
nitrocellulose or polyvinylidene difluoride (PVDF) (Figure 2.16). Blotting was first 
performed by Southern in 1975 to transfer DNA from agarose gels to nitrocellulose 
membranes [33]. Since then blotting has been applied to both RNA and proteins in both 
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agarose and polyacrylamide gels [34, 35]. Towbin et al. came up with the electrophoretic 
transfer of proteins from polyacrylamide gels [36]. Western blotting also known as 
protein blotting or immunoblotting consists of the following steps: 
 
• Immobilization of proteins on a membrane by electrophoretic transfer from a 
gel (Figure 2.16) 
• Unoccupied sites on the membrane are saturated (blocked) to prevent non-
specific binding of the primary antibody – blocking is done with 5% non fat 
dry milk or bovine serum albumin (BSA) 
• The blot is probed using primary antibody against the protein of interest 
• Secondary antibody that is specific for the primary antibody is used for mainly 
amplification purposes. The secondary antibody can be radiolabeled or 
conjugated with an enzyme   
•  Incubation with detection reagents to generate signals that can be quantified 
• Detection using autoradiography  
• Analyze using image analysis software 
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Figure 2.16 Gel-membrane sandwich in western blotting 
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A number of blotting membranes are available each with a particular advantage 
depending on the needs of the experiment. The most commonly used membranes are 
nitrocellulose (NC) and poly (vinylidene difluoride) (PVDF). Nitrocellulose was one of 
the first membranes used for western blotting. The membrane can be easily wetted and is 
compatible with a wide variety of detection systems. When using nitrocellulose, the 
transfer buffer should have methanol. PVDF is a hydrophobic support suitable for 
proteins. PVDF has a high binding capacity, is more mechanically, and chemically stable 
than nitrocellulose. PVDF membranes need to be pre-wetted with methanol but the 
transfer buffer need not contain methanol. Once the proteins are transferred to the 
membrane, blocked and incubated with the primary antibody for the specific protein of 
interest, the membrane is incubated with the secondary antibody that is specific for the 
primary antibody. The secondary antibody can be labeled with either enzyme or 
radioactive element. The labeling method involving enzyme conjugated secondary 
antibody specifically the horseradish peroxidase conjugated secondary antibody system 
(ECL) for detection will be discussed in detail. 
 
Enhanced Chemiluminescence Labeling (ECL) 
 
Luminescence is defined as the emission of light resulting from the dissipation of energy 
from a substance in an excited state. In chemiluminescence, the excitation is brought 
about by a chemical reaction. One of the most clearly understood system is the 
horseradish peroxidase/H2O2 catalyzed oxidation of luminol in alkaline conditions. The 
luminol is in an excited state following oxidation and then decays to the ground state by 
emitting the excess energy in the form of light. Enhanced chemiluminescence is achieved 
by carrying out the oxidation of luminol in the presence of enhancers like phenols [37] 
(Figure 2.17). This increases the light output approximately 1000 fold and also extends 
the time of light emission. The light produced by this enhanced chemiluminescence peaks 
after 5-20 min and the decays slowly. The maximum light emission is at 428 nm and this 
can be detected by exposure to X-ray film. The X-ray film is then developed and the 
bands analyzed using image analysis software.   
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Figure 2.17 ECL detection 
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2.5 STATISTICAL TREATMENT OF DATA 
 
 
Several statistical approaches were used to determine the significance of data obtained, 
including analysis of variance (ANOVA) with Dunnett’s post hoc test (ABSTAT) for cell 
viability data and 2-tailed student’s t test for the differential expression of proteins in 2-
DE gels (PD Quest).  
 
• Cell viability data 
 
Cell viability studies were carried out in 96-well culture plates. The cell cutures were 
treated with various concentrations of malathion-25 µM, 50 µM, 100 µM, 250 µM, 500 
µM, 1000 and 2000 µM of malathion. The cells in eight wells were treated with each 
concentration of malathion and the absorbance of the formazan crystals formed were 
recorded using a multi-well plate reader. The absorbance from malathion treated cells 
were calculated as percentage of absorbance from control cells (not treated with 
malathion). ANOVA with Dunnett’s post hoc test was performed to determine the 
significance of the data. 
 
• Malathion study 
 
2-DE was performed four times on whole cell lysate from control cell cultures (no 
malathion) and cell cultures treated with 100 μM malathion for 24 hours and 2 times each 
on 100 μM malathion for 48 hours, its corresponding control samples and 2 times each on 
50 μM malathion for 48 hours and the corresponding control samples. The average 
number of spots detected from the fluorescence-stained gel images using the PD Quest 
software was about 400 spots in the treated and control gels. Spot quantity was measured 
using PD Quest software. Spot quantity is the total intensity of the spot and this 
corresponds to the amount of protein in the actual spot in the gel. PD Quest software uses 
Gaussian modeling to create “ideal” spots that can be easily identified and quantified. A 
Gaussian spot is a 3-D representation of the original scanned spot and this conversion of 
the scanned image to Gaussian image is carried out because the image of a spot conforms 
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to a Gaussian curve. The formula for calculating the quantity of Gaussian spots in PD 
Quest is: 
 
yxheightspot σσπ ∗∗∗  
 
where,  
spot height is the peak of the Gaussian representation of the spot 
that is measured in optical density (OD), 
σx is the standard deviation of the Gaussian distribution of the spot 
in the direction of the X axis and  
σy is the standard deviation of the Gaussian distribution of the spot 
in the direction of the Y axis. 
 
Normalization of the spot quantity is carried out to avoid any non-expression related 
variations. The spot quantities were normalized to the total density of the gel image. In 
this normalization method, the raw quantity of each protein spot in the gel is divided by 
the total intensity of the all pixels in the image. Duplicate gels were run for 16 hour and 
48 hour treated samples and their corresponding control samples (no treatment with 
malathion) while four gels each were run for 24 hour malathion treatment and its 
corresponding control sample.  The PD Quest software was used to perform statistical 
analysis of the differential protein expression. The software allows the selection of 
various statistical tests that can be used to determine the significance of data. The 
normalized spot quantities from gels carried out for treatments and their corresponding 
control samples were subjected to student’s t test. Student’s t test determines the 
significance of difference in mean spot volumes between treated and control samples. 
The difference in spot volume was considered significant at p values <0.05 at confidence 
level of 95%.  
 
• AD CSF study 
 
A volume of 400 μL each of post mortem human ventricular CSF from 6 AD subjects and 
6 control subjects (normal) were individually subjected to crude isolation of albumin-
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interactome using Microcon cut-off filters and 2-DE was carried out on each of these 
samples. The protein spot quantities were calculated using PD Quest software, as 
described above. Similar to the malathion study, spot quantities were normalized to total 
density of the gel image. Normalized spot quantities were compared between AD and 
control subjects and statistical significance of differences in spot quantities was 
determined by Student’s t test using the PD Quest software. The difference in spot 
volume was considered significant at p values <0.05 at confidence level of 95%. 
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CHAPTER THREE 
 
A FLUORESCENT RUTHENIUM COMPLEX FOR STAINING PROTEINS 
SEPARATED BY SDS-PAGE 
 
3.1 Introduction 
 
Two-dimensional gel electrophoresis (2-DE) is a technique that involves the separation of 
complex mixtures of proteins based upon their isoelectric point and molecular weight [1]. 
2-DE is a major player in proteomics, the success of which depends on the detection 
method used to visualize and quantify proteins in the gel. A myriad of staining and 
visualization protocols are available for proteins [38-43]. Radioactive labeling is by far 
the most sensitive method of detection[44] but because of inherent problems like hazards 
involved in handling radioactive materials, limited shelf-life, waste disposal and non-
suitability for subsequent mass spectrometry analysis, it has been replaced by other dyes. 
 
 Traditional protein stains that are commonly employed include Coomassie Brilliant Blue 
R-250 (CBB R-250), colloidal Coomassie blue G-250 (CBB G-250) and silver stains. 
Coomassie brilliant blue R-250 involves easy staining and de-staining of proteins in gels 
[45, 46]. However, the major disadvantage of this dye is its low sensitivity. CBB R-250 
can detect μg to sub-μg levels of proteins [40, 47]. Therefore, either high loads of protein 
must be used or the analysis is limited to most abundant proteins. CBB R-250 is a non-
polar, sulfonated aromatic dye (Figure 3.1), a solution of which is made up in methanol 
and acetic acid, and the gel is incubated in this staining solution. Acetic acid enhances the 
ionic interaction of the dye with the basic amino acids like arginine and lysine as well as 
hydrophobic interaction with amino acids like tyrosine, tryptophan, histidine and 
phenylalanine in proteins [45]. The excess dye is removed by incubating the gel in a 
solution of methanol and acetic acid. Sensitivity is improved with the use of Coomassie 
G-250 (a dimethylated derivative of CBB R-250) (Figure 3.2, [48]). CBB G-250 interacts 
with the protein in a manner similar to CBB R-250 but it is a colloidal suspension and has 
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minimum background staining. CBB G-250 can detect 1 ng of protein; however, involves 
a number of repeated staining and de-staining steps and is laborious and time consuming.  
 
 
 
                       
 
 
 
 
Figure 3.1 Structure of Coomassie brilliant blue R-250 (CBB R-250) 
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Figure 3.2 Structure of Coomassie brilliant blue G-250 (CBB G-250) 
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Another protein stain that is commonly employed in gel electrophoresis is acidic silver 
nitrate (AgNO3). Even though silver nitrate stain has better sensitivity (down to 0.5 ng of 
protein) than CBB R-250, it generally involves multiple steps that often require freshly 
prepared reagents and critical timing that result in constant hands-on activity. Typically, 
two kinds of silver staining are used for the detection of proteins in gels: acidic silver 
nitrate and alkaline silver diamine [42]. The acidic silver nitrate staining protocol relies 
on the impregnation of the gel with silver ions and its subsequent reduction to metallic 
silver at alkaline pH using formaldehyde [47, 49]. The alkaline silver diamine involves 
the formation of soluble silver diamine complexes with the proteins and subsequent 
reduction of the silver with formaldehyde in an acidified developer [47, 49]. Silver ions 
interact with amino acids like cysteine, lysine and histidine in proteins. Silver stain has 
poor dynamic range [50]. There is also evidence of peptide losses with silver stain and 
problems in identification by mass spectrometry [51].  
 
An alternative to the use of the above mentioned colorimetric dyes is fluorescent protein 
labels. With recent developments in new imaging systems, fluorescent detection of 
proteins has re-surfaced. Fluorescent detection of proteins can be divided into two 
categories: covalent and non-covalent. In covalent labeling, proteins are derivatized with 
fluorescent compounds prior to separation by electrophoresis. A critical factor that should 
be kept in mind while using these compounds is the difference in migration of derivatized 
and un-derivatized proteins in the gel. Also, derivatization of proteins is not always 100% 
efficient, and in some cases could lead to other non-specific side reactions that can 
possibly affect interpretation of mass spectra. Non-covalent labeling, in contrast, is 
performed after electrophoresis. Here the fluorophore interacts directly with the protein 
or via SDS-protein complex non-covalently. Sypro Ruby is a ruthenium-based metal 
complex luminescent stain developed by Molecular Probes (Eugene, OR) [43]. 
Advantages of Sypro Ruby include high sensitivity and high linear dynamic range; 
however, it is highly expensive to buy commercially patented Sypro Ruby and hence not 
cost-effective. Rabilloud et al. reported the synthesis and use of Ruthenium [52] 
tris(bathophenanthroline disulfonate) [RuBPS] for detection of proteins in gels with 
minimal interference on subsequent analysis using mass spectrometry [53]. RuBPS is a 
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fluorescent ruthenium complex that can be synthesized in the lab and has been shown to 
detect proteins separated by SDS-PAGE with high sensitivity and high linear range. 
Since RuBPS can be prepared in the lab, it offers varied possibilities for modifications 
and improvements in formulation. In addition, different staining and destaining protocols 
have been reported for RuBPS [54-56]. Lamanda et al. have improved RuBPS staining 
by mainly changing the reagent concentration, pH and solvent for staining and destaining 
of the chelate.   
 
We explored the possibility of using RuBPS staining solution in our lab and proceeded to 
synthesize the ruthenium complex in-house using the Rabilloud protocol. Five hundred 
milliliter of Sypro Ruby solution can be used to stain only 2 large format gels and it is not 
advisable to re-use the stain. Considering the number of gels run in our lab on a daily 
basis, we wanted to explore cost-effective options for fluorescent staining.  
 
The goal of this project was to synthesize and optimize the formulation of a ruthenium 
complex that could be used as a cost-effective fluorescent protein stain after gel 
electrophoresis.     
 
3.2 Materials and Methods 
 
3.2a Chemicals 
 
Low range marker proteins for SDS-PAGE (Bio-Rad Labs, CA) had equal amounts of 
rabbit muscle phosphorylase B (97 kDa), bovine serum albumin (66 kDa), hen egg white 
ovalbumin (45 kDa), bovine carbonic anhydrase (31 kDa), soybean trypsin inhibitor (21 
kDa), hen egg white lysozyme (14 kDa). The silver nitrate stain (ProteoSilver Plus) was 
from Sigma (St. Louis, MO), Colloidal Coomassie Blue from Fisher Scientific (Fairlawn, 
NJ) and Sypro Ruby was obtained from Molecular probes (Eugene, OR). Other 
electrophoresis chemicals like SDS, ammonium persulfate, TEMED, acrylamide, 
bisacrylamide, tris base and glycine were purchased from Sigma (St. Louis, MO). 
Potassium pentachloro ruthenate was purchased from Alfa Aesar (Ward Hill, MA), 
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bathophenanthroline and bathophenanthroline disulfonate were purchased from GFS 
Chemicals (Columbus, OH) and the fluorescent RuMS was purchased from Biotium 
(Hayward, CA). 
 
3.2b Synthesis of Ruthenium II tris (bathophenanthroline disulfonate) (RuBPS) 
 
RuBPS (Figure 3.3) was synthesized using the protocol published by Rabilloud et al.[53]. 
Briefly, 0.089 g of potassium pentachloro aqua ruthenate (K2Cl5 Ru.H2O) was dissolved 
in 10 mL of boiling water and kept under reflux. A reddish brown solution was obtained. 
A three molar equivalent of bathophenanthroline disulfonate, disodium salt (0.4 g) was 
added to the solution and refluxing was continued for about 20 min till the solution 
turned deep greenish brown. A reducing solution of 8 mM sodium ascorbate dissolved in 
10 mL of water was prepared and added to the solution and refluxing was continued for 
another 20 min until the solution turned orange brown. After cooling, the pH was 
adjusted to 7 with sodium hydroxide and the volume was adjusted to 50 mL with absolute 
alcohol. The final concentration of the stock solution was approximately 500 μM. 
 
3.2c Synthesis of Ruthenium II (bis (bathophenanthroline disulfonate) 
(bathophenanthroline)) (RuDS) 
 
RuDS (Figure 3.4) was synthesized similar to RuBPS as described in the previous 
section. However, 2 molar equivalents of bathophenanthroline disulfonate disodium salt 
(0.2684 g) and one molar equivalent of bathophenanthroline (0.0833 g) were mixed with 
0.089 g of ruthenium salt, refluxed and the synthesis continued as explained in the 
previous section. The concentration of RuDS solution is 500 μM. 
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Figure 3.3 Structure of Ruthenium II tris (bathophenanthroline disulfonate) (RuBPS)  
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Figure 3.4 Structure of Ruthenium II (bis (bathophenanthroline disulfonate) 
(bathophenanthroline)) (RuDS) 
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3.2d Synthesis of Ruthenium II (bis (bathophenanthroline) (bathophenanthroline 
disulfonate)) (RuMS) 
 
The fluorescent ruthenium chelate RuMS (Figure 3.5) was synthesized as described 
previously [53] with slight modifications. A 0.089 g of potassium pentachloro aqua 
ruthenate (K2Cl5 Ru.H2O) was dissolved in 10 mL of boiling water and kept under reflux. 
A reddish brown solution was obtained. One molar equivalent of bathophenanthroline 
disulfonate, disodium salt (0.1342 g) and 2 molar equivalents of bathophenanthroline 
(0.1666 g) were added and refluxing was continued for another 20 min until the solution 
turned deep greenish brown. A reducing solution of 8 mM sodium ascorbate dissolved in 
10 mL of water was added to the refluxing solution and refluxing was continued for 
another 20 min until the solution turned orange brown. After cooling, the pH was 
adjusted to 7 with sodium hydroxide and volume adjusted to 50 mL with absolute 
alcohol. The final concentration of stock solution was approximately 500 μM. 
 
3.2e 1D gel electrophoresis 
 
Proteins that make up the low range molecular weight markers from Bio-Rad were 
separated by SDS-PAGE in the standard Laemmeli Tris-glycine system [13]. The 
molecular weight markers were diluted 100 and 2000 fold in SDS sample buffer to reach 
a concentration of 20 and 1 ng/μL respectively for each protein in the mixture. The 
required volumes were loaded on top of a 12% separating and 4% stacking mini 
polyacrylamide gel (7 cm) to give appropriate amounts of each protein band ranging from 
100 ng to 0.5 ng. The running buffer contained 25 mM Tris, 192 mM glycine and 0.1% 
SDS, pH 8.3 and electrophoresis was performed at constant 150 V until the dye front 
reached the bottom of the gel.  
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Figure 3.5 Structure of Ruthenium II (bis (bathophenanthroline) (bathophenanthroline 
disulfonate)) (RuMS) 
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3.2f Characterization of in-house synthesized ruthenium complexes 
 
• Fluorescence spectroscopy 
 
Excitation and emission spectra of RuMS was obtained using Spex 1681 0.22 m 
spectrofluorometer. Emission wavelength was set to 610 nm and excitation spectrum was 
collected from 250 to 550 nm. For the emission spectrum, the excitation wavelength was 
set to 470 nm and the spectrum was collected from 500 to 750 nm.  
 
• MALDI-TOF mass spectrometry 
 
Both MALDI and laser desoprtion mass spectra were generated for the in-house 
synthesized ruthenium complexes using the Bruker Autoflex time-of-flight mass 
spectrometer (Billerica, MA). For MALDI spectra, a solution of 1 μL HCCA (10 mg/mL 
of α-cyano-4-hydroxycinnamic acid in 90% acetone and 2% TFA) was spotted on a 
sample target. A volume of 0.2 μL stock ruthenium complex solution was spotted on the 
matrix spot, allowed to air dry and spectra were acquired.   
 
• Paper chromatography 
 
Paper chromatography was carried out on a Whatmann filter paper with various 
percentages of solvents like tetrahydrofuran, water and ethanol as solvents. Two 
microliter of the in-house synthesized ruthenium complexes were spotted about 1 cm 
above the base of the paper and separation carried out in a closed chamber until the 
solvent front traveled about three fourths of the distance on the paper.  
 
• Crystallization   
 
Crystallization of in-house synthesized ruthenium complexes was carried out to obtain X-
ray crystallography data on these different complexes. Various percentages of solvents 
like ethanol, isopropyl alcohol and THF were tried for this purpose.   
 
                                                                          66  
3.2g Staining of mini gels 
 
• Colloidal Coomassie blue stain 
 
Colloidal Coomassie blue staining of SDS-PAGE gels were performed as described by 
Neuhoff et al. [48]. Briefly, gels were fixed with 50 mL of aqueous solution containing 
1.3% (w/v) of ortho phosphoric acid and 20% (v/v) methanol for 1 hour. Staining 
solution was prepared by mixing 1 mL of freshly prepared staining solution B (containing 
aqueous 5% (w/v) Coomassie brilliant Blue G-250) and 40 mL of aqueous staining 
solution A (containing 2% w/v of ortho phosphoric acid, 10% w/v ammonium sulfate) 
with 10 mL of methanol. The gels were stained overnight in the staining solution. The 
next day, gels were transferred into a neutralization buffer containing aqueous 0.1 M 
Tris-base pH 6.5 (titrated with ortho phosphoric acid) for 2 min. The background was 
then washed with 25% methanol solution for less than 1 min and gels were transferred 
into an aqueous stabilizing solution containing 20% ammonium sulfate. The gels stay in 
the stabilization solution for a day and further staining was carried out as mentioned 
above without the fixing step. Staining was repeated three times which improved 
sensitivity and at the end of the third staining step about 0.5 ng of protein was detected. 
The volumes mentioned here are for one gel.  
 
• Silver stain 
 
Silver staining was performed using Pierce Proteosilver Plus kit (Rockford, IL). Staining 
was carried out as per manufacturer’s instruction. Briefly, the gels were fixed in 50% 
ethanol and 10% acetic acid solution overnight. Thenthe gels were washed with 30% 
ethanol for 10 min, decanted the ethanol solution and washed with ultra pure water for 10 
min. The gels were incubated in the sensitizing solution (500 μL of Proteosilver 
Sensitizer in 50 mL ultra pure water) for about 10 min. Gels were washed twice with 
water for 10 min each and then incubated in silver solution (500 μL of Proteosilver Silver 
in 50 mL ultra pure water). After a brief wash in water, the gels were developed in the 
developer solution (2.5 mL of Proteosilver developer and 50 μL developer 2 in 50 mL of 
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ultrapure water) until desired staining is achieved and 2.5 mL of Proteosilver stop 
solution was added to this developer solution to stop the reaction and incubated the gel in 
this solution for about 5 min. Carbon dioxide formed was seen as bubbles in the solution. 
The solution was discarded and the gels were incubated in ultrapure water for about 15 
min. The gels were stored in pure water. All solutions were prepared freshly before use. 
Silver nitrate binds to proteins (amino acids- cysteine, lysine and histidine) in the gel 
under weakly acidic pH. The silver ions bound to proteins are reduced by formaldehyde 
at alkaline pH to form metallic silver which gives the protein black to dark brown color 
the intensity of which depends on the concentration of protein present.  
 
• Sypro Ruby staining 
 
Gels were stained with Sypro Ruby per manufacturer’s instructions [43]. Briefly, gels 
were incubated in the Sypro Ruby solution overnight. The volume of staining solution 
used is about 50 mL per mini gel, which is roughly 10 times the volume of the gel. After 
staining, gels were rinsed in 10% methanol and 7% acetic acid for at least 30 min to 
remove residual dye and then stored in fresh pure water.  
 
• Ruthenium II tris (bathophenanthroline disulfonate) staining 
 
Staining and destaining for RuBPS was performed using the most recent modified 
protocol [56]. Briefly, proteins in the gel were fixed using 30% ethanol and 10% acetic 
acid solution overnight. The gels were washed with 20% ethanol three times 30 min each 
and then incubated in 150 nM (15 μL in 50 mL of 20% ethanol) staining solution for 6 
hours. The gels were equilibrated with water for about 10 min and then background stain 
was removed by washing in destaining solution containing 40% ethanol and 10% acetic 
acid overnight. The gels were then washed in water for 10 min and scanned. 
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• Ruthenium II (bis (bathophenanthroline disulfonate)) (bathophenathroline) 
staining (RuDS) 
 
Staining of gels with the RuDS form of the ruthenium complex was performed similar to 
RuBPS staining protocol with some modifications. Gels were fixed overnight with 30% 
ethanol and 10% glacial acetic acid and washed with 20% ethanol solution three times 30 
min each time. Gels were incubated in staining solution containing 150 nM of RuDS in 
20% ethanol (15 μL of the stock in 50 mL of 20% ethanol) overnight, quickly rinsed with 
water and then destained with 10% ethanol and 5% acetic acid till desired intensity was 
obtained and the gel was scanned.  
 
• Ruthenium II (bis (bathophenanthroline) (bathophenanthroline disulfonate)) 
staining (RuMS) 
 
Various solvents were tested for optimal staining of proteins with RuMS. The protocol 
that gave best signal to noise ratio is described here. Briefly, RuBPS staining and 
destaining protocol [53] was used with slight modification. The gels were fixed overnight 
with 30% v/v ethanol and 10% v/v acetic acid. The gels were then rinsed with 20% 
ethanol three times 30 min each and incubated in staining solution overnight in 20% 
ethanol containing 150 nM of the ruthenium chelate (15 μL of stock solution in 50 mL 
20% ethanol). Gels were washed for at least 15 min with water. Stained gels were stored 
in pure water.  
 
• Commercial RuMS staining 
 
A stock staining solution of 16 μM of commercial source of RuMS was prepared by 
dissolving 1 mg of the fluorescent compound in 50 mL of absolute alcohol. An aliquot of 
the stock staining solution (4 mL in 20% ethanol – 125nM) was used to stain proteins in 
gels. 
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3.2h Imaging of stained gels 
 
Stained gels were scanned with a Versadoc 3000 scanner from Bio-Rad (Hercules, CA). 
Sypro Ruby and ruthenium chelate stained gels were visualized using 520 nm emission 
filter and UV light. CBB G-250 and silver stained gels were visualized on a white light 
background using a 610 nm emission filter. Exposure time for Sypro Ruby and ruthenium 
complex stained gels were 2.5 sec while for colloidal Coomassie and silver exposure time 
was 0.5 sec. Images were analyzed by Quantity One software. Band volumes were 
estimated after applying global background correction. The images were taken under 
essentially identical settings and with the same instrumentation to enable direct 
comparison.    
 
3.2i In-gel proteolysis 
 
Protein bands were excised from the gel using the Spot-cutter from Bio-Rad and in-gel 
proteolysis was carried out with trypsin. In brief, the gel pieces were washed 6 times 
alternating with 50 mM NH4HCO3  and 1:1 ACN: NH4HCO3 (50 mM) for 5 min each at 
20°C and dried with ACN for 10 min at 20°C. A volume of 10 μL of trypsin (66.67 ng) in 
25 mM NH4HCO3 was added and gel pieces allowed to swell for 30 min at 20°C and 
digested at 50°C for 4 hours. Peptides were extracted with 10 μL of 1% aq. formic acid at 
20°C for 30 min. 
 
3.2j In-gel trypsin digestion of proteins from silver stained gels 
 
Trypsin digestion of proteins from silver stained gels was performed as described by 
Mann et al. [57] with slight modifications. In short, all pre-washing steps were omitted. 
The gels plugs were excised and shrunk with acetonitrile and dried in a vacuum 
centrifuge. A volume of 10 mM dithiothreitol (DTT) in 50 mM NH4HCO3 sufficient 
enough to cover the gels pieces was added and incubated at 56°C for 1 hour. After 
cooling the samples to room temperature, 55 mM iodoacetamide in 50 mM NH4HCO3 
was added and incubated at room temperature for 45 min in the dark. The gel pieces were 
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then washed with 50 mM NH4HCO3 for 10 min, dehydrated with acetonitrile. Ten μL of 
trypsin (66.67 ng) in 25 mM NH4HCO3 was added and gel pieces allowed to swell for 30 
min at 20°C and digested at 37°C overnight. Peptides were extracted with one change of 
25 mM NH4HCO3  and three changes of 5% formic acid in 50% acetonitrile at room 
temperature for 20 min each time and dried down.  
 
3.2k MALDI-TOF mass spectrometry 
 
MALDI-TOF mass spectra were generated using Bruker Autoflex (Billerica, MA) in the 
reflectron mode. HCCA matrix solution was spotted on an Anchorchip target and 1.5 μL 
of peptide solution was spotted on top of the matrix and allowed to dry. On-target 
washing was carried out with 0.2% TFA. The spectra were externally calibrated against 
the monoisotopic mass of a standard solution containing 1 µg/µL bradykinin ([M+H]+  
757.399), vasopressin ([M+H]+ 1084.445), angiotension II ([M+H]+1046.542), substance 
P ([M+H]+ 1347.735) and oxidized form of substance P ([M+H]+ 1363.731) and 
internally calibrated using the known trypsin autolysis peaks. Database search was 
performed using the Mascot software (www.matrixscience.com). 
 
3.2l Liquid Chromatography-Tandem Mass spectrometry  
 
The trypsin digested samples were analyzed using a Thermo Corporation’s LCQ Classic 
quadrupole ion trap mass spectrometer (San Jose, CA). The tryptic peptides were 
resolved on a fused silica capillary column. The column was fabricated in-house by 
packing 15 cm of Phenomenex Polymer X (3 μm particle size) into a 320 μm I.D fused 
silica capillary using a home-made stainless steel packing cell pressurized with helium to 
1000 psi. The tryptic peptides were eluted using a typical gradient elution. Spectra were 
acquired with a probe spray voltage of 4 kV and a heated capillary temperature of 175ºC.  
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3.3 Results 
 
3.3a Characterization of ruthenium complexes 
 
• Fluorescence spectroscopy 
 
Excitation and emission spectra of the ruthenium complex RuMS synthesized in the lab 
were recorded using a Spex 1681 spectrofluorometer (Figure 3.6). There are two 
absorption peaks for the complex similar to Sypro Ruby, one at ~280 nm and a broad one 
at ~450 nm. The fluorescence emission spectrum has one broad peak at 610nm.  
 
• MALDI-TOF mass spectrometry 
 
Mass spectrometry was employed to characterize the in-house synthesized ruthenium 
complexes. The base peak observed in all the spectra obtained for the various ruthenium 
complexes is an m/z of 766 (Figure 3.7-3.9). Table 3.1 gives the different mass peaks that 
were observed in the MALDI-TOF spectra for various in-house synthesized ruthenium 
complexes.  
 
• Paper chromatography 
 
The highly polar nature of sulfonic acid groups in the ruthenium complexes makes it 
difficult to separate the complexes using thin layer chromatography (TLC). Since the 
silanol groups in silica gel are also polar, the polar complex binds tightly to the solid 
phase and will not move much with the mobile phase. Under such circumstance, paper 
chromatography is a better option to resolve the polar complexes. Table 3.2 summarizes 
the chromatographic data for these compounds. 
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Figure 3.6 Excitation (A) and Emission (B) spectra of in-house RuMS 
 
 
 
 
 
 
Em = 610 nm 
Ex = 470 nm 
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Table 3.1 Peaks observed in MALDI-TOF mass spectrum of different ruthenium 
complexes synthesized in-house. x – indicates ion not observed while  - indicates observation of 
the ion in the mass spectrum  
 
 
Form of Complex 
 
 
 
 
Peaks 
(m/z) 
 
 
RuNS 
(all 
nonsulfonated 
ligand) 
 
 
RuMS 
 
RuDS 
 
RuBPS 
 
 
 
 
Probable ion 
 
 
457.96 
 
x 
 
x 
 
x 
 
 
(base peak) 
 
Found in sulfonated ligand mass 
spectrum 
 
766.05 
 
 
 
(base peak) 
 
 
(base peak) 
 
 
(base peak) 
 
x 
 
Ruthenium attached to two 
bathophenanthrolines 
 
 
801.02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ruthenium attached to two 
bathophenanthrolines and a Cl  
 
 
817.49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
Very small amount found in non 
sulfonated ligand mass spectrum 
 
 
1098 
 
 
 
 
 
 
 
 
x 
 
x 
 
Ruthenium + three bathophenanthroline 
 
 
1113 
 
 
 
 
 
 
 
 
 
 
 
x 
 
Very small amount found in the non-
sulfonated ligand 
 
 
1194 
 
 
x 
 
 
 
 
 
 
 
 
 
 
Ruthenium MS minus a SO3 
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Figure 3.7 MALDI-TOF spectrum of ruthenium tris bathophenanthroline using HCCA matrix. Inset A is expanded mass range from 
750-850 m/z and inset B is expanded mass range from 1080-1150 m/z   
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Figure 3.8 MALDI-TOF spectra of in-house synthesized RuMS complexes using HCCA matrix. Inset A is expanded mass range 
from 750-850 m/z and inset B is expanded mass range from 1080-1150 m/z   
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Figure 3.9 MALDI-TOF spectra of in-house synthesized RuDS complexes using HCCA matrix. Inset A is expanded mass range 
from 750-850 m/z and inset B is expanded mass range from 1080-1150 m/z   
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Figure 3.10 MALDI-TOF spectra of in-house synthesized RuBPS complexes using HCCA matrix.   
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 Table3.2. Summary of chromatographic data for various in-house synthesized ruthenium 
complexes. 
 
 
Rf values (distance traveled by the component/distance 
traveled by the solvent) 
 
Compound 
Water 50:50 water: THF 
In-house RuMS 0.42, 0 0.16, 0.33 
RuDS 0.42, 1 0.66, 0.83 
RuBPS 0.42, 1 0.66, 0.83 
Commercial RuMS 0.42 1.0 
 
 
3.3b Staining efficiency of various ruthenium complexes synthesized in-house  
 
A comparison of the effectiveness of three different in-house synthesized ruthenium 
complexes showed that RuMS form worked best by detecting 0.5-1 ng of protein (Figure 
3.11). Sensitivity of the RuBPS was only about 5 ng of protein. 
 
3.3c Optimization of in-house RuMS stain 
 
A critical parameter for successful staining of proteins is the formulation of the stain in a 
suitable solvent. Various solvents like ethanol, methanol and isopropyl alcohol were used 
as solvent for the formulation of RuMS (Figure 3.12, 3.13). The concentration of RuMS 
in the working solution was also optimized (Figure 3.14). Desired staining of proteins 
with minimal background was obtained with 150 nM RuMS in 20% ethanol solution. 
When solvent other than ethanol was used or when greater concentration of ethanol was 
used in the formulation, there was increased background staining due to non-specific 
binding of the stain to the polyacrylamide matrix. 
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Figure 3.11 Serial dilutions of standard low range marker proteins stained with in-house 
synthesized ruthenium complexes.The amount of protein indicated is nanogram of each 
low-range marker protein.   
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A 
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Figure 3.12 Optimization of solvent for staining proteins with in-house synthesized 
RuMS. (A) 20% methanol, (B) 20% ethanol and (C) 20% isopropyl alcohol. The amount 
of protein indicated is nanogram of each low-range marker protein.   
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Figure 3.13 Optimization of ethanol composition for in-house RuMS staining solution. 
(A) 20% ethanol and (B) 50% ethanol. The amount of protein indicated is nanogram of 
each low-range marker protein.   
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Figure 3.14 Optimization of concentration of in-house RuMS in the staining solution. 
(A) 150 nM RuMS and (B) 200 nM RuMS. The amount of protein indicated is nanogram 
of each low-range marker protein.   
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3.3d Optimization of commercial RuMS stain  
 
Commercial RuMS was purchased from Biotium (Hayward, CA) and used to stain 
proteins in gels. Figure 3.15 and 3.16 show the gel images for the optimization of solvent 
for commercial RuMS stain. Figure 3.17 is the gel image for the optimization of 
concentration of RuMS in the staining solution. The commercial RuMS staining was 
compared to the in-house synthesized RuMS stained gel (Figure 3.18).  
 
 
 
 
 
 
Figure 3.15 Optimization of solvent composition for commercial RuMS staining 
solution. Different solvents were used to stain the gels (A) 50% aq. ethanol, (B) 50% aq. 
isopropyl alcohol. The amount of protein indicated is nanogram of each low-range 
marker protein.   
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Figure 3.16 Optimization of solvent composition for commercial RuMS staining 
solution. Different solvents were used to stain the gels (A) 20% aq. ethanol and (B) 20% 
aq. isopropyl alcohol. 20% aq. ethanol gave the maximum sensitivity with least 
background staining. The amount of protein indicated is nanogram of each low-range 
marker protein.   
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Figure 3.17 Optimization of concentration of commercial RuMS in the staining solution. 
(A) 62.5 nM (B) 125 nM and (C) 250 nM of commercial RuMS in staining solution. The 
amount of protein indicated is nanogram of each low-range marker protein.   
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Figure 3.18 Comparison in staining between in-house synthesized RuMS and 
commercial RuMS. The amount of protein indicated is nanogram of each low-range 
marker protein.   
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3.3e Sensitivity of various staining solutions 
 
To assess the staining sensitivity of silver, colloidal coomassie, Sypro Ruby and in-house 
ruthenium II (bis (bathophenanthroline) (bathophenanthroline disulfonate)), serial 
dilutions of the low range molecular weight markers from 100 to 0.5 ng per lane was 
separated by SDS-PAGE. A batch of three gels was run for each stain and all 12 gels 
were run to the same pattern. Figure 3.19 gives the representative gels stained with 
colloidal Coomassie, silver, commercial Sypro Ruby and in-lab made ruthenium 
complex.  
 
3.3f Linear dynamic range 
 
To compare the linearity in staining of standard proteins between different stains, the 
volume of the protein band which represented the total pixel density of each band with 
the background density removed were measured using Quantity One imaging software 
and exported to Microsoft Excel (Table 3.3, Figure 3.20 and 3.21). The band volumes for 
5 ng of standard proteins were normalized to values from Sypro ruby stained gel and the 
histogram plotted to compare sensitivity of the different stains (Figure 3.22).  
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Figure 3.19 Representative gels stained with colloidal CCB G250 (A), Silver nitrate (B), 
in-house synthesized RuMS (C) and Sypro Ruby (D). The amount of protein indicated is 
nanogram of each low-range marker protein.   
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Figure 3.20 Linearity of staining of standard proteins using colloidal Coomassie (A) and 
silver (B). Key for proteins ( ) phosphorylase B; ( ) bovine serum albumin; ( ) 
ovalbumin; ( ) carbonic anhydrase; ( ) trypsin inhibitor; ( ) lysozyme 
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Figure 3.21 Linearity of staining of standard proteins using in-house RuMS (a) and 
Sypro Ruby (b). Key for proteins ( ) phosphorylase B; ( ) bovine serum albumin; ( ) 
ovalbumin; ( ) carbonic anhydrase; ( ) trypsin inhibitor; ( ) lysozyme 
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Table 3.3 Band volumes for different loads of standard proteins in gels stained with 
different staining solutions 
 
  Protein band volume ± standard deviation  
(intensity units/ mm2) 
 
  
Amount  
of 
 protein  
loaded 
(ng) 
 
 
Phosphorylase 
 
 
 
BSA 
 
 
 
Ovalbumin 
 
 
 
Carbonic 
anhydrase 
 
 
 
Trypsin  
Inhibitor 
 
 
 
Lysozyme 
100 1550 ± 8.9 1690 ± 9.3 1581 ± 9.8 1756 ± 8.1 2089 ± 18 1818 ± 12 
50 1337 ± 10 1470 ± 7.5 1401 ± 9.7 1585 ± 9.0 1760 ± 13 1640 ± 16 
25 1198 ± 12 1298 ± 4.1 1269 ± 9.0 1403 ± 9.4 1497 ± 18 1336 ± 15 
10 1076 ± 8 1172 ± 5.4 1137 ± 9.2 1306± 6.5 1352 ± 17 1228 ± 11 
5 1010 ± 6 1132 ± 1.4 1108 ± 8.4 1260 ± 4.1 1277 ± 17 1170 ± 12 
1 1001 ± 6 1070 ± 5.6 1098 ± 4.3 1204 ± 2.1 1191 ± 16 1114 ± 12 
 
 
 
Silver 
½ 991 ± 6 1095 ± 0.33 1066 ± 4.4 1194 ± 3.0 1045 ± 23 1086 ± 11 
100 1345 ± 11  1432± 8.70 1036 ± 10 1573 ± 7.5 1880 ±0.9 1167 ± 13 
50 1053 ± 10 1160 ± 10 860 ± 11 1293 ± 9.5 1401 ±8.0 854 ± 13 
25 905 ± 16 1006 ± 12 771 ± 12 1132 ± 10 1185 ± 12 697 ± 16 
10 816 ± 16 902 ± 13 723 ± 13 1029 ± 17 1000 ±8.9 553 ± 14 
5 748 ± 18 848 ± 13 676 ± 18 961 ± 16 877 ± 6.4 N/A 
1 675 ± 22 756 ± 14 N/A 871 ± 11 783 ± 7.6 N/A 
 
 
 
CCB G250 
½ 656 ± 22 720 ± 15 N/A 741 ± 7.5 717 ± 4.6 N/A 
100 683 ± 2.0 848 ± 1.5 652 ± 3.4 581 ± 2.9 1175 ±1.0 502 ± 2.2 
50 452 ± 2.4 503 ± 3.7 427 ± 1.9 360 ± 3.1 662 ± 2.2 332 ± 3.0 
25 335 ± 3.6 340 ± 3.8 323 ± 4.9 246 ± 3.3 451 ± 4.0 257 ± 4.3 
10 269 ± 4.8 234 ± 4.7 243 ± 4.5 204 ± 1.5 283 ± 2.5 203 ± 1.5 
5 236 ± 5.1 140 ± 0.71 186 ± 1.6 186 ± 5.4 199 ± 4.5 155 ± 7.7 
1 176 ± 3.4 124 ± 4.0 145 ± 6.2 157 ± 4.5 136 ± 7.4 142 ± 11 
 
 
 
Sypro 
Ruby 
½ 156 ± 5.1 105 ± 2.6 110 ± 1.8 119 ± 5.1 113 ± .88 113 ± 1.8 
100 321 ± 3.6  371 ± 1.7 415 ± 3.4 358 ± 2.4 525 ± 1.6 339 ± 3.8 
50 262 ± 3.3 294 ± 2.8 345 ± 3.4 285 ± 4.1 392 ± 3.0 274 ± 3.6 
25 233 ± 5.1 249 ± 2.3 285 ± 4.3 257 ± 2.1 318 ± 1.2 238 ± 4.6 
10 222 ± 3.5 224 ± 1.7 265 ± 4.0 228 ± 2.9 282 ± 1.6 212 ± 2.5 
5 210 ± 2.0 219 ± 1.4 256 ± 2.1 219 ± 1.6 255 ± 5.0 198 ± 4.4 
1 201 ± 1.1 206 ± 5.5 243 ± 4.1 206 ± 3.0 223 ± 4.7 191 ± 3.8 
 
 
 
RuMS 
½ 195 ± 2.0 194 ± 2.7 242 ± 4.5 205 ± 3.8 202 ± 3.3 184 ± 2.8 
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Figure 3.22 Histogram of normalized band volume for 5 ng of standard proteins (Phos-
phoshorylase A, BSA- bovine serum albumin, Oval- ovalbumin, CA- carbonic anhydrase, 
Tryp- trypsin inhibitor and Lyso- lysozyme) in gel stained with different stains.   
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3.3g Compatibility with mass spectrometry 
 
Improved detection of protein alone is not sufficient for successful proteomic studies. 
The stain must be compatible with subsequent protein identification by mass 
spectrometry. To evaluate the compatibility of different stains with mass spectrometry, 
gels plugs were harvested and in-gel proteolysis was carried out with trypsin. The 
resulting tryptic peptides were subjected to both matrix assisted laser desorption 
ionization (MALDI-TOF) and liquid chromatography tandem mass spectrometry (LC-
MS/MS). 
 
• Stain compatibility with MALDI-TOF 
 
Tryptic peptides were subjected to MALDI-MS as described earlier. A representative 
peptide mass fingerprint (PMF) analysis for all the 100 ng BSA protein is shown in figure 
3.23. The summarized MALDI data from all the trypsin-digested proteins is provided in 
table 3.4 
 
• Stain compatibility with LC-MS/MS 
 
Data dependent MS/MS experiments were performed on a Thermo LCQ Classic 
quadrupole ion trap mass spectrometer. Mass spectra were searched against the human 
sub database from the Swiss-Prot database using Mascot algorithm. One missed trypsin 
cleavage was allowed and a variable modification of oxidation of methionine was set. 
Peptide tolerance and MS/MS tolerance were both set at ± 0.8 Da. Representative spectra 
are shown in figure 3.24. Table 3.5 summarizes the LC-MS/MS data for all the trypsin- 
digested samples. 
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Figure 3.23 MALDI-TOF spectra for 100 ng of bovine serum albumin from gels stained 
with different stains.  
 
 
 
1479.947
927.481
1567.958987.488
1439.933 1640.191 1900.305
0
200
400
600
800
1000
1200
Intensity. 
[a.u.] 
1000 1200 1400 1600 1800 m/z
1479.632
927.497 
1439.681
1639.637
1305.680 
1249.572 1163.561 1900.3280 
200 
400 
600 
800 
1000 1200 1400 1600 1800 m/z
1640.114
927.451 
977.382 
1001.558
1193.679 
1479.963
0 
50  
100 
150 
200 
1000 1200 1400 1600 1800 m/z
1400.871 
1141.922 
0
200
400
600
Intensity
 [a.u.] 
1000 1200 1400 1600 1800 m/z
Intensity 
[a.u.] 
Coomassie G250 Silver nitrate 
Sypro Ruby In-house RuMS 
Intensity 
[a.u.] 
 
                                                                          95   
Table 3.4 Summary of MALDI-TOF data for different protein loads of standard proteins (BSA- bovine serum albumin and 
trypsin inhibitor)  in gel stained with various stains- CCB G250- colloidal coomassie, silver nitrate, Sypro Ruby and in-house 
RuMS.   
 
Stain 
 
Protein 
 
ng of 
protein 
 
# of  
peptides 
detected  
 
Database  
match 
 
Mowse 
score 
 
%  
Coverage 
 
 
Sequence of matched  peptides 
 
100 
 
7 
 
yes 
 
92 
 
11 
IETMREK (M-oxidized), YLYEIAR,NECFLSHK, 
ALKAWSVAR, DTHKSEIAHR, LGEYGFQNALIVR 
 
50 
 
4 
 
no 
 
55 
 
n/a 
YLYEIAR, DTHKSEIAHR, LGEYGFQNALIVR,  
KVPQVSTPTLVEVSR 
 
25 
 
 
3 
 
no 
 
40 
 
n/a 
YLYEIAR, LGEYGFQNALIVR,  
KVPQVSTPTLVEVSR 
 
10 
 
 
2 
 
no 
 
28 
 
n/a 
QNCDQFEK,  
NYQEAKDAFLGSFLYEYSR 
 
 
 
 
 
 
BSA 
5 0 no n/a n/a n/a 
 
100 
 
4 
 
yes 
 
77 
 
22 
GIGTIISSPYR, NKPLVVQFQK,  
VSDDEFNNYK, 
 AAPTGNERCPLTVVQSR 
 
50 
 
3 
 
yes 
 
57 
 
13 
AAPTGNER, GIGTIISSPYR, 
 FIAEGHPLSLK 
 
25 
 
5 
 
yes 
 
95 
 
15 
AAPTGNER, GIGTIISSPYR,  
NKPLVVQFQK,  
GIGTIISSPYRIR, NKPLVVQFQKLDK 
10 0 no n/a n/a n/a 
 
 
 
 
 
 
 
 
 
 
 
CCB 
 G250 
 
 
 
 
Trypsin 
inhibitor 
5 2 no 38 n/a GIGTIISSPYR, NKPLVVQFQK 
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Stain 
 
Protein 
 
ng of  
protein 
 
# of 
peptides  
detected 
 
Database  
match 
 
Mowse 
score 
 
%  
Coverage 
 
Sequence of matched  peptides 
 
100 
 
3 
 
no 
 
40 
 
n/a 
 
TVMENFVAFVDK, LSQKFPK, KQTALVELLK 
 
50 
 
0 
 
no 
 
n/a 
 
n/a 
 
n/a 
 
25 
 
0 
 
no 
 
n/a 
 
n/a 
 
n/a 
 
10 
 
2 
 
no 
 
27 
 
n/a 
 
TVMENFVAFVDK, LCVLHEK 
 
5 
 
 
3 
 
no 
 
40 
 
n/a 
 
LRCASIQK, LUVSTQTALA, CCTESLVNR 
 
 
 
 
 
 
 
 
BSA 
 
1 
 
0 
 
no 
 
n/a 
 
n/a 
 
n/a 
 
 
100 
 
 
8 
 
 
yes 
 
 
134 
 
 
26 
AAPTGNER, NELDKGIGTIISSPYR, GIGTIISSPYR, 
IGENKDAMDGWFR,IGENKDAMDGWFR (M-oxidized), 
 DAMDGWFR, VSDDEFNNYK, NKPLVVQFQK 
 
50 
 
5 
 
yes 
 
76 
 
14 
AAPTGNER, GIGTIISSPYR, IGENKDAMDGWFR, 
DAMDGWFR,DAMDGWFR (M-oxidized) 
 
 
25 
 
 
8 
 
 
yes 
 
 
115 
 
 
21 
AAPTGNER, NELDKGIGTIISSPYR, GIGTIISSPYR, 
 IGENKDAMDGWFR,IGENKDAMDGWFR (M-oxidized), 
 DAMDGWFR,DAMDGWFR (M-oxidized), 
 NKPLVVQFQK 
 
10 
 
0 
 
no 
 
n/a 
 
n/a 
 
n/a 
5 0 no n/a n/a n/a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acidic 
Silver 
nitrate  
 
 
 
 
 
 
 
 
Trypsin inhibitor 
1 0 no n/a n/a n/a 
 
                                                                          97   
 
Stain 
 
Protein 
 
ng of  
protein 
 
# of 
peptides  
detected 
 
Database  
match 
 
Mowse 
score 
 
%  
Coverage 
 
Sequence of matched  peptides 
 
 
100 
 
 
7 
 
 
yes 
 
 
98 
 
 
12 
FKDLGEEHFK, LVNELTEFAK, YLYEIAR, 
DAFLGSFLYEYSR,RHPEYAVSVLLR, 
HLVDEPQNLIK, LGEYGFQNALIVR 
 
 
50 
 
 
8 
 
 
yes 
 
 
104 
 
 
14 
FKDLGEEHFK, LVNELTEFAK,  
YLYEIAR, DAFLGSFLYEYSR,  
RHPEYAVSVLLR,HLVDEPQNLIK, 
 LGEYGFQNALIVR, KVPQVSTPTLVEVSR 
 
25 
 
6 
 
yes 
 
84 
 
10 
FKDLGEEHFK, LVNELTEFAK,  
YLYEIAR, RHPEYAVSVLLR, 
HLVDEPQNLIK, LGEYGFQNALIVR 
10 0 no n/a n/a n/a 
 
 
 
 
 
 
BSA 
5 0 no n/a n/a n/a 
 
100 
 
3 
 
yes 
 
57 
13 AAPTGNER, GIGTIISSPYR,  
FIAEGHPLSLK 
 
50 
 
3 
 
yes 
 
57 
 
13 
AAPTGNER, GIGTIISSPYR,  
NKPLVVQFQK 
 
25 
 
5 
 
yes 
 
95 
 
21 
KNHGLSR, AAPTGNER,  
GIGTIISSPYR, FIAEGHPLSLK, CPLTVVQSR 
 
10 
 
5 
 
yes 
 
95 
 
23 
AAPTGNER, GIGTIISSPYR,  
NKPLVVQFQK, FIAEGHPLSLK, 
 VSDDEFNNYK 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sypro 
Ruby 
 
 
 
 
 
Trypsin 
inhibitor 
5 0 no n/a n/a n/a 
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Stain 
 
Protein 
 
ng of  
protein 
 
# of 
peptides  
detected 
 
Database  
match 
 
Mowse 
score 
 
%  
Coverage 
 
Sequence of matched  peptides 
 
 
100 
 
 
8 
 
 
yes 
 
 
113 
 
 
14 
YLYEIAR, SEIAHRFK,TPVSEKVTK, 
RHPEYAVSVLLR,LGEYGFQNALIVR, 
DAFLGSFLYEYSRKVPQVSTPTLVEVSR, 
LGEYGFQNALIVRYTR 
 
 
 
50 
 
 
 
9 
 
 
 
yes 
 
 
 
130 
 
 
 
14 
YLYEIAR, LVNELTEFAK,  FKDLGEEHFK, 
AFLGSFLYEYSR,  DTHKSEIAHR, RHPEYAVSVLLR,  
LGEYGFQNALIVR,KVPQVSTPTLVEVSR, 
HLVDEPQNLIKQNCDQFEK 
 
25 
 
5 
 
yes 
 
72 
 
17 
YLYEIAR, RHPEYAVSVLLR, LGEYGFQNALIVR, 
DAFLGSFLYEYSR,KVPQVSTPTLVEVSR 
 
10 
 
3 
 
no 
 
43 
 
n/a 
DTHKSEIAHR, HKPKATEEQLK, 
 DDPHACYSTVFDK 
 
 
 
 
 
BSA 
5 1 no 15 n/a LCVLHEK 
 
 
 
100 
 
 
 
7 
 
 
 
yes 
 
 
 
134 
 
 
 
26 
AAPTGNER, DAMDGWFR 
 (M-Oxidized), GIGTIISSPYR, FIAEGHPLSLK, 
NKPLVVQFQK, IGENKDAMDGWFR (M-Oxidized), 
 NELDKGIGTIISSPYR 
 
50 
 
4 
 
yes 
 
76 
 
18 
AAPTGNER, GIGTIISSPYR, 
 NKPLVVQFQK, FIAEGHPLSLK 
 
25 
 
3 
 
yes 
 
57 
 
13 
 
AAPTGNER, GIGTIISSPYR, FIAEGHPLSLK 
 
10 
 
5 
 
yes 
 
95 
 
23 
 
AAPTGNER, CPLTVVQSR 
GIGTIISSPYR,NKPLVVQFQK, FIAEGHPLSLK 
 
 
 
 
 
 
 
 
 
 
 
 
RuMS 
 
 
 
 
 
 
 
Trypsin 
inhibitor 
 
5 
 
0 
 
no 
 
n/a 
 
n/a 
 
n/a 
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Figure 3.24 MS/MS fragmentation of a BSA peptide (HLVDEPQNLIK) from gels 
stained with different stains as indicated. The ion intensity is given with parenthesis 
beside the peptide sequence in the figure.    
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Table 3.5 Summary of LC-MS/MS data for different protein loads of standard proteins (BSA- bovine serum albumin and 
Trypsin inhibitor) from gels stained with various stains  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stain 
 
Protein 
 
ng of 
protein 
 
# of peptides 
matched 
 
Database 
match 
 
Mowse 
score 
 
% 
coverage 
 
Sequence of matched  peptides 
100 2 yes 113 3 HLVDEPQNLIK, LGEYGFQNALIVR 
 
50 
 
3 
 
yes 
 
113 
 
6 
HLVDEPQNLIK, LGEYGFQNALIVR,  
KVPQVSTPTLVEVSR 
 
25 
 
2 
 
yes 
 
102 
 
4 
DEFLGTFLYEYSR, 
KAPQVSTPTLVEIGR 
10 0 no n/a n/a n/a 
 
 
 
BSA 
5 0 no n/a n/a n/a 
 
 
100 
 
 
6 
 
 
yes 
 
 
213 
 
 
27 
NELDKGIGTIISSPYR,  
GIGTIISSPYR, FIAEGHPLSLK, 
IGENKDAMDGWFR, VSDDEFNNYK, 
NKPLVVQFQK 
 
 
50 
 
 
6 
 
 
yes 
 
 
267 
 
 
27 
NELDKGIGTIISSPYR, 
 GIGTIISSPYR, FIAEGHPLSLK, 
IGENKDAMDGWFR,VSDDEFNNYK, 
NKPLVVQFQK 
 
25 
 
2 
 
yes 
 
57 
 
13 
NELDKGIGTIISSPYR,  
IGENKDAMDGWFR 
 
10 
 
2 
 
yes 
 
54 
 
12 
NELDKGIGTIISSPYR,  
FIAEGHPLSLK 
 
 
 
 
 
 
 
 
 
CCB 
G250 
 
 
 
 
 
 
Trypsin 
inhibitor 
5 0 no n/a n/a n/a 
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Stain 
 
Protein 
 
ng of 
protein 
 
# of peptides 
matched 
 
Database 
match 
 
Mowse 
score 
 
% 
coverage 
 
Sequence of matched  peptides 
 
 
 
100 
 
 
 
9 
 
 
 
yes 
 
 
 
421 
 
 
 
16 
FKDLGEEHFK, LVNELTEFAK,RHPYFYAPELLYYANK,  
HPYFYAPELLYYANK,DAFLGSFYEYSR, 
RHPEYAVSVLLR,HLVDEPQNLIK, LGEYGFQNALIVR, 
KVPQVSTPTLVEVSR 
 
50 
 
7 
 
yes 
 
295 
 
11 
LVNELTEFAK, RHPEYAVSVLLR, DAFLGSFLYEYSR, HLVDEPQNLIK 
LGEYGFQNALIVR, HPEYAVSVLLR, LVVSTQTALA 
 
25 
 
2 
 
yes 
 
76 
 
3 
 
LGEYGFQNALIVR, HPEYAVSVLLR 
 
10 
 
0 
 
no 
 
n/a 
 
n/a 
 
n/a 
 
 
 
 
 
 
BSA 
 
5 
 
0 
 
no 
 
n/a 
 
n/a 
 
n/a 
 
100 
 
3 
 
yes 
 
78 
 
14 
 
GIGTIISSPYR, VSDDEFNNYK, NKPLVVQFQK 
 
50 
 
5 
 
yes 
 
225 
 
23 
GIGTIISSPYR, FIAEGHPLSLK, VSDDEFNNYK, NKPLVVQFQK, 
DAMDGWFR 
 
25 
 
0 
 
no 
 
n/a 
 
n/a 
 
n/a 
 
10 
 
0 
 
no 
 
n/a 
 
n/a 
 
n/a 
 
 
 
 
 
 
 
 
 
 
 
Acidic 
Silver 
nitrate  
 
 
 
 
 
 
 
Trypsin inhibitor 
 
5 
 
0 
 
no 
 
n/a 
 
n/a 
 
n/a 
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Stain 
 
Protein 
 
ng of  
protein 
 
# of peptides 
matched 
 
Database  
match 
 
Mowse 
score 
 
% 
coverage 
 
Sequence of matched  peptides 
 
 
100 
 
 
6 
 
 
yes 
 
 
220 
 
 
12 
DAFLGSFLYEYSR, 
RHPEYAVSVLLR, HLVDEPQNLIK, 
LGEYGFQNALIVR, 
KVPQVSTPTLVEVSR, 
TVMENFVAFDK 
50 2 yes 56 3 LGEYGFQNALIVR, LVNELTEFAK 
 
25 
 
4 
 
yes 
 
148 
 
8 
DAFLGSFLYEYSR, HLVDEPQNLIK, 
LGEYGFQNALIVR,  
KVPQVSTPTLVEVSR 
10 2 yes 52 4 KVPQVSTPTLVEVSR, 
LVNELTEFAK 
 
 
 
 
 
 
BSA 
5 0 no n/a n/a n/a 
 
100 
 
4 
 
yes 
 
170 
 
17 
NELDKGIGTIISSPYR, GIGTIISSPYR, 
FIAEGHPLSLK, VSDDEFNNYK 
 
50 
 
5 
 
yes 
 
210 
 
21 
NELDKGIGTIISSPYR, GIGTIISSPYR, 
FIAEGHPLSLK, VSDDEFNNYK, 
NKPLVVQFQK 
25 4 yes 146 19 GIGTIISSPYR, FIAEGHPLSLK, 
VSDDEFNNYK, NKPLVVQFQK 
10 2 yes 62 9 GIGTIISSPYR, NKPLVVQFQK 
 
 
 
 
 
 
 
 
 
 
 
 
Sypro Ruby  
 
 
 
Trypsin 
inhibitor 
5 0 no n/a n/a n/a 
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Stain 
 
Protein 
 
ng of  
protein 
 
# of peptides 
matched 
 
Database  
match 
 
Mowse 
score 
 
% 
coverage 
 
Sequence of matched  peptides 
 
 
 
100 
 
 
 
12 
 
 
 
yes 
 
 
 
558 
 
 
 
19 
LVVSTQTALA, QTALVELLK, KQTALVELLK, LVNELTEFAK,  
HPEYAVSVLLR, RHPEYAVSVLLR, HLVDEPQNLIK, 
LGEYGFQNALIVR, TVMENFVAFVDK (M-oxidized), 
DAFLGSFLYEYSR, KVPQVSTPTLVEVSR, HPYFYAPELLYYANK 
 
 
50 
 
 
12 
 
 
yes 
 
 
590 
 
 
22 
AEFVEVTK, YLYEIAR, QTALVELLK, LVNELTEFAK, FKDLGEEHFK, 
HLVDEPQNLIK, RHPEYAVSVLLR,GEYGFQNALIVR, 
KVPQVSTPTLVEVSR, TVMENFVAFVDK (M-oxidized), 
DAFLGSFLYEYSR, RHPYFYAPELLYYANK 
25 1 yes 51 2 LGEYGFQNALIVR 
10 1 yes 42 1 HLVDEPQNLIK 
 
 
 
 
 
BSA 
5 0 no n/a n/a n/a 
 
100 
 
5 
 
yes 
 
283 
 
21 
NELDKGIGTIISSPYR, GIGTIISSPYR, FIAEGHPLSLK, VSDDEFNNYK, 
NKPLVVQFQK 
 
50 
 
6 
 
yes 
 
333 
 
27 
NELDKGIGTIISSPYR, GIGTIISSPYR, FIAEGHPLSLK, VSDDEFNNYK, 
NKPLVVQFQK, IGENKDAMDGWFR (M-oxidized) 
 
25 
 
3 
 
yes 
 
80 
 
12 
NELDKGIGTIISSPYR, GIGTIISSPYR, FIAEGHPLSLK 
10 1 no 21 4 VSDDEFNNYK 
 
 
 
 
 
 
 
 
 
 
 
 
RuMS 
 
 
 
 
 
 
Trypsin 
inhibitor 
5 0 no n/a n/a n/a 
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3.4 Discussion 
 
The primary aim of this work was to synthesize a fluorescent ruthenium complex to use 
as a cost-effective stain in visualizing proteins in gels after electrophoresis. A 
commercially available fluorescent protein stain is the Sypro Ruby, which has high 
sensitivity and linear dynamic range crucial for a successful proteomic study utilizing 2-
DE. However, 500 mL of Sypro Ruby solution can be used to stain only two large format 
gels. Considering the huge number of gels run in a typical proteomic lab like ours, use of 
Sypro Ruby is not very cost-effective. Rabilloud et al. synthesized RuBPS in-lab to use 
as an alternative to the expensive Sypro Ruby [53]. This prompted us to test the usability 
of this RuBPS in our lab and we synthesized the chelate in-house using the protocol 
published by Rabilloud et al. As shown in figure 3.11, the sensitivity of the RuBPS stain 
synthesized in-house was relatively poor, with a detection limit of about 5 ng of protein. 
Since RuBPS is ruthenium attached to three bathophenanthroline disulfonate ligands, we 
explored the possibility of having both sulfonated and non-sulfonated 
bathophenanthroline moieties attached to the central ruthenium atom. Our rational was 
that different kinds of ligands may result in a synergistic effect in interacting with the 
protein and thereby enhance sensitivity. Analysis of the commercial Sypro Ruby by 
MALDI-TOF in our lab showed evidence for the presence of a non-sulfonated ligand in 
the solution (data not shown). This impelled us to synthesize ruthenium complex with 
both sulfonated and non-sulfonated ligands and hence two complexes RuMS and RuDS 
were synthesized in addition to RuBPS. Synthesis of RuMS and RuDS were carried out 
using modification of protocol published by Rabilloud [53].  
 
3.4a Characterization of in-house synthesized ruthenium complexes 
 
Various techniques like fluorescence spectroscopy, mass spectrometry and paper 
chromatography were carried out to characterize the in-house synthesized ruthenium 
complexes. Fluorescence spectroscopy of all the three ruthenium complexes synthesized 
in-house gave spectra similar to Sypro Ruby in overall appearance and in values for λex 
and λem maxima. Figure 3.6 gives the excitation and emission spectra for RuMS, for 
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example. There are two absorption peaks, one at ~280 nm and a broad one at ~450 nm. 
The fluorescence emission spectrum has one broad peak at 610nm. The similar spectra 
obtained for the ruthenium complexes indicate that they possess similar fluorescence 
properties. 
 
RuNS (ruthenium attached to three bathophenanthroline ligands – no sulfonates) was 
bought from a commercial source and solution made up in-house. The various in-house 
synthesized ruthenium complexes and RuNS were subjected to MALDI-TOF mass 
spectrometry. Different matrices were employed like HCCA, SA and DCTB, but none 
enabled visualization of the expected m/z peak (RuNS (ruthenium tris 
bathophenanthroline) [M+H]+  = 1098, RuMS [M+H]+ = 1258, RuDS [M+H]+ = 1464 and 
RuBPS [M+H]+ = 1670). The base peak observed in all the spectra obtained was an m/z 
of 766. From spectra (Figures 3.7-3.10) obtained for the three complexes including RuNS 
in HCCA matrix, it is clear that each compound is breaking apart and some of the peaks 
observed match the m/z for fragments of the original complex. The peak with m/z = 766 
could be the ruthenium ion attached to 2 bathophenanthrolines ligands. Table 3.1 gives 
different mass peaks that were observed in the MALDI-TOF spectra for the various 
complexes. The mass spectral characterization of in-house synthesized ruthenium 
complexes was not successful in clearly elucidating the structure.  
 
Paper chromatography was performed to help us in the identification of these complexes. 
Table 3.2 summarizes the retention factors (Rf) obtained for ruthenium complexes in two 
different solvents. Two compounds were seen in each of the ruthenium complexes shown 
by the two Rf values. RuDS and RuBPS have similar retention factors indicating that the 
major constituents in both these preparations are the same compounds. RuMS, on the 
other hand, had different Rf values compared to RuDS and RuBPS. There is one spot in 
RuMS with Rf value of zero in water indicating that it is highly polar in nature. This 
could be the sulfonated ligand or some other polar ruthenium complex. All the three 
ruthenium complexes appeared to have one compound common to all. The commercial 
RuMS had an Rf value or 0.42 in water that is present in all the in-house synthesized 
ruthenium complexes. Comaprison of Rf values between commercial and in-house RuMS 
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complex indicated that the in-house synthesized RuMS was indeed made up of RuMS 
complex and one other complex with Rf value of zero. 
 
The three ruthenium complexes differed in terms of their staining abilities (Figure 3.11). 
In-house RuMS provided the greatest sensitivity with a limit of detection of 0.5 to 1 ng, 
versus 5-10 ng for RuBPS and 25-50 ng for RuDS. Since RuMS clearly had the best 
sensitivity among the three complexes, characterization of RuMS is important. Mass 
spectral data clearly indicates that the ruthenium complexes are highly unstable and 
fragment in the mass spectrometer. However, from the fragmentation pattern there is 
evidence for the presence of RuMS complex in the RuMS stock solution. Paper 
chromatography data indicates that the RuMS solution synthesized is a mixture of two 
complexes. The difficulty faced in obtaining crystals from the RuMS solution (in an 
attempt to characterize the complex by X-ray crystallography) further suggests that the 
solution is a mixture and not pure RuMS complex. Due to the paucity of this material, 
further structural elucidations were not pursued. However, the data suggests that the in-
house synthesized RuMS solution contained RuMS and another minor component. 
 
Since RuMS gave the most sensitivity in staining proteins, the following discussions will 
be mainly focused on RuMS. The next section is a discussion on the optimization 
protocols for RuMS staining that were carried out to achieve the maximum sensitivity.   
 
3.4b Optimization of staining protocol using in-house RuMS 
 
Solvent composition of the staining solution is highly critical for successful staining. 
Therefore, various solvents like ethanol, methanol and isopropyl alcohol were used as 
solvent for the formulation of RuMS stock solution. As seen in figures 3.12 and 3.13, the 
stain had little background and high sensitivity when ethanol was used as a solvent. The 
concentration of RuMS in the working solution was also optimized (Figure 3.14). Desired 
staining of proteins with minimal background staining was obtained with 150 nM RuMS 
in 20% ethanol solution. When solvents other than ethanol were used or when greater 
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concentrations of ethanol were used in the formulation, there was increased background 
staining due to non-specific binding of the stain to the polyacrylamide matrix. 
 
The optimized staining protocol of the in-house synthesized RuMS detected proteins 
down to 0.5 ng in gels. As discussed earlier, greatest challenge was in characterizing the 
synthesized complex. Even though there was significant evidence for the presence of 
RuMS complex in the stock solution, there is lack of concrete data to support this 
observation. We looked at other ways to confirm the identification. In our search to do so, 
we came to know of a company Biotium (Hayward, CA) that was started during the 
course of this work, sells the fluorescent ruthenium complexes. The commercial RuMS 
was purchased in order to test its staining efficiency using standard marker proteins. The 
in-house synthesized RuMS stain was compared to this commercial RuMS in terms of 
sensitivity and specificity and to give further structural information on the synthetic stain 
by inference. Again for commercial RuMS, the formulation is very critical and hence 
various solvents like 20% v/v, and 50% v/v of both ethanol and isopropyl alcohol were 
used as solvents. As seen in figures 3.15 and 3.16, the stain had little background and 
high sensitivity when ethanol was used as the solvent. The background staining was high 
when isopropyl alcohol was used. Different percentage of ethanol also gave high 
background due to non-specific binding of the stain to the gel matrix. Therefore, the most 
suitable solvent for ruthenium complex to stain proteins with high sensitivity but with 
minimal background staining of the gel was obtained with 20% ethanol in the final 
working solution. Concentration of ruthenium complex in the staining solution was also 
optimized (Figure 3.17). Desired staining of the proteins with again minimal background 
staining was obtained with 100 nM of in-house RuMS and 125 nM commercial RuMS, 
both in 20% ethanol solution.  
 
There exists subtle difference in staining efficiency of the in-house synthesized RuMS 
compared to the 99% pure commercial RuMS (Figure 3.18). In commercial RuMS 
stained gel, more non-specific binding occurs even at 10 ng of protein while there is 
negligible background with the in-house RuMS staining solution, leading us to speculate 
that the minor component present in the in-house synthesized RuMS solution enhanced 
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the staining ability of the ruthenium complex. From the paper chromatography data, we 
suspect this contaminant is most probably RuBPS, another form of ruthenium complex. 
RuMS and RuBPS have similar ligands attached to the central ruthenium atom. However, 
they differ in the number of sulfonate groups attached to the bathophenanthroline ligands. 
RuMS has two sulfonate groups attached to one bathophenanthroline ligand while 
RuBPS has six sulfonate groups. Thus RuMS is more hydrophobic than RuBPS complex. 
Goldstein et al. have reported the crystal structure of ruthenium tris bathophenanthroline 
complex (RuNS) in which they propose that the bathophenanthroline ligands of different 
molecules stack-up to form a cluster [58]. The features seen in the crystal and molecular 
structure of ruthenium tris bathophenanthroline can be used to construct models for the 
interaction between the different forms of ruthenium complexes in RuMS staining 
solution that can explain the improved sensitivity observed with the in-house RuMS.  
 
In one plausible model, one of the hydrophobic bathophenanthroline groups of RuMS 
interact with hydrophobic residues in the protein. The other two ligands of RuMS, 
namely bathophenanthroline disulfonate and bathophenanthroline are aligned outside. 
The sulfonate group has a tetrahedral structure and since the group is not in the same 
plane as the aromatic ring, it destabilizes possible π-π stacking of its 
bathophenanthroline/phenyl groups with bathophenanthroline/phenyl groups of another 
ruthenium complex. However, the bathophenanthroline moiety with no sulfonate is 
accessible for π-π stacking and a second dye molecule can easily stack-up with this 
complex. In this way, the dye molecules stack-up with each other so as to allow for more 
dye molecules to bind to a protein, thereby significantly increasing the dye to protein 
ratio with an amplication in the signal generated. This stacking up of planar ring 
structures with extensive conjugation of π orbitals has been reported by Skoog et al. and 
Congdon et al. [59, 60]. The stacking of coomassie dye molecules with a similar structure 
as that of the ruthenium complex has been proposed for the improved sensitivity with the 
blue silver protocol [61]. If this same concept of π-stacking occurs in the case of our “in-
house RuMS” staining protocol, this would very well explain the substantial increment in 
sensitivity. Due to the presence of two different forms of ruthenium complexes in the in-
house synthesized RuMS staining solution, there are more numbers of dye molecules 
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binding to proteins. So even low levels of protein are detected since more dye molecules 
bind. On the other hand, with just the RuMS form in the staining solution, as in the case 
of commercial RuMS, there is only one form of ruthenium complex. Even though the 
stacking-up of the dye molecules is possible, RuMS being more hydrophobic than 
RuBPS, also non-specifically binds to the polyacrylamide gel matrix which considerably 
reduces sensitivity. 
 
Hence by having both RuMS and RuBPS in a staining solution, we achieve the right 
balance in hydrophobicity and hydrophilicity of the final staining solution required to 
detect the proteins with improved sensitivity. The characterization of the in-house 
syntheized RuMS staining solution is necessary to validate the proposed model and future 
work should involve new experiments characterizing the material to ensure exploitation 
of the in-house synthesized RuMS stain’s potential to the fullest.    
 
The optimized formulation of the in-house synthesized RuMS stain was compared with 
other stains for its sensitivity, linear dynamic range and compatibility with mass 
spectrometry. 
 
3.4c Comparison of sensitivity of various stains 
 
Figure 3.19 gives identically prepared gels stained with colloidal Coomassie, silver, 
commercial Sypro Ruby and in-lab synthesized RuMS. Clearly, colloidal Coomassie can 
detect up to 0.5 ng of protein, however only after repeated staining for three times. Silver 
can also detect down to 0.5 ng of protein but the background was darker at lower ng level 
of protein, and the gel showed inherent artifacts due to silver staining. Both Sypro ruby 
and in-lab synthesized fluorescent RuMS had comparable sensitivities and could detect 
0.5 -1 ng of protein. Commercial RuMS had a sensitivity of about 1 ng. It is clear from 
the gels that there is some amount of difference in sensitivity from protein to protein 
which depends on the inherent amino acid composition of each protein and how the stains 
interact with them. Ovalbumin and lysozyme showed differential staining with colloidal 
Coomassie. This could be explained because of the heavy glycosylation on ovalbumin 
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that interferes with the binding of the dye to the protein as reported by Fountoulakis et al. 
[62]. As previously reported in colorimetric labeling of protein [63-65], lysozyme was 
more lightly stained with Coomassie down to about 10 ng. This could also be due to the 
glycosylation in lysozyme. In the case of silver staining, trypsin inhibitor and lysozyme 
proteins stained more intensely than the other protein markers and showed artifacts 
associated with this staining method. Sypro Ruby and in-lab synthesized RuMS showed 
much less protein to protein variability. 
 
3.4d Linearity in staining response 
 
To minimize protein-to-protein variability, stain and batch differences, the mean band 
volume from three gels run and stained with either of the dyes was plotted against the ng 
of protein loaded (Table 3.3, Figure 3.20 and 3.21). For each protein band selected, linear 
treadlines were added and R2 values determined. The in-lab synthesized RuMS was 
found to be comparable to commercially available Sypro Ruby in terms of its linearity, 
but the staining intensity was greater than with Sypro Ruby and with greater signal to 
noise ratio. Both Sypro Ruby and in-house RuMS showed linear response from 0.5 to 100 
ng protein. Silver staining, as reported earlier, is sensitive down to 1 ng and maybe even 
0.5 ng of protein. But since the band volume at 0.5 ng protein load is very close to the 
band volume for 1 ng protein, it showed a linearity of dilution from 1 to 50 ng of protein. 
The linearity in response for colloidal Coomassie stained gels was 5 ng to 100 ng. There 
was considerable batch-to-batch difference in silver staining most likely owing to 
variability introduced due to critical timing. Relative standard deviation (%RSD) was less 
than ± 5 for both Sypro Ruby and RuMS, which shows good batch-to-batch 
reproducibility.  
 
Figures 3.20 and 3.21 give the graphs of the linear relationships for raw band volumes of 
proteins from gels after background subtraction. The band volumes for 5 ng of BSA from 
gels stained with the different staining solutions were normalized and histogram plotted 
(Figure 3.22). From the bar graph, we can see that there is no significant difference 
between the different stains – CCB G 250, silver nitrate, in-house RuMS and Sypro 
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Ruby- in terms of sensitivity. Though the stains had similar sensitivity, each stain had its 
own limitations. CCB G250 had sensitivity down in the ng levels of proteins only after 
repeated staining and destaining steps for at least three times. This is a very time 
consuming process that takes up to a week. Silver nitrate on the other hand, had very poor 
reproducibility due to a constant hands-on protocol that required routine preparation of 
fresh solutions. Sypro Ruby had good sensitivity but the major disadvantage was the cost 
involved in buying the stain. In-house synthesized RuMS had comparable sensitivity to 
Sypro Ruby and was very cost-effective. 
   
3.4e Compatibility of stains with mass spectrometry 
 
Once proteins are separated by 2-DE, they are visualized using a suitable staining 
solution and the protein spot profiles are analyzed using image analysis software. The 
protein spots of interest are then excised and subjected to enzymatic digestion. The 
resulting peptide fragments are then analyzed using mass spectrometry (MS). With 
fluorescent stains, the sensitivity of the protein stains has improved and the challenge is 
now to acquire good mass spectra from especially low abundance proteins. Therefore, it 
is imperative that the dye does not interfere with MS methods. Interfering dyes (like 
silver nitrate) can result in ion suppression resulting in fewer measurable peptides 
obtained and a reduction in signal intensity.  
 
Two complementary MS methods used for proteomic studies are MALDI-TOF and ES-
LC-MS/MS. To evaluate the compatibility of different stains with these two mass 
spectrometry methods, gel plugs were harvested and digested with trypsin. The resulting 
tryptic peptides were subjected to both matrix assisted laser desorption ionization 
(MALDI-TOF) and liquid chromatography tandem mass spectrometry (LC-MS/MS).  
    
• Stain compatibility with MALDI-TOF 
 
Tryptic peptides were subjected to MALDI-MS as described earlier. A representative 
peptide mass fingerprint (PMF) analysis for all the 100 ng BSA protein is shown in figure 
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3.23. The summarized MALDI data from all the trypsin digested proteins is provided in 
Table 3.4. The number of successfully identified peptides and the resultant sequence 
coverage were slightly better for the in-lab synthesized stain than for commercial Sypro 
Ruby. Although silver staining is a very sensitive visualization method, poor mass spectra 
were obtained. Out of 12 proteins that were subjected to MALDI-TOF after silver stain, 
peptides were detected for only 6 samples. No peptides from BSA were correctly 
identified after MALDI-TOF. Low peptide recovery and sequence coverage of silver 
stained proteins may be due to their modification by formaldehyde (alkylates α and ε 
amino groups of proteins) during the staining process. Unfortunately, formaldehyde 
cannot be omitted or substituted for in the staining protocol.  
 
Colloidal Coomassie performed fairly well in the MS compatibility study, however it is 
very difficult to get rid of the stain completely, and this could pose difficulties with MS 
identification. Also the gel stained with colloidal Coomassie was stabilized in a saturated 
solution of ammonium sulfate which could interfere with PMF analysis. It should be 
noted from table 3.4 that different staining methods enabled different peptides to be 
identified. Our data indicate that both fluorescent stains namely; Sypro Ruby and in-
house RuMS are fully compatible for protein identification by peptide mass finger 
printing using MALDI-TOF mass spectrometry.    
 
• Stain compatibility with ES-LC-MS/MS 
 
Data dependent MS/MS experiments were performed on a Thermo LCQ Classic 
quadrupole ion trap mass spectrometer. Mass spectra were searched against the human 
sub-database from the Swiss-Prot database using the Mascot algorithm. One missed 
trypsin cleavage was allowed and a variable modification of oxidation of methionine was 
set. Peptide tolerance and MS/MS tolerance were both set at ± 0.8 Da. Representative 
ES-LC-MS/MS spectra are shown in figure 3.24. Table 3.5 summarizes the LC-MS/MS 
data for all the trypsin digested samples. Silver staining yielded few matches when 
compared to other stains. Fewer peptides were seen for proteins from silver stained gels. 
Colloidal Coomassie seemed to perform fairly better than the silver staining method. 
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Sypro Ruby and in-lab synthesized stain gave the most number of peptides detected with 
highest Mowse score and sequence coverage. 
 
In conclusion, all stains tested in this work demonstrate some degree of MS 
compatibility. Silver stain gave significantly better results with LC-MS/MS than 
MALDI-TOF and colloidal Coomassie gave slightly better results with LC-MS/MS than 
MALDI-TOF. The in-lab synthesized RuMS stain is slightly better than commercially 
available Sypro Ruby in terms of MS compatibility. More peptides were recovered and 
detected by both MALDI-TOF and LC-MS/MS for proteins stained with the in-lab stain 
and gave better Mascot search results with high Mowse score and sequence coverage.  
 
• Evaluation of protein sequence coverage 
 
The level of protein sequence coverage for the six marker proteins stained with different 
stains is shown in Tables 3.4 and 3.5. Coverage was determined from the Mascot search 
results for proteins that gave significant identification by searching against the protein 
database. For proteins that did not give a significant match but had peptides detected by 
the mass spectrometer, coverage was calculated manually. Sequence coverage for 
proteins extracted from in-lab RuMS stained gels was better than that obtained from 
Sypro Ruby stained gels. It is important to note here that higher protein coverage is not 
necessary for protein identification, especially with ES-MS/MS.   
 
3.4f Cost-effectiveness of RuMS stain 
 
The specific aim of this project was to synthesize a fluorescent ruthenium complex in-
house to be able to use it as a cost-effective alternative to Sypro Ruby. The following 
section explains how RuMS synthesized in our lab proved to be a cost-effective protein 
stain. 
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In most proteomics labs, 2-DE is employed to analyze the proteome and hence staining 
solutions are used in huge quantities. The goal of this project is to synthesize a ruthenium 
complex that can be used as a cost-effective alternative to expensive Sypro Ruby. This 
section discusses the cost-effectiveness of the in-house synthesized RuMS staining 
solution in comparison to the commercial RuMS and Sypro Ruby. Sypro Ruby as 
mentioned earlier is highly sensitive and has linear response over a wide range of protein 
load but is highly expensive. An alternative to Sypro Ruby should be able to stain the 
proteins with similar sensitivity and give linear dynamic range but in a much more cost-
effective manner. Commercial Sypro Ruby costs approximately $200 and it can be used 
to stain only two large format (20 x 20 cm) gels. A half liter solution of our in-house 
synthesized RuMS costs about $100 to buy the required chemicals and solvents and an 
aliquot of 1.5 mL is used to stain one gel. Hence 500 mL of the in-house staining solution 
can be used to stain ~ 330 gels. Chemicals worth $200 can be used to synthesize 1 L of 
staining solution which can be used to stain roughly about 600 gels. Commercial RuMS 
costs about $150 which can be used to make 250 mL of 16 nM solution. Forty mL of this 
staining solution can stain one large format gel. Hence one 250 mL solution can be used 
to stain 6 gels. A summary of pros and cons of the fluorescent stains evaluated is shown 
in the flow chart below (Table 3.6).  
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Table 3.6 Pros and cons of various fluorescent stains. 
 
 
Sypro Ruby 
 
 
Commercial RuMS 
 
In-house RuMS 
 
Highly sensitive (0.5ng of 
protein) 
 
 
Highly sensitive (1 ng of 
protein) 
 
Highly sensitive (1- 0.5 ng 
of proteins) 
 
MS compatible 
 
MS compatible 
 
MS compatible 
 
Easy staining and 
destaining protocol 
 
Easy staining protocol and 
no destaining required 
 
 
Easy staining protocol and 
no destaining required 
 
 
Expensive (2 gels) 
 
More cost-effective (6 gels) 
 
Most cost-effective (600 
gels) 
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3.5 Conclusion 
 
For a successful bottom-up proteomics involving 2-DE, an essential requirement is a 
protein staining technique that is sensitive, quantitative and compatible with MS. Using 
standard proteins on SDS-PAGE, we have showed that the ruthenium complex (RuMS) 
synthesized in our lab after optimization of the staining formulation is very similar in 
staining properties to commercially available fluorescent protein stain Sypro Ruby in 
terms of both sensitivity and linear dynamic range. Our results show that in-house RuMS 
has better compatibility with mass spectrometric identification than Sypro Ruby both in 
terms of the “goodness” of fit between the theoretical and observed peptide masses 
during the database search using the Mascot algorithm and in terms of better protein 
sequence coverage. The staining protocol is also simple and easy to follow with 
effectively no destaining required. Colloidal Coomassie and silver staining methods are 
commonly used but have pitfalls when used in proteomic studies, such as low linear 
dynamic range, batch-to-batch and protein-to-protein variations and incompatibility with 
further mass spectrometric identification of proteins. In-lab synthesized ruthenium 
complex stain is routinely used in our laboratory to stain 2-DE gels (example shown in 
Figure 3.25) and has given satisfactory results with respect to sensitivity and mass 
spectrometric identification by both MALDI-TOF and LC-MS/MS.  
 
Even though the characterization of the RuMS solution was not successful, the presence 
of RuMS is evident from the mass spectral data. Other characterization attempts indicated 
the presence of an additional minor component present in the solution, which we 
speculate to be RuBPS form. Comparing the staining efficiency between the in-house 
synthesized RuMS and commercial RuMS, in-house RuMS had a better signal-to-noise 
ratio and this could be explained by the additional component in the RuMS solution. As 
explained earlier, presence of both RuMS and RuBPS enable a synergistic effect in the 
binding of the dye molecules to the protein and there is amplification of the signal. This 
allows for even low levels of proteins to be detected as number of dye molecules stack-up 
to give an amplified signal. The capability of synthesizing the fluorescent complex in-
house proves to be very cost-effective. Sypro Ruby is highly expensive and 500 mL of 
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the solution can be used to stain only two large format gels; however for the same amount 
of money in terms of reagents (not including man power or quality control) 1 L of RuMS 
can be synthesized in-house which can be used to stain hundreds of gels. Thus, the 
optimized formulation of the in-house RuMS staining solution proved to be the most 
cost-effective alternative to the commercially available Sypro Ruby.  
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Figure 3.25 2-DE gel from 400 μg of SY5Y whole cell lysate stained with in-house 
synthesized RuMS staining solution. The gel image acquired using Versadoc was 
inverted so that the spots are darker than the background.   
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CHAPTER FOUR 
 
PROTEOMIC INVESTIGATION OF MALATHION-INDUCED DIFFERENTIAL 
PROTEIN EXPRESSION IN HUMAN NEUROBLASTOMA CELLS 
 
4.1 Introduction 
 
Pesticides play a vital role in agricultural and industrial pest control. However, 
widespread use and overuse of these chemicals have increased awareness of the potential 
pesticide-related health hazards. An example is the class of organophosphates (OP) that 
are important chemical compounds used mainly as crop protective pesticides. Potent 
organophosphate such as chlorpyrifos is usable as insecticide yet is also capable of 
causing learning disabilities especially in exposed young children [66]. Animal studies 
have reported that exposure to chlorpyrifos can cause developmental neurotoxicity by 
affecting basic processes of neuronal development like axonogenesis, neuritogenesis and 
synaptic function [66-69]. This led to the restriction in the use of chlorpyrifos in the 
United States [70, 71].        
 
Malathion, another organophosphate (with a different leaving group) is used widely in 
both agriculture and domestic areas because it is thought to be a more benign OP. About 
3.4 million pounds have been applied to non-agricultural areas such as golf courses, 
public and home gardens for the Mediterranean fruit fly quarantine and mosquito 
abatement to-date [72]. Close to 17 million pounds of malathion are sprayed annually in 
the U.S. to control boll weevils on cotton and other pests [73]. In 1999, malathion was 
also used in eradication of West Nile virus carrying mosquitoes.  
 
On one end of the spectrum is the more potent OP chlorpyrifos shown to cause 
developmental neurotoxicity that has been banned from domestic use while on the other 
end there is the “less toxic” malathion that is used extensively for both agriculture and 
house-hold purposes. The effect of the more potent OP, chlorpyrifos on levels of protein 
was studied in our lab using SY5Y as model system. Since it is equally important to 
 
                                                                          120  
study the effect of a benign OP as a control that made up the other end of the spectrum of 
OP toxicity, the proteomic investigation on the effect of malathion was carried out. The 
initial hypothesis is that malathion does not cause any significant change in levels of 
protein. SY5Y cell cultures were used as model system to test the effect of malathion 
using proteomics techniques.        
 
The primary mode of action of malathion and other OPs (including chlorpyrifos) in 
insects is inhibition of acetylcholinesterase (AChE) and thus interfere with normal 
functioning of the nervous system. In vivo AChE inhibition occurs when malaoxon, a 
metabolite of malathion, binds to acetylcholinesterase; thus, symptoms may be delayed 
after exposure owing to the need for metabolism. Covalent AChE binding results in 
accumulation of acetylcholine at the synapse causing repeated stimulation of neurons and 
a number of neurotoxic effects – especially muscarinic and nicotinic effects. Muscarinic 
effects include: Salivation, Lacrimation, Urination, Diarrhea, GI upset and Emesis 
(acronym: SLUDGE). Nicotinic effects include: tachycardia, muscle fasciculation and 
respiratory shutdown resulting from diaphragmatic failure, which ultimately causes 
death. 
 
Previous studies have shown that malathion induces genotoxicity [74]. Using animal 
models, researches have shown that malathion greatly inhibits AChE in the cerebellum 
and hippocampus [75]. Experimental animal studies have revealed that malathion causes 
chromosomal aberrations and micronuclei formation [76-78]. Malathion is also now 
known to be an inhibitor of gap junction intercellular communication (GJIC) [79]. 
Akhgair et al. measured the levels of thiobarbituric acid reactive substances (TBARS) in 
the liver and blood of rats and showed that malathion inhibition of AChE activity was 
accompanied by oxidative stress [80]. In addition to its mutagenic, carcinogenic and 
teratogenic effects determined by in vitro and in vivo studies [81, 82], malathion reduces 
antibody titers to different antigens in a dose-dependent manner in experimental animals. 
This effect was most pronounced during the secondary immune response [83, 84]. 
Malathion was also shown to induce allergic reactions in children [85]. Rodgers et al. 
reported that malathion causes dysregulation of peritoneal mast cells [86].  
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There exists a number of possible ways humans get exposed to pesticides, which could be 
due to one or more of the following reasons: accidental poisoning, occupational exposure 
and off-target exposure from aerial spraying of the pesticide in crop fields. In view of the 
widespread use of pesticides, the potential is very high for repeated exposures to one or 
simultaneous exposure to various pesticides. Pesticide intoxication poses severe problems 
which can be exacerbated if not prevented. Most of the reports studying toxicity of 
malathion were focused on secondary effects after exposure, symptomology in particular. 
There is an overall lack of information on the protein targets and their levels that can be 
altered after exposure to pesticides. Significant biochemical pathways may be hindered 
by organophosphate insecticides exposed enzymes, receptors or structural proteins.  
 
Proteomic investigation of the effect of malathion was performed using human 
neuroblastoma cell (SY5Y cells). The SY5Y neuroblastoma cell line was used as it 
exhibits neuronal phenotype which provides a convenient model system to study 
neurotoxicity of organophosphates [87]. SY5Y cells express muscarinic acetylcholine 
receptors [88], mostly subtype M3 [89] and exhibit higher activities of neurotoxic 
esterases (NTE) and acetylcholinesterase compared to other cell lines [90]. Barber et al. 
showed that organophosphate-treated human neuroblastoma cells gave similar responses 
to those in hens exposed to these compounds which are currently the Environmental 
Protection agency (EPA) prescribed animal model to test OP toxicity [91-93]. Barber et 
al. thereby validated SY5Y cells as a useful model and Ehrich et al. also validated the use 
of human neuroblastoma cells for the initial screening of OPs [89]. Criticism exists that 
neuroblastoma cells are not a part of “normal” tissue and the responses seen may be 
consequence of cancerous behavior. However, asking pointed questions and strategically 
designing the experiments with well-defined end-points can minimize this fear. As a 
minimum criterion, this involves carefully comparing the control (no malathion 
treatment) against the treated samples. Veronesi et al. agree that the in vitro system using 
human cell lines that house the target enzymes for the OPs are relevant to risk assessment 
[94]. Also cells of human origin provide good models for studying OP toxicity because of 
the direct correlation to humans as opposed to animal studies in which extrapolation of 
the results to humans is needed.  
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The initial hypothesis that malathion does not cause any significant change in levels of 
proteins was proved false. We present evidence that malathion does cause significant 
change in protein levels in SY5Y cells exposed to the organophosphate. With the aid of 
proteomic tools such as two-dimensional gel electrophoresis (2-DE) and mass 
spectrometry, we have identified the candidate SY5Y proteins whose levels were altered 
(up- or down-regulated) after treatment with malathion. Finally, western blot analysis 
was carried out to confirm alterations in levels of specific proteins seen in 2DE studies. 
We found that many chaperone proteins and metabolic enzymes were down-regulated 
coordinately, suggesting that malathion perturbs protein turnover. We hypothesized that 
the decrease in chaperone proteins may sensitize the cells to oxidative stress as shown by 
in vivo and in vitro studies.  
 
4.2 Materials and Methods 
 
4.2a Materials 
 
Isoelectric pH gradient (IPG) strips (0.5 mm wide, 17 cm long, pH 3-10 linear), urea, Tris 
(electrophoresis grade), IPG rehydration /sample buffer containing 8M urea, 2% CHAPS, 
50 mM DTT, 0.2% Bio-Lyte 3/10 ampholyte, trace bromophenol blue, readyprep overlay 
agarose and mineral oil were obtained from Bio-Rad (Hercules, CA). SDS, TEMED, 
ammonium persulfate, ammonium bicarbonate, acetonitrile, formic acid, acrylamide, 
bisacrylamide and were purchased from Sigma (St.Louis, MO). For protein staining in 
gels, ruthenium complex prepared in our lab was employed. DTT, iodoacetamide, glacial 
acetic acid (ACS grade), glycine (tissue culture grade) and methanol (HPLC grade) were 
all purchased from Fisher Scientific (Fair Lawn, NJ). Lyophilized sequencing grade 
modified trypsin was purchased from Promega (Madison, WI). Fused silica capillary 
tubing 320 μm I.D. x 435 μm O.D. for liquid chromatography column was purchased 
from Polymicro Technologies (Phoenix, AZ) while the reverse phase packing material 
Polymer X (3 μm) was purchased from Phenomenex (Torrance, CA). All other LC 
accessories including zero dead volume (ZDV) unions, frits, ferrules were obtained from 
Upchurch Scientific (Oak Harbor, WA).  
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4.2b Cell Culture 
 
SY5Y neuroblastoma (American Type Culture Collection CRL 2266) [87] cells were 
grown to confluence in 75 cm2 flasks in Dulbecco’s minimum essential medium 
supplemented with 55 mM glucose, 26 mM NaHCO3, 16 mM KCl, 1.36 mM pyruvic 
acid, 2 mM glutamine, 10 mg/mL gentamicin sulfate and 10%v/v clarified bovine serum 
(pH 7.4) in an environment of 94% air/6% CO2 at 37°C. Cultures were split 1:3 every 
two to three days by removal of media and incubation in 0.25% trypsin/0.03% EDTA 
until cells detach. Five mL of media was then added and cells pelleted by centrifugation 
at 3,000 x g for 10min. For each malathion treatment, the cells were switched to Lock’s 
medium and treated with appropriate concentrations of malathion. Following treatment, 
cultures were washed extensively with phosphate buffer saline (pH 7.4) and cells were 
gently scraped into 3 mL PBS and pelleted by centrifugation at 800 x g for 10min. The 
pellet was then resuspended in 200 μL of distilled/deionized water and homogenized 
using a micro Dounce homogenizer. Cell viability test was checked by (3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) (MTT) assay and protein 
content determined using Pierce BCA method.    
 
4.2c Cell Viability Assay 
 
Confluent cultures were split from one flask into three 96-well culture plates. When 
confluent, cultures were switched to Lock’s medium consisting of 154 mM NaCl, 56 mM 
KCl, 2.3 mM CaCl2, 1.0 mM MgCl2, 3.6 mM NaHCO3, 10 mM glucose, 5 mM HEPES 
(pH 7.2) with 10 mg/L gentamicin sulfate and treated with malathion (25 to 2000 μM) in 
1% DMSO. Eight wells per concentration were treated with each concentration or with 
vehicle alone (control). After 24hours, cell viability is assayed by addition of 10 μL or 1 
mg/mL MTT solution that is converted to formazan crystals by the cellular enzymes [95]. 
The level of formazan dye formed is directly correlated to metabolically active cells in 
culture. After addition of MTT, cultures were placed in the incubator for an additional 1 
hour. The media was quickly aspirated and the formazan crystals dissolved in 100 uL 
DMSO. Formazan absorbance was then measured at 620 nm using a multi-well plate 
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reader. Results were calculated for each well as percent of control absorbance and are 
expressed as the mean ± SD control absorbance. Cell viability was also assessed by 
adding 10 μL WST-1(4-[3-(4-Iodophenyly)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3-
benzene disulfonate), which is converted to a water soluble formazan by reductase 
system and is a measure directly in the media. There was no significant difference in 
viability measured by the two assays. Using commercially available software, statistical 
analysis was carried out. ANOVA with Dunnett’s post hoc test was performed for 
differences. 
 
4.2d Malathion Treatment 
 
For proteomic analysis of changes in protein expression in SY5Y neuroblastoma cells, 
the cultures were treated with 100 μM malathion for 24 and 48 hours in the same way as 
the cell viability assay.  
 
4.2e Two-dimensional gel electrophoresis 
 
Pierce BCA method was used to determine protein content [96]. A protein concentration 
of 400 μg of whole cell lysate was dried in a vacuum centrifuge. A volume of 300 μL of 
rehydration buffer was added to the pellet and the solution was loaded on IPG strip and 
after 12 hours of active rehydration at 50 V, the proteins were focused in the Protean IEF 
cell from Bio-Rad using a 6 step program (100 V, 300 V, 500 V, 1000 V and 2500 V for 
1 hour each and 5000 V for 16 hours). A limiting current (50 μA per strip) was 
maintained.  
 
After IEF, the strips were equilibrated (30 min) with 6 M urea, 32 mM DTT, 0.375 M 
Tris-HCl pH6.8, 10%(w/v) SDS, 50% (v/v) glycerol and for 20 min in the dark  with 63 
mM iodoacetamide in the above equilibration buffer instead of urea. Each strip was 
loaded on an 8-16% gradient polyacrylamide gel and proteins were electrophoresed at 30 
mA constant current using a Protean II XL (Bio-Rad) in a buffer that contained 25 mM 
Tris, 192 mM glycine and 0.1% SDS until the blue dye reached the bottom of the gel. 
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4.2f Staining of proteins 
 
The 2-DE separated proteins were stained with a solution of Ruthenium II ((bis 
bathophenanthroline) (bathophenanthroline disulfonate)) that was synthesized in-lab 
using a modified protocol [53]. The gels were fixed in an aqueous solution containing 
30% ethanol and 10% glacial acetic acid overnight. Gels were washed with aqueous 
solution of 20% ethanol three times and incubated overnight in solution containing the 
ruthenium complex. Thereafter, the gels were washed once with distilled water. Stained 
gels were stored in distilled water at 4°C. 
 
4.2g Image and statistical analyses 
 
Stained gels were scanned with a Versadoc 3000 scanner from Bio-Rad (Hercules, CA). 
Images were analyzed using the PD Quest software (Bio-Rad). Spots were detected and 
matched by both automated matching following the instructions in the software and also 
by manual matching. The spot volumes were normalized to the total density in the gel 
image to avoid any non-expression related variations between matched spots. The 
statistical significance of the data was determined by the Student’s t test.  A difference in 
spot volume was considered statistically significant at p<0.05 and confidence level of 
95%. 
 
4.2h In-gel proteolysis of proteins 
 
Protein spots were picked and digested with trypsin using Bruker Daltonics prep/digest 
station. In brief, the gel pieces were washed 6 times alternating with 50 mM NH4HCO3 
and 1:1 ACN: NH4HCO3 (50 mM) for 5 min each at 20°C and dried with ACN for 10 
min at 20°C. A 10 μL volume of trypsin (66.67ng) solution in 25 mM NH4HCO3 was 
added and gel pieces were allowed to swell for 30 min at 20°C. Digestion was allowed to 
proceed for 4 hours at 50°C.  Peptides were extracted after terminating the digestion with 
1 μL of 1% aq. formic acid. 
 
 
                                                                          126  
4.2i MALDI-TOF mass spectrometry analysis 
 
MALDI-TOF mass spectra were generated using Bruker Autoflex (Billerica, MA) in the 
reflectron mode. The Bruker Daltonics prep/digest station was used to spot the matrix and 
the peptide solution on the anchorchip target. Briefly, matrix solution (10 mg/mL of α-
cyano-4-hydroxycinnamic acid in 90% acetone and 2% TFA) was spotted and 1.5 μL of 
peptide solution was added to the matrix spot and allowed to air dry. On target washing 
was carried out with 0.2% TFA. Spectra were recorded and 100-300 laser shots were 
added to one spectrum. The spectra were externally calibrated against the monoisotopic 
mass of a standard solution containing 1 μg/μL Bradykinin ([M+H]+  757.399), 
Vasopressin ([M+H]+ 1084.445), Angiotension II ([M+H]+1046.542), Substance P 
([M+H]+ 1347.735) and oxidized form of Substance P ([M+H]+ 1363.731) and internally 
calibrated using known trypsin autolysis peaks. 
 
4.2j LC-MS/MS analysis 
 
The trypsin digested samples were also analyzed using a Thermo Electron Corporation’s 
LCQ Classic quadrupole ion trap mass spectrometer (San Jose, CA). The tryptic peptides 
were resolved on in-house constructed capillary column. The column was fabricated by 
packing 15 cm of Phenomenex Polymer X (3 μm particle size) into a 320 μm I.D fused 
silica capillary using a home-made stainless steel packing cell pressurized with helium to 
1000 psi. Five μL of tryptic peptides were injected into the column and eluted at a flow 
rate of ~ 4 μL/min, using a binary gradient of 5-80% ACN (with 0.1% formic acid) 
within 55 min. Spectra were acquired with a probe spray voltage of 4 kV and a heated 
capillary temperature of 175°C.  
 
4.2k Database search  
 
• PMF 
The MS data were searched against tryptic peptides sequences from the Swiss-Prot 
database using the Mascot algorithm. The search was restricted to trypsin generated 
 
                                                                          127  
peptides allowing up to two missed cleavages. A variable modification for oxidation of 
methionine and carbamidomethylation of cysteines were set. The taxonomy was human 
and the peptide tolerance was ± 0.5Da.  
 
• LC-MS/MS 
Mass spectra were searched against the human sub database from the Swiss-Prot database 
using Mascot algorithm. One missed trypsin cleavage was allowed and a variable 
modification of oxidation of methionine was set. Peptide tolerance and MS/MS tolerance 
were both set at ± 0.8 Da. 
 
At the above settings for both PMF and LC-MS/MS, probability based Mowse scores 
greater than 33 indicated identity or extensive homology. Additional criteria like more 
than one peptide must be identified and the ion score of at least one peptide must be 
greater than 30 were used to identify proteins.   
 
4.2l Western blot analysis 
 
For western blotting after SDS-PAGE, a standard protocol after Towbin et al. was used 
[36]. Briefly, 25 μg of whole cell lysate from SY5Y treated with 100 μM malathion for 
24 hours and the corresponding control samples were mixed with sample buffer 
containing 60 mM Tris-HCl pH 6.8, 10% glycerol, 10% SDS, 0.1% bromophenol blue 
and 5% β-mercaptoethanol, boiled for 5 min and on a 12% SDS-polyacrylamide gel. 
Electrophoresis was carried out at 100 V for about 2 hours. The proteins were blotted 
onto a nitrocellulose membrane at 100 V for 1 hour. Transfer of proteins to the 
nitrocellulose membrane is confirmed by Ponceau S staining. The membrane was 
blocked with blocking buffer (5% non fat milk in Tris buffer saline containing 0.05% 
Tween-20). After blocking for 1 hour 30 min, the membrane was incubated with the anti-
human rabbit primary antibody in blocking buffer overnight at 4°C. Both UCH L1 and 
rhoGDI antibodies were used at 1:2000 dilutions. After washing, the membranes were 
incubated with the secondary peroxidase conjugated goat anti-rabbit antibody (1:2500 
dilutions in wash buffer). Signals were developed with an enhanced chemiluminescence 
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(ECL) kit from GE Healthcare (Waukesha, Wisconsin). The developed ECL film was 
scanned and the tiff images were analyzed by Scion Image software. Excel was used to 
perform statistical analyses. The GAPDH protein was also probed for to check on the 
efficiency in loading the sample. 
 
4.3 Results 
 
4.3a Dose-dependent effects of malathion on cell viability  
 
Malathion dose-dependently increased cell viability in SY5Y cells after exposure with 
concentrations up to 250 μM for 24 hours. The results were calculated for each well as 
percent of control absorbance (viability) and are expressed as the mean ± SD control 
absorbance (Figure 4.1). Cultures exposed to 1000 and 2000 μM malathion showed 
significantly decreased cell viability compared to control cultures. Surprisingly, lower 
concentrations of malathion (25 μM to 250 μM) significantly increased mitochondrial 
function.  
 
4.3b Identification of proteins using mass spectrometry 
 
Two-dimensional gel electrophoresis was carried out on 400 μg of whole cell lysate 
protein from SY5Y cells and 2-DE map of the whole cell lysate proteins were generated 
(Figure 4.2). Using PD Quest gel image analysis software around 400 proteins spots were 
detected on the 2-DE gel. A total of 122 proteins were identified using mass spectrometry 
after subjecting the proteins to in-gel trypsin proteolysis (Appendix A and B). Mass 
spectra were searched against the human sub database from the Swiss-Prot database using 
the Mascot algorithm [97]. The search parameters described in the methods section gave 
unambiguous protein identification with adequate number of peptides identified and 
reasonable sequence coverage for the proteins. 
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Figure 4.1 Dose dependent effect of malathion on cell viability of SY5Y cultures. Cell 
viability was measured by MTT assay and the percentage control for each treatment is 
expressed as mean ± SD values. 
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4.3c Analysis of SY5Y proteome after treatment with malathion 
 
2-DE was performed four times on whole cell lysate from control cell cultures (no 
malathion) and cell cultures treated with 100 μM malathion for 24 hours and 2 times each 
on 100 μM malathion for 48 hours and their corresponding control samples. The average 
number of spots detected from the fluorescence-stained gel images using the PD Quest 
software was about 400 spots in the treated and control gels. Figure 4.2 shows the typical 
2-DE gel performed on the whole cell lysate from control sample (no malathion 
treatment). 2-DE maps of 400 μg of whole cell lysate from treated cell cultures are shown 
in figures 4.3 to 4.5. From the 400 spots, 123 spots were identified with both MALDI-
TOF and LC- MS/MS combined (Appendix A and B). Twenty one proteins were 
differentially expressed in the malathion treated samples (p<0. 05%) and the fold change 
relative to control is given in Table 4.1. Figure 4.6 shows the sections of gel for the 
differentially expressed proteins UCH L1, GST and for the protein rho GDI that was 
unchanged after treatment along with the histograms. Figure 4.7 gives the gel sections 
and the histogram for calmodulin that was down-regulated by about 2 fold when treated 
with 100 μM malathion for 48 hours. Sixteen proteins were down-regulated and 5 
proteins were up-regulated in the malathion-treated SY5Y cultures. These differentially 
expressed proteins fall under different classes of proteins namely chaperone proteins, 
calcium binding proteins, cytoskelatal proteins and proteins involved in degradation 
pathways. A representative MS/MS spectrum along with the Mascot search results for 
protein UCH L1 is shown in figure 4.8. Figure 4.9 gives the MALDI-TOF mass spectrum 
for protein GRP 75.   
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Figure 4.2 A representative 2D gel image of 400 μg of control SY5Y samples (no 
Malathion) resolved first on a pH 3 to 10 IPG strip, separated on 8-16% gradient 
polyacrylamide gel and annotated with spot numbers. The protein spots were visualized 
by staining with in-lab synthesized fluorescent ruthenium complex. The numbers on the 
annotated gel indicate proteins that were identified by mass spectrometry and correspond 
to numbers assigned in Tables 1 and 2.  
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Figure 4.3 A representative 2D gel image of 400 μg of whole cell lysate from SY5Y cell 
cultures treated with 50 μM malathion for 16 hours and resolved first on a pH 3 to 10 IPG 
strip and separated on 8-16% gradient polyacrylamide gel. The spot numbers indicated in 
the gel are landmark proteins, the protein names of which are given in appendix A and B. 
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Figure 4.4 A representative 2D gel image of 400 μg of whole cell lysate from SY5Y cell 
cultures treated with 100 μM malathion for 24 hours and resolved first on a pH 3 to 10 
IPG strip and separated on 8-16% gradient polyacrylamide gel. The spot numbers 
indicated in the gel are landmark proteins, the protein names of which are given in 
appendix A and B. 
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Figure 4.5 A representative 2D gel image of 400 μg of whole cell lysate from SY5Y cell 
cultures treated with 100 μM malathion for 48 hours and resolved first on a pH 3 to 10 
IPG strip and separated on 8-16% gradient polyacrylamide gel. The spot numbers 
indicated in the gel are landmark proteins, the protein names of which are given in 
appendix A and B. 
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Table 4.1 List of proteins altered due to treatment with malathion. Seq.Cov. % denotes the percentage of protein sequence covered by 
the trypsin digested peptides 
 
Fold Changes 
 
Spot  
# 
 
Protein 
 
Swiss 
Prot 
ID 
 
Theoretical 
Mr 
(kDa) 
 
Theoretical 
pI 
 
Seq.  
Cov. 
% 
 
Mowse  
score 
 
Peptides matched 
16 hr 24 hr 48 hr 
 
 
 
1 
 
 
 
Calmodulin 
 
 
 
 
P62158 
 
 
 
16.7 
 
 
 
4.09 
 
 
 
18 
 
 
 
67 
 
KMK, EAFR, DGDGTITTK 
DGNGYISAAELR 
MADQLTEEQIAEFK 
EAFSLFDKDGDGTITTK, 
LTDESLSMPLISSFCPR 
 
 
 
0.92 
 
 
 
0.84 
 
 
 
0.49 
 
 
6 
Enhancer 
of 
rudimentary 
homolog 
 
 
P84090 
 
 
12.2 
 
 
5.62 
 
 
23 
 
 
62 
 
 
RQAQQAGK 
EKIYVLLR, MYEEHLKR 
 
 
1.2 
 
 
0.74 
 
 
0.30 
 
 
9 
 
 
Calgizzarin 
 
 
 
P31949 
 
 
11.7 
 
 
6.56 
 
 
40 
 
 
102 
ISSPTETER 
TEFLSFMNTELAAFTK 
NQKDPGVLDR,DPGVLDR, 
AVPSQKR 
 
 
0.61 
 
 
1.1 
 
 
0.33 
 
 
10 
 
 
Ubiquitin 
 
 
 
P62988 
 
 
0.85 
 
 
6.56 
 
 
7 
 
 
84 
 
TLSDYNIQK 
TITLEVEPSDTIENVK 
TITLEVEPSDTIENVKAK 
 
 
0.83 
 
 
0.83 
 
 
0.56 
 
12 
 
Galectin 1 
Isoform 1 
 
 
P09382 
 
14.5 
 
5.34 
 
23 
 
180 
 
SFVLNLGK, LPDGYEFK 
LNLEAINYMAADGDFK 
 
 
1.01 
 
1.0 
 
 
0.53 
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Fold Changes 
 
 
 
 
Spot # 
 
 
Protein 
 
 
Swiss 
Prot 
ID 
 
 
Theoretical 
Mr 
(kDa) 
 
 
Theoretical 
pI 
 
 
Seq.  
Cov. 
% 
 
 
Mowse 
score 
 
 
Peptides matched 
16 hr 24 hr 48 hr 
 
13 
 
Galectin 1 
 isoform 2 
 
P09382 
 
14.5 
 
5.34 
 
17 
 
92 
 
 
LPDGYEFK 
LNLEAINYMAADGDFK 
 
1.07 
 
0.68 
 
0.16 
 
 
17 
 
 
Tubulin specific 
Chaperone A 
 
 
 
O75347 
 
 
12.7 
 
 
5.25 
 
 
19 
 
 
74 
 
QAEILQESR 
LEAAYLDLQR 
KQAEILQESR 
RLEAAYLDLQR 
 
 
1.1 
 
 
0.65 
 
 
0.40 
 
 
 
22 
 
 
 
Cyclophilin A 
 
 
 
 
P05092 
 
 
 
17.8 
 
 
 
7.82 
 
 
 
10 
 
 
 
184 
 
FEDENFILK 
ALSTGEKGFGYK 
VSFELFADKVPK 
TEWLDGKHVVFGK 
VKEGMNIVEAMER 
 
 
 
0.8 
 
 
 
1.0 
 
 
 
 
0.58 
 
 
35 
 
 
 
Glyoxalase 1 
 
 
 
Q04760 
 
 
20.5 
 
 
5.25 
 
 
27 
 
 
104 
 
FEELGVK, VLGMTLIQK 
FSLYFLAYEDKNDIPK 
GLAFIQDPDGYWIEILNPK 
 
 
 
1.3 
 
 
0.64 
 
 
0.51 
 
 
42 
 
 
 
Glutathione S 
transferase A4 
 
 
 
O15217 
 
 
25.7 
 
 
 
7.89 
 
 
20 
 
 
71 
 
MLLADQGQSWK 
PPYTVIVYFPVR 
AFLASPEYNLPINGNGKQ 
ALPGQLKTLLSQNQGGK 
 
 
1.1 
 
0.90 
 
1.7 
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Fold Changes 
 
 
    
 
Spot  
# 
 
 
Protein 
 
 
Swiss  
Prot 
ID 
 
 
Theoretical 
Mr 
(kDa) 
 
 
Theoretical 
pI 
 
 
Seq.  
Cov. 
% 
 
 
Mowse 
score 
 
 
Peptides matched 
16 hr 24 hr 48 hr 
 
 
 
43 
 
 
 
 
HSP 27 
 
 
 
P04792 
 
 
 
22.7 
 
 
 
5.98 
 
 
 
21 
 
 
 
148 
 
VPFSLLR 
LFDQAFGLPR 
VSLDVNHFAPDELTVK 
LATQSNEITIPVTFESR 
 
 
 
1.08 
 
 
 
0.52 
 
 
 
0.13 
 
 
 
 
44 
 
 
 
 
DJ 1 protein 
 
 
 
 
 
Q99497 
 
 
 
 
19.8 
 
 
 
 
6.33 
 
 
 
 
15 
 
 
 
 
187 
 
 
ALVILAK, APLVLKD 
GAEEMETVIPVDVMRR 
GPGTSFEFALAIVEALNGKEVAA
QVK 
EGPYDVVVLPGGNLGAQNLSES
AAVKEILK 
 
 
 
 
0.87 
 
 
 
 
0.82 
 
 
 
 
0.57 
 
 
 
 
52 
 
 
 
 
UCH L 1 
Isoform 1 
 
 
 
 
 
P09936 
 
 
 
 
24.8 
 
 
 
 
5.33 
 
 
 
 
34 
 
 
 
 
269 
 
 
 
LGVAGQWR, QFLSETEK 
LGFEDGSVLK 
QIEELKGQEVSPK 
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0.58 
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62 
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29 
 
 
 
190 
 
ELASQPDVD 
QSLGELIGTLNAAK 
KQSLGELIGTLNAAK 
VVLAYEPVWAIGTGK 
GFLVGGALKPEFVDIINAK 
 
 
 
1.1 
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Prohibitin 
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38 
 
 
 
 
94 
 
DLQNVNITLR 
VLPSITTEILK 
FDAGELITQR 
QVSDDLTER 
QVAQQEAER 
NVPVITGSK 
EFTEAVEAK 
IFTSIGEDYDER 
ILFRPVASQLPR 
KLEAAEDIAYQLSR 
 
 
 
 
 
1.1 
 
 
 
 
 
1.46 
 
 
 
 
 
 
1.51 
 
 
 
72 
 
 
 
F actin  
Capping 
 protein 
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32.9 
 
 
 
5.45 
 
 
 
24 
 
 
 
107 
 
VSDEEKVR, 
LLLNNDNLLR 
FITHAPFNEVFNDVR 
IEGYEDEHGDLGNSR 
FDHLRK, ESCDSALR 
 
 
 
 
1.8 
 
 
 
2.7 
 
 
 
5.2 
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Tcomplex protein 
1 ε subunit 
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19 
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AVTIFIR, NLIRDNR 
FSELTAEK, 
VGGRLEDTK 
MIIEEA,IADGYEQAAR 
QQISLATQMVR 
MLVIEQCKNSR 
IDDIRKPGESEE 
DVDFELIKVEGK 
KQQISLATQMVR 
EKFEEMIQQIK 
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not 
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HSP 60 
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33 
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GYISPYFINTSK 
GVMLAVDAVIAELKK 
ISSIQSIVPALEIANAHR 
TLNDELEIIEGMKFDR 
IQEIIEQLVTTSEYEKEK 
QSKPVTTPEEIAQVATIS
ANGDK 
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0.39 
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Fold Changes 
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Glucose regulated 
protein 
 
 
 
 
 
 
 
P11021 
 
 
 
 
 
 
70.4 
 
 
 
 
 
 
5.01 
 
 
 
 
 
 
23 
 
 
 
 
 
 
176 
LTPEEIER, ITITNDQNR 
VYEGERPLTK,  
EFFNGKEPSR 
VEIIANDQGNR, 
 DAGTIAGLNVMR 
SDIDEIVLVGGSTR 
AKFEELNMDLFR 
NGRVEIIANDQGNR 
KSDIDEIVLVGGSTR 
TKPYIQVDIGGGQTK 
IINEPTAAAIAYGLDKR 
STMKPVQKVLEDSDLK 
 
 
 
 
 
 
0.97 
 
 
 
 
 
 
1.76 
 
 
 
 
 
 
1.75 
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68.7 
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29 
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DNMALQR, LVGMPAKR 
YAEEDRR, VLENAEGAR 
NVPFKIVR,DSTGENIR 
KDSETGENIR,RYDDPEVQK 
DAGQISGLNVLR, 
VQQTVQDLFGR,AIVTDLIR, 
TTPSVVAFTADGER 
SDIGEVILVGGMTR, 
AFEGIVTDLIRR 
LYSPSQIGAFVLMK, 
LGTLIGIPPAPR 
VQQTVQDLFGRAPSK 
NAVITVPAYFNDSQR 
QAVTNPNNTFYATKR 
SQVFSTAADGQTQVEIK 
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Vimentin 
 
 
 
 
 
 
 
 
P08670 
 
 
 
 
 
 
 
53.5 
 
 
 
 
 
 
 
5.06 
 
 
 
 
 
 
 
19 
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MALDIEIATYRK, 
HLREYQDLLNVK 
KVESLQEEIAFLK 
ILLAELEQLKGQGK 
ISLPLPNFSSLNLR 
ETNLDSLPLVDTHSK 
FADLSEAANRNNDALR 
ETNLDSLPLVDTHSKR 
EMEENFAVEAANYQDTIGR 
LLQDDFSLADAINTEFKNTR 
QMREMEENFAANYQDTIGR 
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0.68 
 
 
 
 
 
 
 
0.53 
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Figure 4.6 Close-up of the gel sections showing differential expression of protein UCH 
L1(spot # 52), rho GDI (spot # 40) and GST (spot # 42) (A) and protein calmodulin (spot 
#1)(B) between control (CTRL), 16 hour (MAL 16), 24 hour (MAL 24) and 48 hour 
(MAL 48) malathion treated SY5Y cells. The protein spots are numbered corresponding 
to appendix A and B. The difference in expression is shown in the histogram at the 
bottom of the gel picture. The expression profile is presented as bar chart with error bars. 
Each bar represents intensity ± S.D. of blots from quadruplet runs for control (CTRL) and 
24 hour malathion (MAL 24) treated samples while duplicate for 16 hour (MAL 16) and 
48 hour malathion treatment (MAL 48).   
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Figure 4.7 Close-up of the gel sections showing differential expression of protein 
calmodulin (spot #1) between control (CTRL), 16 hour (MAL 16), 24 hour (MAL 24) 
and 48 hour (MAL 48) malathion treated SY5Y cells. The protein spots are numbered 
corresponding to appendix A and B. The difference in expression is shown in the 
histogram at the bottom of the gel picture. The expression profile is presented as bar chart 
with error bars. Each bar represents intensity ± S.D. of blots from quadruplet runs for 
control (CTRL) and 24 hour malathion (MAL 24) treated samples while duplicate for 16 
hour (MAL 16) and 48 hour malathion treatment (MAL 48).   
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Figure 4.8 Representative example of MS/MS spectrum for the peptide fragment 
MQLKPMEINPEMLNK along with the database search result for protein UCH L1 
 
MS/MS Fragmentation of 
MQLKPMEINPEMLNK Found in 
UCHL1 
Mascot search result for UCH L1 
Sequence Coverage: 34% Matched peptides shown in Bold Black  
 
1 MQLKPMEINP EMLNKVLSRL GVAGQWRFVD VLGLEE 
ESLG SVPAPACALL 51 LLFPLTAQHE NFRKKQIEEL 
KGQEVSPKVY FMKQTIGNSC GTIGLIHAVA 101 NNQDK 
LGFED GSVLKQFLSE TEKMSPEDRA KCFEKNEAIQ 
AAHDAVAQEG 151 QCRVDDKVNF HFILFNNVDG 
HLYELDGRMP FPVNHGASSE DTLLKDAAKV 201 
CREFTEREQG EVRFSAVALC KAA  
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Figure 4.9 Representative MALDI-TOF spectrum for the for protein GRP 75 along with 
the matched peptides shown in bold black 
 
 
 
MALDI-TOF mass spectrum 
of GRP 75 
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Sequence Coverage: 30% Matched peptides shown in Bold Black  
 
1 MISASRAAAA RLVGAAASRG PTAARHQDSW NGLSHEAFRL 
VSRRDYASEA 51 IKGAVVGIDL GTTNSCVAVM EGKQAKVLEN 
AEGARTTPSV VAFTADGERL 101 VGMPAKRQAV TNPNNTFYAT 
KRLIGRRYDD PEVQKDIKNV PFKIVRASNG 151 DAWVEAHGKL 
YSPSQIGAFV LMKMKETAEN YLGHTAKNAV ITVPAYFNDS 201 
QRQATKDAGQ ISGLNVLRVI NEPTAAALAY GLDKSEDKVI 
AVYDLGGGTF 251 DISILEIQKG VFEVKSTNGD TFLGGEDFDQ 
ALLRHIVKEF KRETGVDLTK 301 DNMALQRVRE AAEKAKCELS 
SSVQTDINLP YLTMDSSGPK HLNMKLTRAQ 351 FEGIVTDLIR 
RTIAPCQKAM QDAEVSKSDI GEVILVGGMT RMPKVQQTVQ 401 
DLFGRAPSKA VNPDEAVAIG AAIQGGVLAG DVTDVLLLDV 
TPLSLGIETL 451 GGVFTKLINR NTTIPTKKSQ VFSTAADGQT 
QVEIKVCQGE REMAGDNKLL 501 GQFTLIGIPP APRGVPQIEV 
TFDIDANGIV HVSAKDKGTG REQQIVIQSS 551 GGLSKDDIEN 
MVKNAEKYAE EDRRKKERVE AVNMAEGIIH DTETKMEEFK 601 
DQLPADECNK LKEEISKMRE LLARKDSETG ENIRQAASSL 
QQASLKLFEM 651 AYKKMASERE GSGSSGTGEQ KEDQKEEKQ  
   2000 
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4.3d Validation of the 2-DE results by Western Blotting  
 
To confirm the fidelity of results obtained by 2-DE, western blot analysis was carried out 
for two proteins: one protein that was significantly down-regulated namely UCH L1 and 
one protein rho GDI that was unchanged due to treatment with malathion. The western 
blot data correlate with the 2-DE result for the analyzed proteins (Figure 4.10).  
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                                               UCH L1                rho GDI 
 
Figure 4.10 Western blot analysis of protein UCH L1 that was upregulated in malathion 
treated samples and rhoGDI that was changed due to treatment. The difference in 
expression is shown in the histogram. The expression profile is presented as grouped bar 
chart with error bars. Each bar represents relative intensity (% of control) ± S.D. of blots 
from duplicate runs. 
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Western blot bands were normalized to GAPDH bands and quantified in comparison to 
control cells. Data are given as percentages of the control value (mean ± SD; n = 2 
experiments; p<0.05). Exposure to 100 μM malathion for 24 hours results in a significant 
decrease in UCH L 1 however, no significant change is seen in rho GDI protein.  
 
4.4 Discussion 
 
Large quantities of organophosphates are being used as insecticides to control pests in 
both agricultural and domestic areas. The widespread use of malathion has created 
awareness of related adverse effects on particularly non-target organisms. Most of the 
reports studying toxicity of malathion were focused on secondary effects after exposure 
and symptomology in particular. On the other hand, specific mechanisms involved in 
malathion-induced in vitro toxicity have not been extensively described. The study is the 
first proteomic investigation of the alteration in protein levels after treatment with 
malathion using SY5Y cells as model system. These studies enable us to better 
understand the underlying mechanisms by which malathion can potentially induce 
toxicity.   
 
4.4a Cell viability 
 
Cell viability measurements based on MTT assay assess the mitochondrial activity of 
healthy cells in a sample [95]. Treatment of SY5Y cells with 100 μM malathion for 24 
hours lead to about 25% increase in the amount of MTT reduction compared to control 
cell cultures (not treated with malathion) (Figure 4.1). MTT is reduced to formazan by 
mitochondrial enzymes present exclusively in viable cells. Increased MTT reduction seen 
when cultures were treated with 25 to 250 μM malathion denotes enhancement of 
mitochondrial function in these cells. However, it does not provide any information on 
the actual number of viable cells. In other words there could actually be fewer viable cells 
present in the culture after treatment with malathion which show increased mitochondrial 
activity. Treatment with concentrations greater that 1000 μM malathion caused 
significant decrease in mitochondrial activity relative to control. 
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For our proteomic investigation, the SY5Y cell cultures may be treated with 
concentrations of malathion ranging from 25 to 250 μM (Figure 4.1). It was however, 
decided to treat the SY5Y cells with 100 μM malathion for two time periods namely: 24 
hours and 48 hours and 50 μM malathion for 16 hours. This was done to enable 
comparison of malathion toxic effects with another study that involving another 
organophosphate insecticide, namely chlorpyrifos, on the SY5Y proteome. Chlorpyrifos 
was also being studied in the lab and it was important that similar responses to the cell 
viability assay for both chlorpyrifos and malathion were to be maintained to compare 
their toxic effects.  
4.4b Alteration in levels of proteins after treatment with malathion 
Investigation of the SY5Y proteome after treatment with malathion showed significant 
change in the levels of specific proteins when comparing results for control SY5Y 
samples (no treatment) and malathion-treated samples. SY5Y cultures treated with 50 μM 
malathion for 16 hours showed slight alteration in protein levels; these alterations became 
more conspicuous in cultures treated with 100 μM malathion for a period of 24 and 48 
hours (Table 4.1). The PD Quest software used for detection of the protein spots was also 
used to estimate the protein spot volume that is directly proportional to the level of 
protein in the sample. Normalization of the spot volume to the total density in the gel 
image was carried out to avoid any non-expression related changes. A difference in spot 
volume (and hence the protein level) was considered statistically significant at p<0.05 
and confidence level of 95%.  
 
The proteins whose levels were altered significantly after treatment with malathion fall 
under five major classes of proteins: calcium binding proteins, chaperones, protein 
involved in degradation pathways, cytoskeletal proteins and other miscellaneous proteins. 
Each class of proteins is individually discussed in the following section. 
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• Calcium binding proteins 
 
Calmodulin (spot #1) and calgizzarin (spot #9) are two calcium (Ca2+) modulators whose 
levels were down-regulated by two and three fold respectively in SY5Y cell cultures after 
treatment with 100 μM malathion for a period of 48 hours. There exists numerous 
cellular processes within the eukaryotic cells that are Ca2+ dependent and/or Ca2+ 
regulated as reviewed by Clapham [98]. Calmodulin [99] is an ubiquitous protein that can 
bind up to 4 Ca2+ ions and regulate various signaling pathways within the cell. Some of 
CaM targets include: cyclic nucleotide metabolism, phosphorylation pathways, 
dephosphorylation and calcium transport [100]. It has been reported that oxidative 
modification of CaM results in degradation of the protein by the proteosome and 
subsequently a decrease in the levels of functional CaM in rats [101]. Since CaM is the 
major Ca2+ binding protein, reduction in calmodulin affects calcium levels within cells. 
Calgizzarin is another Ca2+ binding protein that regulates various cellular events 
including protein phosphorylation, enzyme activation, interaction with cytoskeletal 
proteins and calcium homeostasis [102].  
 
A balance in cytosolic calcium concentration is maintained not only by calcium binding 
proteins but also by various other intracellular calcium buffers like mitochondria [103-
105]. But both calmodulin and calgizzarin that are primarily responsible for maintaining 
calcium homeostasis within the cell were significantly down-regulated in cell cultures 
treated with malathion compared to control cultures. The down-regulation of calmodulin 
and calgizzarin in malathion-treated SY5Y cell cultures may result in an imbalance in 
calcium concentration within the cell affecting various signaling pathways.  
  
• Chaperones 
 
Chaperones are proteins that assist in the proper folding of other proteins by preventing 
misfolding, unfolding misfolded proteins and maintaining unfolded conformations by 
providing molecular and physical environments for correct folding. Many chaperones are 
heat shock proteins (see more below) that are highly expressed during cellular stress to 
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facilitate proper protein folding [106]. Some chaperones act to repair the potential 
damage caused by misfolding while others are involved in folding newly synthesized 
proteins as they are extruded from the ribosome. Other types of chaperones are involved 
in transport across membranes, for example in the mitochondria and endoplasmic 
reticulum [107, 108]. Chaperone proteins that are involved in the proper folding of 
nascent proteins into their native functional state are also called chaperonins.  
 
a. Heat shock proteins 
 
Heat shock proteins (Hsp) are present during normal conditions whose expression is 
greatly induced during stress [109, 110]. A common aspect of stress is generation of 
misfolded proteins; when the stress is intense heat shock proteins are highly expressed to 
cope with the increase in misfolded proteins. For this reason Hsps are also referred to as 
stress proteins. Hsps are also considered to play a general role in protection against 
cellular injury [111-113]. Hsps are highly conserved across species and since they play 
vital role in protein translocation, folding and assembly are also known as molecular 
chaperones [114, 115]. The Hsps are named according to their molecular weight and are 
classified as small Hsps (between 10 – 30kDa) and large Hsps (greater than 30 kDa). A 
number of heat shock proteins were identified in the whole cell lysate from SY5Y cells 
(Appendix A and B and Table 4.1). The two heat shock proteins whose levels were 
significantly altered after treatment with malathion are Hsp 27 and Hsp 60.  
 
Hsp 27 belongs to a class of small heat shock proteins (sHsps) that can protect cells from 
oxidative stress [116, 117]. sHsps act as molecular chaperones preventing unfolded 
proteins from irreversible aggregation [118-120] and along with other factors such as 
Hsp70 and adenosine tri-phosphate (ATP), they facilitate productive refolding of 
unfolded proteins [121, 122]. Four protein spots #43, #48, #49 and #56 in figure 4.2 were 
identified as Hsp 27 by mass spectrometry and the most acidic form [9] was down-
regulated significantly in SY5Y cells treated with malathion, yet without any significant 
change in the total Hsp levels between control and treated samples. It is known that Hsp 
27 has three phosphorylation sites (Ser15, Ser78 and Ser82) that can be potentially 
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phosphorylated by protein kinases [123, 124] and phosphorylation decreases the pI of a 
protein. The protein spots identified, as Hsp 27 may be the different phosphorylated 
forms. Both Lavoie et al. and Loktionova et al. report that phosphorylation of Hsp 27 
changes the quaternary structure of Hsp 27 resulting in the formation of dimers and 
tetramers of the protein, which in turn is responsible for stabilization of actin 
microfilaments by acting as actin capping protein [125, 126]. Down-regulation of the 
most acidic isoform of Hsp 27 (phosphorylated) in malathion-treated cells suggests 
disruption of actin polymerization.  
 
Hsp 60 is an essential mitochondrial protein that promotes the folding of several proteins 
imported into the mitochondrial matrix [127, 128]. Hsp 60 also refolds and prevents 
aggregation of denatured proteins [129]. Three protein spots #108, #112 and #113 were 
identified as Hsp 60 (Figure 4.2). Fratelli et al. report three isoforms of Hsp 60 in 
oxidatively stressed human T lymphocytes, a result of glutathionylation (post-
translational modification) of the protein [130]. Our results indicated that the most acidic 
isoform was identified to be down-regulated in the malathion treated SY5Y cells. Taking 
into account that the main role of Hsp 60 is in the proper folding of proteins within the 
mitochondria, the down-regulation of the acidic form in the malathion treated SY5Y cell 
cultures could result in an accumulation of misfolded proteins within the mitochondria.  
 
To reiterate, the acidic isoforms of both stress proteins Hsp 27 and Hsp 60 were 
significantly down-regulated in malathion-treated SY5Y cell cultures. The down-
regulation of these proteins could also contribute to an increased susceptibility of the 
cells to oxidative stress since these chaperones are thought to attenuate the proteolysis of 
misfolded proteins (formed as a result of oxidative stress) by binding to them and 
assisting in their repair. Further characterization of the function of each protein isoform 
may reveal in-depth information about the relevance of these findings. 
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b. Chaperonins 
 
A number of other chaperones were identified as significantly altered after treatment with 
malathion in SY5Y cells. These included tubulin-specific chaperone A, cyclophilin A, 
prohibitin, T complex 1 protein, glucose-regulated protein 78 (GRP 78) and glucose-
regulated protein 75 (GRP 75). Tubulin specific chaperone A protein is essential for the 
formation of functional tubulin heteromers and binds to tubulin folding intermediate 
formed by the synthesis of tubulin polypeptide with chaperonin T complex protein [131]. 
T complex protein (TCP) in addition to its role in formation of tubulin, also aids in the 
folding of other proteins [132, 133]. It is thought to act in concert with various protein 
degradation and modification pathways and maintain cellular homeostasis. TCP was up-
regulated 2.5 fold in the SY5Y cells treated with malathion. The up-regulation of TCP is 
an indication that SY5Y cells treated with malathion are stressed.  
 
Spots #20, #21, #22 and #23 in figure 4.2 were all identified as peptidyl prolyl cis-trans 
isomerase (cyclophilin A). From the amino acid composition of the protein, the 
isoelectric point is expected to be 7.8; however, based on the computed course of the pH 
gradient and the positions of other identified proteins in the gel, the actual pI spans a 
range from 7 through 8. Three isoforms of cyclophilin A have been reported earlier with 
possibility of phosphorylation as PTM [134]. In our study, four different isoforms were 
identified. There was no significant change in total protein level, however, spot #22 was 
significantly down-regulated in malathion-treated samples. Cyclophilin A catalyzes the 
cis-trans isomerization of proline imidic peptide bonds in oligopeptides and accelerates 
protein folding [135]. Cyclophilin A has been implicated in diverse functions such as the 
heat-shock response [136], in the nuclear import of some proteins [137] and in various 
signal tranduction pathways [138], but its exact function is not fully understood. It has 
also been demonstrated that decreasing the level of cyclophilin A in neuronal B50 cells 
inhibits the activation of caspases that are involved in triggering apoptosis [139]. There is 
however, no information in the literature on the specific role of these different isoforms 
of the protein, but the significant change in the levels of one particular isoform (acidic 
isoform) after treatment with malathion is definitely worth exploring. It is possible that 
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malathion is triggering apoptosis in the SY5Y cells, but decreased cyclophilin A isoform 
(may be the functional isoform) renders the cells resistant to apoptosis.   
 
Spot #67 was identified as prohibitin, a mitochondrial protein. Prohibitin is a membrane 
chaperonin that stabilizes mitochondrial proteins [140]. Prohibitin also plays a pivotal 
role in cell cycle regulation, aging, apoptosis and mitochondrial function [141, 142]. 
Coates et al. showed that prohibitin was up-regulated during metabolic stress due to 
imbalance in the synthesis of mitochondrial proteins [143]. Prohibitin was also up-
regulated in malathion-treated SY5Y cells by a factor of 1.5 fold when compared to 
control cultures which could very well be due to malathion-induced mitochondrial stress.  
 
Two glucose regulated proteins GRP 78 (spot # 109) and GRP 75 (spot #110) were 
identified as significantly altered in SY5Y cells after treatment with malathion. GRP 78 
has been implicated in unfolded protein response (UPR) during which it is up-regulated 
to correct the misfolded proteins [144]. GRP 78 transiently binds to a wide repertoire of 
proteins traversing the endoplasmic reticulum (ER) and facilitates their correct folding, 
glycosylation, assembly and turnover [145-147]. It is reported that GRP 78 induction 
protects cells from undergoing apoptosis and maintain cell viability under ER stress [148, 
149]. Induction of the corresponding grp78 gene can occur in response to different 
stimuli including glucose starvation, hypoxia and ER Ca2+ pool depletion [150]. 
Interestingly, GRP 78 was also up-regulated in SY5Y cells treated with malathion. GRP 
75 on the other hand was down-regulated significantly in malathion-treated SY5Y cells. 
GRP 75 is involved in the transport of proteins and their assembly inside the 
mitochondria [151]. Furthermore, GRP 75 may influence the pattern of proteins 
synthesized in the mitochondria, facilitate the assembly of mitochondrial proteins and 
then protect the proteins from proteolytic degradation [152, 153]. The alterations in levels 
of these ER and mitochondria specific glucose regulated proteins indicate malathion 
induced stress to these organelles in SY5Y cells. 
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• Proteins involved in ubiquitin proteosome pathway 
 
Studies indicate that most intracellular protein degradation takes place via the ubiquitin 
proteosome pathway (UPP) [154]. The UPP maintains cellular homeostasis by removing 
misfolded dysfunctional proteins. Ubiquitin carboxy terminal hydrolase L1 (UCH L1) 
(spot # 52 and # 54) is an essential enzyme in the UPP that is specifically involved in the 
recycling of ubiquitin by releasing it from the polyubiquitin tail [154] . Choi et al. report 
the presence of three different isoforms of UCH L1 in the brain of Alzheimer’s disease 
(AD) patients [155]. It should be noted here that we have identified two isoforms that 
have similar molecular weight but different isoelectric points (pIs). The more acidic 
isoform was down-regulated about 2 fold when SY5Y cell cultures were treated with 100 
μM malathion for a period of 48 hours. In addition to the hydrolase activity, it has been 
suggested that UCH L1 is also a regulator of apoptosis [156].  
 
The UPP involves ubiquitination of damaged or misfolded proteins that is to signal the 
degradation of proteins; however, damaged proteins are not removed when ubiquitin is 
reduced or mutated [157]. There is evidence that UCH L1 associates with ubiquitin 
during the UPP [156, 157]. It has been reported that UCH L1 deletion in mice cause 
gracile axonal dystrophy (gad), a recessive neurodegenerative disease [158]. In our study 
both UCH L1 (an acidic isoform) and ubiquitin were identified to be down-regulated in 
malathion-treated SY5Y cell cultures. We know that under stress most proteins can 
become misfolded and non-functional. Down-regulation of these two critical proteins 
involved in the removal of dysfunctional proteins in the malathion treated SY5Y cells 
could render the cells more susceptible to the accumulation of toxic misfolded proteins. 
Further study is required to identify the PTM and elucidate the functional significance of 
the acidic isoform of UCH L1.  
 
• Cytoskeletal proteins 
 
Seven proteins spots (# 76, #77, # 78, #88, #89, #90, and #122 in figure 4.2) were 
identified as vimentin, the intermediate filament protein. The various isoforms had 
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different molecular weights and pIs. The isoforms differed in molecular weight may be 
result of fragmentation of the parent protein itself, while the isoforms that differed in pI 
resulted most likely from PTMs. Studies have reported that vimentin is essential for 
axonal initiation in differentiating neuroblastoma cells [159]. It is a major contributor to 
the mechanical strength of a cell. Significant down-regulation of one isoform of vimentin 
was observed in SY5Y cells exposed to malathion along with a down-regulation of total 
vimentin levels when compared to control cultures. Spot # 72 was identified as F actin 
capping protein; this is a cytoskeletal-associated protein that was significantly up-
regulated by 5 fold in malathion-treated cultures. F actin capping protein is involved in 
capping the barbed ends of the actin filaments during polymerization and thus prevents 
the addition of actin units to the end [160]. The alterations in the levels of these structural 
proteins in malathion-treated SY5Y cells indicate disruption of cytoskeletal architecture. 
 
• Miscellaneous proteins 
 
Two isoforms of galectin-1 (spot # 12 and 13) were identified and both were down-
regulated in SY5Y cell cultures treated with malathion. Galectin-1, a β-galactoside-
binding lectin has been suggested to play a role in cell adhesion, proliferation and 
apoptosis [161]. Galectin-1 also acts as a negative growth regulator in neuroblastoma 
cells, and, in fact, galectin-1 is a probable effector in the sialidase-dependent growth 
control of neuroblastoma cells [162]. DJ-1 protein (spot # 44), a multifunctional protein 
involved in transcription and oxidative stress, is down-regulated after treatment with 
malathion. Deletion of the DJ-1 gene is associated with Parkinson’s disease which is 
thought to be due to the loss of the DJ-1 protein [163]. It has also been suggested that the 
loss of DJ-1 protein in neurons makes the cells more susceptible to oxidative stress and 
ER stress [164]. In the malathion-treated SY5Y cell cultures that show evidence for 
stress, down-regulation of DJ-1 protein can make these cells more vulnerable to ER 
stress.   
 
 Triose phosphate isomerase (spot # 62) catalyzes the isomerization of dihydroxyacetone 
phosphate to D-glyceraldehyde 3-phosphate [165]. The isomerization involves the 
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formation of the cytotoxic intermediate methylglyoxal, which is eliminated by glyoxalase 
1 (spot #35) preventing the formation of advanced glycation end products [166]. Down-
regulation of both these proteins in SY5Y cell cultures treated with malathion is 
intriguing but further investigation needs to be done to elucidate the significance. 
Glutathione S transferase A4 (spot # 42) is a phase 2 detoxifying enzyme that conjugates 
glutathione to a number of toxic electrophiles [167]. Lechner et al. report that GST 
activity in rat liver homogenate was increased two fold after treatment with malathion 
[168]. The increased levels of this enzyme in malathion-treated SY5Y cells suggest that it 
may carry out a protective measure against the insult. It is clear that malathion has the 
potential to disrupt cellular antioxidant defenses in SY5Y cell cultures. Spot # 6 was 
identified as enhancer of rudimentary homolog and the protein is a transcriptional co-
regulator that is highly conserved from plants to humans [169]. Little is known about its 
function, but its down-regulation observed in SY5Y cells treated with malathion can have 
consequences in the transcription machinery.          
 
The alteration in protein levels in SY5Y cell cultures after treatment with malathion is an 
important finding in regard to the OP toxicity, since there has been limited literature in 
this area. The level of any protein in a cell at any given time is controlled by the rate of 
transcription of the gene, efficiency of translation of the mRNA into the protein and the 
rate of degradation of the protein in the cell. 2-DE offers a powerful way of taking a 
snapshot of the state cells are, at a given time. However it should be noted that whether 
the alteration in protein levels studied by 2-DE is due to imbalance in proteolysis and 
protein synthesis warrants further investigation. Based on the altered levels of major 
proteins identified in our study, we propose the following model for the effect of 
malathion (Figure 4.11).   
 
Reports have indicated that organophosphates in addition to inhibiting AChE, can 
directly bind to muscarinic receptors (which are receptors for AChE) present in cells 
[170, 171]. Similarly, malathion can bind to muscarinic receptors present in the SY5Y 
cells. Binding of malathion to the receptor stimulates the phosphotidyl inositol pathway 
and activates the enzyme phospholipase C. Phospholipase C hydrolyzes phosphoinositide 
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bis-phosphate to inositol tri-phosphate (IP3) and diacylglycerol (DAG), IP3 acts as a 
second messenger and stimulates the release of calcium into the cytoplasm from 
intracellular stores like the ER. Increased cytoplasmic calcium has been reported as a 
definite event in the mechanism of many OP induced neuronal disorders [172, 173]. 
Elevation in intracellular calcium was also reported during an early phase of malathion 
induced apoptosis in the grass carp cell line ZC 7901 [174]. The increase in cytoplasmic 
calcium levels might be due to decreased activity of calcium expelling systems. Two 
calcium modulators: calmodulin and calgizzarin were significantly down-regulated in the 
malathion treated SY5Y cells. Ca2+ ATPase is another important calcium effluxing 
enzyme that extrudes calcium in order to maintain calcium homeostasis. Sharma et al. 
report the decrease in Ca2+ ATPase activity in hens after exposure to OP [175]. Though 
there is no direct indication of reduced Ca2+ ATPase in the malathion-treated SY5Y cells, 
the various other observations point out that malathion might increase cytoplasmic 
calcium levels. Since calcium is a known second messenger, increased levels of calcium 
within the malathion-treated SY5Y cells could lead to a cascade of intracellular events 
including impairment of mitochondrial oxidative phosphorylation and generation of free 
radicals [176].  
 
Mitochondria start to accumulate calcium when the cytoplasmic calcium concentration is 
over a threshold value and this occurs via a uniporter that is driven by the mitochondrial 
membrane potential [177, 178]. Hansford [179] and McCormack [180] found three Ca2+-
stimulated mitochondrial dehydrogenases: pyruvate dehydrogenase, α-ketoglutarate 
dehydrogenase and isocitrate dehydrogenase coupled to the electron-transport system. 
Activation of these dehydrogenases results in stimulation of both electron transport and 
ADP phosphorylation. The greater MTT reduction (mainly brought about by 
mitochondrial dehydrogenases) that was observed in the malathion treated SY5Y cell 
cultures can be explained by the stimulation of the above mentioned mitochondrial 
dehydrogenases by increased calcium concentration within the mitochondria. The uptake 
of calcium also activates mitochondrial phospholipases (like phospholipase A that 
catalyze the formation of arachidonic acid; reactive oxygen species generator) and seems 
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to trigger increased production of reactive oxygen species (ROS) [181-183] as well as 
release of mitochondrial proteins, some of which are proapoptogenic [184].  
 
Cadenas et al. report that in normal cells up to 5% of the oxygen reduced by 
mitochondria is converted by complex I of the respiratory chain to superoxide [185]. 
While ROS are proposed to play important roles in coordinating and regulating a number 
of cellular signaling pathways (redox signaling), oxidative stress results when the 
formation of ROS exceeds the capacity of antioxidant defense systems [186]. Increased 
mitochondrial activity coupled to imbalance in Ca 2+ ion concentration within the 
mitochondria results in increased production of ROS. Oxidative stress has already been 
implicated in malathion-induced cytotoxicity [80]. The production of ROS damages the 
cell structures including the DNA, proteins and lipids [187].  
 
Free radicals attack cell and organelle membranes, decrease the membrane fluidity by 
modifying lipids via a process termed lipid peroxidation and significantly alter membrane 
properties and possibly even disrupt the function of membrane-associated proteins [188]. 
Free radical oxidation causes proteins unfold/misfold [189-191]. Grune et al. 
demonstrated that oxidative modifications of proteins significantly accelerate protein 
aggregation and crosslinking [192]. To maintain proteins in a properly folded state, cells 
utilize a variety of chaperones that facilitate refolding, and if a protein is unable to be 
refolded it is degraded, often via the ubiquitin-proteasome pathway (UPP). However, in 
the malathion treated SY5Y cells, the chaperone proteins namely heat shock proteins, 
TCP, cyclophilin A and other proteins involved in UPP like ubiquitin and UCH L1 were 
significantly down-regulated. This means that in the SY5Y cells exposed to malathion, 
the damaged proteins may not be efficiently removed/degraded leading to their toxic 
accumulation.  
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Figure 4.11 Proposed model for malathion induced cytotoxicity in neuroblastoma cells. 
Malathion binds to muscarinic acid receptor and stimulates the phospholipase pathway resulting 
in production of inositol tri phosphate (IP3). IP3 binds to its receptors present in endoplasmic 
reticulum (ER) and causes the release of Ca2+ from the ER. Down-regulation of calcium 
modulators like calmodulin, calgizarrin and Ca-ATPase causes increase in cytosolic Ca2+ and 
results in calcium influx into the mitochondria. Imbalance in Ca2+ inside the mitochondria causes 
stimulation of various lipases, proteases and other enzymes. Activation of phospholipase A2 
causes increased generation of reactive oxygen species (ROS). The electron transport chain 
(ETC) is also activated and this adds to the ROS produced. The increased ROS and down-
regulation of antioxidant systems result in oxidative stress. The free radicals generated cause a 
number of undesirable effects that includes damage to the membrane and protein misfolding. The 
hydroxyl radical generated can cause ER stress that is seen in the up-regulation of GRP 78 
protein. Both ER and mitochondria are stressed due to treatment with malathion that is seen by 
the up-regulation of the stress specific proteins. Down-regulation of UCH L1, ubiquitin and other 
chaperone proteins that are involved in the removal of misfolded proteins indicates potential 
accumulation within the cells that can lead to malathion-induced cytotoxicity.      
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Since malathion is thought to cause oxidative stress, one would predict that in response 
the levels of Hsps would be high in SY5Y cells exposed to malathion. Yet, 2-DE data 
find low levels of these proteins, thus the paradoxically low levels of Hsps accentuate the 
oxidative damage incurred by exposure to malathion leaving the cells vulnerable and 
more prone to such damage. 
 
Another organelle that is susceptible to ROS damage is the ER. The free radicals 
generated within the mitochondria are converted to H2O2 by the enzyme superoxide 
dismutase [193]. The H2O2 so formed can react with intracellular Fe2+ ions possibly by 
Fenton reaction and result in the formation of hydroxyl radicals that are highly 
undesirable for ER and induce ER stress [194]. In addition to this oxidative stress due to 
ROS, ER is also susceptible to protein misfolding. Proteins unable to fold correctly cause 
ER stress and activate the unfolded protein response (UPR). As stated earlier, GRP 78 is 
a protein that is up-regulated when the ER is under stress due to misfolded proteins [148, 
149]. In the SY5Y cells treated with malathion too the GRP 78 was significantly up-
regulated indicating that malathion is capable of causing ER stress in these 
neuroblastoma cells. While increase in GRP 78 indicates ER stress, a decrease in DJ-1 
protein levels also points out at an ER stressed environment. DJ-1 protein was down-
regulated significantly when the SY5Y cells were treated with malathion.  
 
In addition to ER, mitochondria being one of the major sites of ROS production in a cell 
are also highly sensitive to impairment in ROS levels. Prohibitin, a mitochondrial specific 
stress protein was significantly up-regulated in SY5Y cells treated with malathion. This 
indicates malathion-induced stress to the organelle. Chen et al. reported that malathion 
induced cytotoxicty in grass carp cells by directing damaging mitochondria due to 
intracellular Ca2+ elevation, generation of reactive oxygen species (ROS) and ATP 
depletion [174]. Taken together, our results suggest that malathion induces oxidative 
stress leading to possible misfolding of protein that can potentially accumulate and cause 
cytotoxicity in neuroblastoma cell cultures.      
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The 2-DE technique employed is a powerful tool to investigate differential protein 
expression in a complex system because it has the ability to resolve a complex mixture of 
proteins like that of the whole cell lysate. However, it should be realized that 2-DE can 
only provide a snapshot of the most abundant proteins that are expressed at a given time 
point. Although these results allow a glimpse of malathion toxicity at the proteome level, 
it is hard to know if such alteration is a cause or a consequence of the treatment. Future 
work should be focused on the sub-proteome of mitochondria and ER from SY5Y cells 
after treatment with malathion. This will provide insight into the biochemical pathways 
that are associated with stress caused by malathion. 
 
Although neuroblastoma cells are the preferred model to test the in vitro toxicity caused 
by organophosphates, it should be realized that they are cancerous in. More precise 
information about the implication to human exposure can be deduced by employing 
primary cell lines (non-cancerous) or from animal studies. Overall, the current study 
provides a foundation for studies on cell culture, pesticide exposure and altered levels of 
proteins.   
 
4.5 Conclusion 
 
The hypothesis tested is exposure of SY5Y cells to malathion causes alteration in protein 
levels. The current study identified a number of stress response proteins, including 
calcium binding proteins, proteins involved in degradation pathways, cytoskeletal and 
tumor suppressor proteins to be significantly altered following treatment with malathion 
in the SY5Y cell cultures. The identification of differential protein expression in SY5Y 
cells after treatment with malathion is an important finding in regard to the OP toxicity, 
since there has been limited knowledge in this area.  
 
In conclusion, the data obtained in this study represent the first proteome profiling of 
SY5Y cells response to malathion. It was observed that there was significant alteration in 
levels of proteins when the cells were treated with 100 μM malathion for a period of 24 
hours that was exaggerated when the exposure was prolonged for 48 hours. This means 
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that the changes seen in protein levels could be an early indication of impending cellular 
damage. Cumulative evidence from previous experiments along with our data shows that 
oxidative stress is an important trigger for malathion toxicity. In our study, 122 proteins 
were identified from the SY5Y whole cell lysate out of which 21 proteins were 
significantly altered after treatment with malathion. Sixteen proteins were down-
regulated while 5 proteins were up-regulated due to treatment with malathion. Our results 
suggest that exposure to malathion causes perturbation in calcium homeostasis within the 
mitochondria that leads to generation of free radicals, accumulation of misfolded proteins 
and cause stress to mitochondria and ER in the SY5Y cell cultures. With increased 
awareness in pesticide related adverse effects, this oxidative stress induced by malathion 
in human neuroblastoma cells becomes especially critical when it comes to non-target 
exposure of elderly individuals to malathion. Such individuals, who are already 
susceptible to the damaging effects of oxidative stress due to process of aging, are 
exposed to malathion there is all possibility that the undesirable effects be more 
exacerbated. However, implication of this finding has to be further investigated using 
either primary cell lines and/or animal models to be able to extrapolate the effect to 
humans as well.  
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CHAPTER FIVE 
 
COMPARISON OF ALBUMIN-INTERACTOME IN VENTRICULAR 
CEREBROSPINAL FLUID BETWEEN ALZHEIMER’S DISEASE AND 
NORMAL SUBJECTS  
 
5.1 Introduction 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is 
characterized by deterioration of cognitive functions and is the most common form of 
dementia [195]. AD symptoms form a continuum with normal aging-related memory loss 
and this makes diagnosis difficult. Currently the only way to confirm AD is during 
autopsy of the patient by examining the brain for the presence of senile plaques and 
neurofibrillary tangles that are hallmarks of AD [196]. Protein β amyloid 1-42 (Aβ42) is 
the main protein that constitutes the senile plaques in the brain [197, 198]. Cerebrospinal 
fluid (CSF) from AD patients has reduced levels of Aβ42 relative to normal individuals, 
but there is no clear explanation for this [199-202]. Neurofibrilliary tangles in the brain of 
AD patients are a result of hyperphosphorylation of the tau protein (9). Aβ42, total tau 
(T-tau) and phosphorylated tau (P-tau) have been suggested as diagnostic markers for AD 
in clinical practice [203]. The changes in the levels of these proteins, however, overlap 
with other neurodegenerative disorders and hence are not specific to AD.  
 
The development of valid and reliable biomarkers that signify the disease condition is 
essential for the clinical diagnosis of AD. Biological fluids like serum, urine and 
cerebrospinal fluid (CSF) are being tested for AD biomarkers. CSF is most suited for the 
identification of biomarkers for diseases affecting especially the brain. CSF produced by 
the choroids plexus is a complex mixture of proteins and a difference in levels of these 
proteins indicate a disease condition [204]. CSF is in direct contact with the extra-cellular 
space of the brain and there is constant exchange of substances between the CSF and the 
brain. Hence, any change in the brain due to the disease pathology must be reflected in 
the surrounding CSF.  
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The CSF proteome has been characterized by several researchers, some of them 
elucidating the proteome [75-89] and others aimed at discovering biomarkers for 
neurodegenerative diseases like AD [90-99]. A major challenge involved in the analysis 
of CSF is the complexity of the sample. There exists enormous dynamic range in the 
levels of CSF proteins ranging from μg to ng. Albumin and immunoglobulins are the 
most abundant proteins found in the CSF constituting on average about 50% and 25%, 
respectively [205]. The complexity of CSF makes fractionation an essential step in the 
analysis of the proteome. Different methods can be used to achieve this, which include 
acetone precipitation, ultrafiltration, HPLC, capillary isoelectric focusing, liquid IEF and 
traditional 2-DE. By a combination of albumin and immunoglobulin depletion and 
MUDPIT analysis, 249 proteins were identified in human ventricular CSF [206]. 
Normally, to facilitate the analysis of low abundance proteins in biological fluids like 
serum and CSF, the most abundant proteins- albumin and immunoglobulins- are depleted 
using commercially available depletion kits or by using specific antibodies [207-209]. 
Albumin is a carrier and transport protein that interacts with a number of other small 
proteins and peptides [210-212]. Depletion of albumin could lead to the concomitant 
removal of low molecular weight proteins and result in the loss of information from these 
potentially interesting proteins and peptides [213]. However, selective isolation of this 
“interactome” fraction ( that consists of albumin interacting proteins) will enable 
identification of these low molecular weight proteins that are also potential biomarkers 
for the AD. 
 
The primary goal of this project was to isolate and compare the albumin-interactome in 
CSF between AD and normal subjects. Changes in protein levels in this fraction of the 
CSF proteome can provide insights into the disease pathology and help understand the 
progression of the disease.  
 
A crude isolation of the albumin-interactome was performed using membrane cut-off 
filters. A number of proteins along with their different isoforms as a result of post-
translational modifications (PTM) were observed in the albumin-containing fraction that 
showed significant difference in expression levels between CSF from AD and normal 
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subjects. To pinpoint the proteins that make up the albumin-interactome, 
immunoprecipitation of albumin from CSF was carried out. Our results clearly indicated 
the successful isolation of the albumin-interactome by immunoprecipitation, which 
thereby enabled the identification of proteins that are otherwise difficult to identify by 
direct analysis of CSF. Analysis of the 2-DE gel from the cut-off filter study showed 
differences in expression of specific isoforms of proteins that constituted the albumin-
interactome, emphasizing the importance of elucidation of PTMs along with studies 
related to levels of each isoform as opposed to examining the total protein content for 
biomarker discovery.  
  
5.2 Materials and Methods 
 
5.2a Materials 
 
Cut-off filters were purchased from Millipore (Billerica, MA). Protein G sepharose beads 
were purchased from GE healthcare (Princeton, NJ) and the rabbit anti-human albumin 
antibody was a product of Research Diagnostics Inc. (Flanders, NJ). Spin-X centrifuge 
tube filters with cellulose acetate membranes having a pore size of 0.45 μm were 
acquired from Corning Incorporated Life Sciences (Acton, MA). Dimethyl pimelimidate 
(DMP), sodium borate, acrylamide, bisacrylamide, ethanolamine and ammonium 
persulfate were purchased from Sigma (St. Louis, MO). Sodium phosphate monobasic 
and dibasic, phosphoric acid, Tris-HCl, methanol, formic acid and acetonitrile were 
obtained from Fisher Scientific (Fair Lawn, NJ). Ammonium sulfate was obtained from 
EMD chemicals (Gibbstown, NJ). Protein staining reagent Coomassie G250, TEMED 
and the low-range marker proteins were purchased from Bio-Rad (Hercules, CA). 
Lyophilized sequencing grade modified trypsin was purchased from Promega (Madison, 
WI). Fused silica capillary tubing 320 μm I.D. x 435 μm O.D. for liquid chromatography 
column was purchased from Polymicro Technologies (Phoenix, AZ) while the reverse 
phase packing material Polymer X (3 μm) was purchased from Phenomenex (Torrance, 
CA). All other LC accessories including zero dead volume (ZDV) unions, frits, ferrules 
were obtained from Upchurch Scientific (Oak Harbor, WA)   
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5.2b Human ventricular CSF sample  
 
Post mortem human CSF samples were obtained from Sanders-Brown Center on Aging 
(University of Kentucky, Lexington, KY). CSF samples were collected during autopsy 
from 6 AD and 6 normal control subjects. All AD subjects met NINCDS-ADRDA 
workgroup criteria for the clinical diagnosis of probable AD [214]. The subjects also met 
the criteria for histopathologic diagnosis of AD [215]. Control CSF samples were 
obtained from subjects who underwent annual neuropsychological testing as a part of 
normal volunteer, longitudinal aging studies at Sanders-Brown Center on Aging and were 
without a history of dementia or any other neurological disease. Evaluation of control 
brains revealed only age related alterations. CSF samples were collected as described 
previously by Lovell et al. [216]. Immediately after collection, 2 mL aliquots of CSF 
samples were stored at -80°C until analysis. The pilot study with Microcon filters used 
ventricular CSF samples from 6 AD and 6 normal age-matched individuals. For 
immunoprecipitation, 200 μL of CSF each from 4 AD samples were pooled together to 
form the pooled AD CSF sample and similarly 200 μL of CSF from 4 normal individuals 
were combined to form the pooled control CSF sample. The samples were pooled to 
minimize the individual differences in protein expression and normalize the amount of 
protein among the population.  
 
5.2c Efficacy of Microcon cut-off filters 
 
The efficacy of cut-off filters was tested using the standard low-range marker proteins. A 
30 kDa cut-off filter was pre-rinsed with distilled water to get rid of any glycerol that 
might be present. A solution of 200 ng of each protein in the low-range marker proteins 
in 150 μL of 0.2% formic acid in 50% ACN was added to the pre-rinsed 30 kDa cut off 
filter and centrifugation was carried out at 4000 g for 15 min. A solution of 100 μL of 
0.2% formic acid in 50% ACN was added to the filter and centrifugation was carried out 
at 1000 g for 1 min. The wash was repeated and the flow-through from the filter was 
collected. A volume of 100 μL of 0.2% formic acid in 50% ACN was added to the filter 
and the above 30 kDa fraction was collected after centrifugation at 1000 g for 1 min. The 
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flow-through and the fraction above 30 kDa (retentate) from the cut-off filter were dried 
in a vacuum centrifuge, 25 μL of sample loading buffer was added, boiled and the sample 
was loaded onto a 12% polyacrylamide gel. Electrophoresis was carried out at constant 
voltage of 200 V until the dye front reached the bottom of the gel.   
 
5.2d Isolation of albumin-interactome using Microcon cut-off filters 
 
A crude isolation of albumin-interactome was performed by subjecting a volume of 400 
μL of post mortem human ventricular CSF from 6 AD and 6 age matched normal subjects 
(control) to fractionation based upon their molecular weight using Microcon 100 kDa and 
50 kDa cut-off filters. The cut-off filters were pre-rinsed with distilled water to remove 
glycerol. CSF was added to the 100 kDa filter that is stacked on top of a 50 kDa cut-off 
filter and centrifugation was carried out at 2000 g for 30 min. The flow-through from the 
50 kDa and the retentate from the above 100 kDa were collected. A solution of 200 μL of 
1 mM DTT in 20% acetonitrile was added to the 50 kDa membrane and after incubation 
for 2 minutes, the between 100 and 50 kDa fraction was collected after centrifugation at 
5000 g for 5 min. The wash was repeated two more times with 200 μL and 100 μL of 
DTT/ACN solution respectively. The washes from the 50 kDa filter were collected and 
added to another fresh pre-rinsed 50 kDa cut-off filter and centrifugation was carried out 
at 5000 g for 5 min to remove albumin (that has a molecular weight of ~ 60 kDa will 
remain above the filter). The flow through from the second 50 kDa cut-off filter that 
contains proteins interacting with albumin, was subjected to 2-DE.   
 
5.2e Crosslinking of anti-human albumin antibody to Protein G beads 
 
Immunoprecipitation of albumin from CSF was carried out after crosslinking to Protein G 
sepharose beads using a modified protocol published by Zhou et al. [213]. Briefly 300 μL 
of wet protein G sepharose beads were added to a Spin-X filter and centrifugation was 
carried out at 1500 g for 1.5 min. Five hundred micro liter of 0.1 M phosphate saline 
buffer (PBS) was added to the beads and centrifugation was carried out at 1500 g for 1.5 
min. The PBS wash was repeated two more times after which the beads were incubated 
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with 100 μL of a 10 μg/ μL stock solution of rabbit anti-human albumin antibody and 400 
μL of PBS for 1 hour on a rocker at room temperature. The beads were subjected to 
centrifugation at 1500 g for 1.5 min to get rid of any unbound antibody. The beads were 
washed three times each with 500 μL of 0.2 M sodium borate buffer pH 9.0. The 
antibodies were crosslinked to Protein G using 500 μL of 25 mM DMP in 0.2 M sodium 
borate buffer pH 9.0. After incubation for 30 min at room temperature on a rocker, the 
beads were centrifuged at 1500 g for 1.5 min to remove the un-reacted DMP. The 
crosslinking of antibody to the beads was carried out two more times with 500 μL 
aliquots of DMP each time. The crosslinking reaction was stopped by a quick rinse with 
500 μL of 0.1 M ethanolamine (pH 9.0) followed by incubation in 500 μL 0.1 M 
ethanolamine for 30 min at room temperature on a rocker. After incubation with 
ethanolamine, the beads were washed twice with 500 μL of PBS to remove any residual 
ethanolamine. The anti-albumin antibody conjugated protein G beads were re-suspended 
in PBS and stored at 4°C until use.  
 
5.2f Immunoprecipitation of albumin-interactome 
 
A volume of 300 μL of the rabbit anti-human albumin antibody conjugated Protein G 
beads was incubated with 250 μL of raw CSF at room temperature on a rocker for 1.5 
hours. The depleted CSF was collected by centrifugation at 1500 g for 1.5 min and the 
beads were washed twice with 500 μL of PBS. Various solvents were tested for optimal 
elution of just the bound proteins. Fifty percent acetonitrile containing 0.2% formic acid 
was the ideal elution buffer under the given conditions and the proteins (after 
immunoprecipitation) were eluted using 200 μL of this solution after incubation at room 
temperature for 2 min. The beads were washed twice with 150 μL of elution buffer and 
the flow-through from the washes was collected in one eppendorf tube. The elute was 
dried in a vacuum centrifuge and re-suspended in 50 μL 1 X SDS loading buffer and 
loaded onto a 12% polyacrylamide gel and electrophoresis was carried out.  
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5.2g 1D gel electrophoresis 
 
Proteins from the efficacy study were subjected to 1D gel electrophoresis. After drying 
the protein sample in the vacuum centrifuge, samples were re-suspended in 50 μL 1x 
loading buffer, boiled for about 5 min, loaded onto a 12% polyacrylamide gel and 
electrophoresis was carried out at constant voltage of 150 V. The gels were stained with a 
colloidal suspension of Coomassie G250. 
 
5.2h 2-DE     
 
The flow-through from the second 50 kDa cut-off filter was subjected to 2-DE. The 
sample was dried in a vacuum centrifuge, re-suspended in 125 μL of sample/rehydration 
buffer containing 8 M urea, 2% CHAPS, 50 mM DTT, ampholytes and bromophenol 
blue and loaded on IPG strip. After 12 hours of active rehydration period at 50 V, the 
proteins were focused in the Protean IEF cell from Bio-Rad using a 4-step program (300 
V, 1000 V, 2500 V for 1 hour each and 4500 V for 4 hours). A limiting current (50 µA 
per strip) was maintained. After IEF, the strips were equilibrated (30 min) with 6 M urea, 
32 mM DTT, 0.375 M Tris-HCl pH6.8, 10%(w/v) SDS, 50% (v/v) glycerol and for 20 
min in the dark with 63 mM iodoacetamide in the above equilibration buffer instead of 
urea. Each strip was loaded on a 12% polyacrylamide gel and electrophoresis was carried 
out at 150 V using a Protean II mini (Bio-Rad) in a buffer that contained 25 mM Tris, 
192 mM glycine and 0.1% SDS until the blue dye reached the bottom of the gel. The 2-
DE separated proteins were stained with a solution of colloidal Coomassie G 250 [56].  
 
5.2i Image and statistical analyses 
 
Stained gels were scanned with a Versadoc 3000 scanner from Bio-Rad. Images were 
analyzed using the PD Quest software from Bio-Rad. Spots were detected and matched 
by both automated matching following the instructions in the software and also by 
manual matching. Normalization was carried out to avoid any non-expression related 
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variations between matched spots. A difference in spot volume was considered 
statistically significant at p<0.05 and confidence level of 95%. 
 
5.2j Identification of proteins using mass spectrometry  
 
Proteins of interest were excised from the gel and in-gel proteolysis was carried out with 
trypsin. In brief, the gel pieces were washed 6 times alternating with 50 mM NH4HCO3  
and 1:1 ACN: NH4HCO3 (50 mM) for 5 min each at 20°C and dried with ACN for 10 
min at 20°C. A volume of 10 μL of trypsin (66.67 ng) in 25 mM NH4HCO3 was added 
and gel pieces allowed to swell for 30 min at 20°C and digested at 50°C for 4 hours. 
Peptides were extracted with 10 μL of 1% aq. formic acid at 20°C for 30 min.The tryptic 
peptides were analyzed using a Thermo Electron Corporation’s LCQ Classic quadrupole 
ion trap mass spectrometer (San Jose, CA). Briefly, the tryptic peptides were resolved on 
a 15 cm in-house C18 packed capillary column and eluted using a typical gradient elution 
within 55 min. Spectra were acquired with a probe spray voltage of 4 kV and a heated 
capillary temperature of 175°C. The resulting mass spectra were searched against the 
human sub database from the Swiss-Prot database using Mascot algorithm and the protein 
was identified.  
 
5.3 Results  
 
5.3a 2-DE of un-processed CSF 
 
A volume of 150 μL of CSF was subjected to 2-DE. It was observed that albumin, light 
and heavy chains of immunoglobulins were the major proteins that were present in the 
gel (Figure 5.1).  
 
5.3b Efficacy of Microcon cut-off filters 
 
The efficacy of Microcon cut-off filters was tested using low range molecular weight 
marker proteins. As seen from figures 5.2 and 5.3, greater than 80% of proteins less than 
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30 kDa were filtered through while only roughly about 20% remained above the filter. 
Seventy percent of the protein sample whose molecular weight same as that of the cut-off 
value is filtered through. The cut-off filters fractionated the proteins efficiently. 
 
 
 
 
 
      
 
 
 
Figure 5.1 A volume of 150 μL of un-processed CSF was subjected to 2-DE. A volume 
of 125 μL of sample buffer was added to the sample that was dried in vacuum centrifuge. 
2-DE was carried out using a 7 cm IPG strip pH 3-10 and a mini (7 cm) 12% 
polyacrylamide separating gel. The gel was stained with colloidal Coomassie G250. 
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Figure 5.2 Efficacy of Microcon 30 kDa cut-off filter. A solution of 200 ng of each 
protein in the low-range standard proteins in 150 μL of 0.2% formic acid in 50% ACN 
was added to the pre-rinsed 30 kDa cut off filter and centrifugation was carried out at 
4000 g for 15 min. The cut-off filter was washed with 2 x 100 μL of 0.2% formic acid in 
50% CAN. The flow-through and the retentate were collected and loaded on a 12% 
polyacrylamide gel and electrophoresis carried out. 
 
 
 
 
 
 
 
     Protein            Filtrate           Retentate  
97 
 
66 
 
45 
 
 
31 
 
 
 
21 
 
 
14 
Mr 
(kDa) 
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Table 5.1 Protein recovery using Microcon cut-off filters 
 
 
Protein 
 
 
Total 
protein 
(Band 
volume / %) 
 
Flow 
through 
(Band 
volume / %) 
 
Retentate 
(Band 
volume / %) 
Carbonic 
anhydrase 
 
1534/100 
 
923/60 
 
496/32 
 
Trypsin 
inhibitor  
 
 
1344/100 
 
1142/85 
 
362/27 
 
Lysozyme 
 
 
245/100 
 
227/93 
 
15/5 
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Figure 5.3 Recovery of proteins using 30 kDa cut-off filters (     ) Retentate (    ) Flow 
through and (   ) whole protein. 
CA 
(31 kDa) 
Tryp 
Inhibitor 
(21 kDa) 
Lysozyme 
(14 kDa) 
Percentage 
of protein 
 
  174
5.3c Crude isolation of albumin-interactome using Microcon cut-off filters 
 
Two molecular weight cut-off filters; 100 kDa and 50 kDa were employed to fractionate 
ventricular CSF and three fractions were obtained (above 100 kDa, between 100 and 50 
kDa and below 50 kDa). The between 100 and 50 kDa fraction was denatured with 
DTT/ACN solution and filtered through another 50 kDa cut-off filter and the filtrate that 
contains only the small proteins interacting with albumin was analyzed by 2-DE. Figures 
5.4 and 5.5 show the composite gel image containing proteins from both AD and control 
sample set and the representative images of CSF proteins from AD and control subjects 
generated by PD Quest software respectively.  
 
Twenty one protein spots were identified and 9 proteins showed significant changes in 
expression levels between AD and control (p <0.05) (Table 5.2 and 5.3) subjects. In-gel 
proteolysis was carried out with trypsin, the tryptic peptides were separated in a reverse 
phase capillary column and the amino acid sequence was determined. Therefore, an 
accurate and unambiguous identification is achieved. Comparing the intensities of protein 
spots between six AD and six normal individuals, 9 proteins were significantly altered 
(p<0.05). These altered proteins are summarized in Table 5.2. Proteins that were 
significantly reduced in CSF of AD patients included one isoform (basic) of 
prostaglandin D2 synthase (PGDS2), one isoform (more basic) of transthyretin, and two 
isoforms of phosphotidyl ethanolamine binding protein. Proteins that were significantly 
up-regulated in AD included retinol binding protein and four isoforms of PGDS2 with 
one isoform being present exclusively in AD CSF.  
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Figure 5.4 Composite (master) gel from the image analysis software shows all protein 
spots present in both populations – AD and control. The spot numbers correlate to the 
protein names in Table 5.1.   
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Figure 5.5 Two-dimensional electrophoresis analysis of proteins in the albumin 
containing fraction after fractionation using cut-off filters. (A) AD and (B) control.  
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Table 5.2 List of proteins identified by LC-MS/MS in samples from the 2-DE gel using 
cut-off filters 
 
 
 
Spot 
 # 
 
 
 
Protein 
 
 
Mr 
(kDa) 
 
 
pI 
 
 
Sequence 
coverage (%) 
 
 
Mowse 
score 
 
 
Peptides matched 
 
1 
 
β 2 microglobulin 
 
 
 
11.7 
 
6.07 
 
16 
 
80 
 
VEHSDLSFSK 
VNHVTLSQPK 
 
 
2 
 
β 2 microglobulin 
 
 
11.7 
 
6.07 
 
16 
 
60 
 
VEHSDLSFSK 
VNHVTLSQPK 
 
 
3 
 
Cystatin C 
 
 
13.3 
 
8.75 
 
18 
 
97 
 
LVGGPMDASVEEEGVR 
ALDFAVGEYNK 
 
 
4 
 
Cystatin C 
 
 
13.3 
 
8.75 
 
7 
 
51 
 
ALDFAVGEYNK 
 
 
5 
 
Cu-Zn SOD  
 
 
15.8 
 
5.7 
 
9 
 
36 
 
GDGPVQGIINFEQK 
 
 
6 
 
 
Cu-Zn SOD 
 
 
 
15.8 
 
 
5.7 
 
 
15 
 
 
73 
 
GDGPVQGIINFEQK 
LACGVIGIAQ 
 
 
7 
 
 
Transthyretin 
 
 
 
 
 
13.7 
 
 
5.35 
 
 
39 
 
 
 
 
153 
 
AADDTWEPFASGK 
TSESGELHGLTTEEEFVEGIYK 
YTIAALLSPYSYSTAVVTNPKE 
 
 
 
 
8 
 
 
 
Transthyretin 
 
 
 
 
13.7 
 
 
 
5.35 
 
 
 
64 
 
 
 
307 
 
GSPAINVAVHVFR 
KAADDTWEPFASGK 
TSESGELHGLTTEEEFVEGIYK 
ALGISPFHAEVVFTANDSGPR 
YTIAALLSPSYSTTAVVTNPKE 
 
 
 
9 
 
 
Plasma retinol 
binding protein 
(RBP) 
 
 
21 
 
 
5.27 
 
 
20 
 
 
52 
 
 
KDPEGLFLQDNIVAEFSVDETG
QMSATAK 
MKYWGVASFLQK 
 
 
 
10 
 
 
Neuropolypeptide 
h3 (PEBP) 
 
 
 
20.9 
 
 
7.43 
 
 
26 
 
 
159 
 
NRPTSISWDGLDSGK 
LYTLVVTDPDAPSR 
GNDISSGTVLSDYVGSGPPK 
 
Contd. next page 
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Spot 
number 
 
 
 
Protein 
 
 
Mr (kDa) 
 
 
pI 
 
 
Sequence 
coverage 
(%) 
 
 
Mowse 
score 
 
 
Peptides matched 
 
 
11 
 
 
Neuropolypeptide h3 
 
 
 
20.9 
 
 
7.43 
 
 
10 
 
 
56 
 
 
GNDISSGTVLSDYVGSGPPK 
 
 
 
12 
 
 
Carbonic anhydrase II 
(CA II) 
 
 
 
29.1 
 
 
6.86 
 
 
3 
 
 
40 
 
 
VVDVLDSIK 
 
13 
 
Carbonic anhydrase II 
 
 
29.1 
 
6.86 
 
16 
 
94 
 
YDPSLKPLSVSYDQATSLR 
AVQQPDGLAVLGIFLK 
VVDVLDSIK 
 
 
 
14 
 
 
Prostaglandin D2 
synthase(PGD2S) 
 
 
 
18.7 
 
 
8.37 
 
 
20 
 
 
155 
 
TMLLQPAGSLGSYSYR 
FTAFCK 
AQGFTEDTIVFLPQTDK 
 
 
15 
 
 
Prostaglandin D2 
synthase 
 
 
18.7 
 
8.37 
 
17 
 
133 
 
TMLLQPAGSLGSYSYR 
AQGFTEDTIVFLPQTDK 
 
 
16 
 
 
Prostaglandin D2 
synthase 
 
 
18.7 
 
8.37 
 
17 
 
124 
 
TMLLQPAGSLGSYSYR 
AQGFTEDTIVFLPQTDK 
 
 
17 
 
 
Prostaglandin D2 
synthase 
 
18.7 
 
8.37 
 
8 
 
61 
 
AQGFTEDTIVFLPQTDK 
 
 
18 
 
 
Prostaglandin D2 
synthase 
 
 
18.7 
 
8.37 
 
17 
 
148 
 
TMLLQPAGSLGSYSYR 
AQGFTEDTIVFLPQTDK 
 
 
 
19 
 
 
Prostaglandin D2 
synthase 
 
 
18.7 
 
 
8.37 
 
 
31 
 
 
108 
 
AALSMCKSVVAPATDGGLTST
FLR 
TMLLQPAGSLGSYSYR 
AQGFTEDTIVFLPQTDK 
 
 
20 
 
 
 
Prostaglandin D2 
synthase 
 
 
 
18.7 
 
 
8.37 
 
 
32 
 
 
200 
 
FLGR, GPGEDFR, FTAFCK, 
AELK,TMLLQPAGSLGSYSYR 
MATLYSR,  
AQGFTEDTIVFLPQTDK 
 
 
21 
 
Prostaglandin D2 
synthase 
 
 
 
18.7 
 
 
8.37 
 
 
8 
 
 
61 
 
 
AQGFTEDTIVFLPQTDK 
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Table 5.3 Differential expression of proteins in AD and control (CTRL) ventricular CSF 
as determined by the image analysis software PD Quest.  
 
 
 
spot # 
 
Protein name 
 
AD 
(spot 
intensity) 
Ratio 
AD:CTRL 
CTRL 
(spot 
intensity) 
Ratio 
CTRL:CTRL
 
19 
 
PGD2S 
 
3984 
 
3.37 
 
1181 
 
1 
 
 
14 
 
PGD2S 
 
12808 
 
1.73 
 
7408 
 
1 
 
 
9 
 
RBP 
 
4891 
 
1.55 
 
3158 
 
1 
 
 
15 
 
PGD2S 
 
23726 
 
1.31 
 
18132 
 
1 
 
 
8 
 
TTR 
 
3654.4 
 
0.33 
 
10956 
 
1 
 
 
21 
 
PGD2S 
 
1689.3 
 
7.37 
 
229.1 
 
1 
 
 
11 
 
PEBP 
 
806.6 
 
0.49 
 
1649.5 
 
1 
 
 
10 
 
PEBP 
 
1438.8 
 
0.45 
 
3185.8 
 
1 
 
 
17 
 
PGD2S 
 
128.9 
 
0.01 
 
12721 
 
1 
 
 
  180
5.3d Optimization of immunoprecipitation of albumin-interactome from CSF  
 
 
Immunoprecipitation using antibodies is the most frequently employed technique to test 
whether two proteins are interacting in vivo. Albumin was used as the bait protein to fish 
out other small proteins that might be interacting with it in the CSF. 
 
• Evaluation of elution buffer 
 
Optimization of the elution condition was carried out and various solvents like 0.01% 
SDS, 20% ACN and 0.2% formic acid in 20% ACN (Figure 5.6) were evaluated for their 
ability to strip proteins bound to the bead without stripping the antibodies itself. This 
study evaluating different buffers in eluting proteins from beads, was carried out in which 
the rabbit anti-albumin antibodies used were not crosslinked to the beads. 
 
Figure 5.7 is a schematic of immunoprecipitation of the albumin-interactome. The gel 
images shown in figures 5.8 to 5.10 are few attempts that were carried out to optimize the 
various parameters in the immunoprecipitation protocol. Figure 5.8 shows the gel image 
of one of the very first attempts to isolate the albumin-interactome from CSF. Ten 
microliter of Protein G bound sepharose beads were incubated with 10 μg of anti-albumin 
antibody at 4°C for 3 hours. The antibody was crosslinked to Protein G after incubation 
with DMP for 30 min. The crosslinking reaction was terminated by incubation with 
ethanolamine for 30 min. The antibody crosslinked beads were incubated with 10 μL of 
CSF for 4 hours at 4°C. Albumin interactome was eluted using 50 μL of 1X SDS-PAGE 
loading buffer. There was no protein observed in the elution fraction. The depleted CSF 
contained some amount of albumin but the bands were all skewed because of the 
presence of high amounts of PBS.  
 
After a series of optimization experiments, it was decided to incubate the antibody with 
Protein G beads at room temperature for 1 hour for binding, incubate the antibody 
containing beads three times with freshly prepared DMP and finally incubate beads with 
CSF for 1 hour and 30 min at room temperature for sufficient binding of the albumin-
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interactome with the antibody. In the next attempt, 200 μL of beads were incubated with 
200 μg of anti-albumin antibody. Crosslinking was carried out as described in the earlier 
section with DMP and 100 μL of un-processed CSF was added and the sample was 
incubated at room temperature for 1 hour and 30 min. Proteins were stripped using 3 x 50 
μL of 1X SDS loading buffer and SDS-PAGE was carried out (Figure 5.9).    
 
 
 
 
 
 
 
 
 
 
Figure 5.6 SDS-PAGE analysis of the CSF proteins eluted from the anti-albumin 
attached Protein G beads. 200 μL of CSF was applied to the beads and eluted with 
different elution buffers. Elute was dried and resuspended in loading buffer and 
electrophoresis carried out at 200 V and gel stained with colloidal Coomassie G 250. The 
proteins identified (numbered on the gel) are given in table 5.4  
 
 
 
 
 
 
 
 
1 
2 
3 
4 
5 
6 
7 
97 
66 
 
 
 
45 
 
31 
 
 
 
21 
 
 
14 
Standard         0.01% SDS          20% ACN              0.2% formic  
                                                                             acid in 20 % ACN 
Mr 
(kDa) 
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Table 5.4 Proteins identified from 1D gel evaluating three elution buffers, by LC-MS/MS  
 
 
 
Band 
number 
 
 
Protein 
 
Swiss-Prot 
 
Molecular 
weight 
(KDa) 
 
Sequence 
coverage 
(%) 
 
Mowse 
score 
 
1 
 
 
Human serum 
albumin 
 
 
P02768 
 
66.5 
 
27 
 
627 
 
2 
 
 
Rabbit Ig 
gamma  chain 
C 
 
 
 
P01870 
 
 
50 
 
 
26 
 
 
203 
 
3 
 
 
Rabbit Ig 
Kappa b4 
chain C 
 
 
 
P01840 
 
 
25 
 
 
36 
 
 
140 
 
4 
 
 
Human 
Serotransferrin 
 
 
P02787 
 
75.1 
 
24 
 
612 
 
5 
 
 
Rabbit Ig 
Kappa b4 
chain C 
 
 
 
P01840 
 
 
25 
 
 
23 
 
 
63 
 
6 
 
 
Rabbit Ig 
gamma  chain 
C 
 
 
 
P01870 
 
 
50 
 
 
27 
 
 
310 
 
7 
 
 
Human 
transthyretin 
 
 
P02766 
 
13.7 
 
59 
 
360 
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Figure 5.7 Schematic for the immunoprecipitation of the albumin-interactome from CSF 
using rabbit anti-albumin antibody (top box, immunoprecipitation; lower box, elution and 
analysis) 
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Figure 5.8 SDS-PAGE analysis of proteins isolated by immunoprecipitation from 10 μL 
CSF using 10 μL of Protein G beads and 10 μg of anti-albumin antibody. Lane 1, 100 ng 
of low range molecular weight markers, Lane 2, 10 μL of un-processed CSF, Lane 3, 
elute fraction using 50 μL of 1X SDS loading buffer and Lane 4, depleted CSF fraction  
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Figure 5.9 SDS-PAGE analysis of the CSF albumin-interactome using Protein G 
sepharose beads. The gel was stained with colloidal Coomassie G 250. Lane 1, 200 ng of 
low range marker proteins. Lane 2, 10 μg of standard HSA protein. Lane 3, 100 μg anti-
albumin antibody. Lane 4, 100 μL of un-processed CSF. Lane 5, elute fraction using 50 
μL 1X SDS-loading buffer.    
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To enable maximum enrichment of the albumin-interactome, larger volumes of Protein G 
beads, anti-albumin antibody and CSF were used. One milligram of anti-albumin 
antibody was added to 300 μL of wet Protein G beads to saturate all the binding sites 
with anti-albumin antibody. The antibody was covalently crosslinked to beads after 
incubation with DMP. Crosslinking reaction was terminated by the addition of 
ethanolamine and beads incubated with 250 μL of CSF (Figure 5.10). This protocol gave 
maximum recovery of albumin and also revealed the presence of other proteins (though 
faint) in addition to albumin. The presence of phosphate buffer saline (PBS) in the 
albumin depleted CSF fraction caused the lateral diffusion of proteins. This distortion 
was prevented by removal of PBS from the albumin depleted fraction using a 3 kDa cut-
off filter. To verify if there is any interaction between the beads and the proteins in CSF, 
beads with no anti-albumin antibody were incubated with 250 μL of CSF and after 
washing off CSF, the beads were stripped and the elute loaded on the polyacrylamide gel 
(lane 6 Figure 5.10). There were some proteins in the CSF that non-specifically bound to 
the beads. Similarly, to test if the proteins in the elution fraction are a result of stripping 
of the Protein G and anti-albumin antibody itself, the beads were incubated with anti-
albumin antibody, crosslinked and eluted using formic acid in ACN. Very faint high 
molecular weight protein bands were observed (lane 5 Figure 5.10). The proteins seen in 
lanes 5 and 6 of figure 5.10 were mostly high molecular weight proteins (> ~50 kDa) that 
are not a part of the fraction-of-interest (the fraction-of-interest being the low molecular 
weight proteins interacting with albumin). 
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Figure 5.10 Immunoprecipitation of albumin-interactome from CSF using anti-albumin 
crosslinked Protein G beads. Anti-albumin antibody was covalently crosslinked to 
Protein G using DMP and then beads were incubated with 250 μL CSF. Lane 1, 200 ng 
of standard proteins. Lane 2, 250 μL CSF. Lane 3, Elute fraction from beads using 0.2% 
formic acid in 50% ACN. Lane 4, albumin depleted CSF. Lane 5, Elute from beads 
incubated with anti-albumin antibody. Lane 6, Elute from beads incubated with CSF (no 
antibody)      
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Immunoprecipitation of the albumin-interactome fraction from pooled CSF samples from 
6 AD and pooled CSF samples from 6 normal individuals was performed using anti-
albumin antibody covalently crosslinked to Protein G beads. Candidate proteins bound to 
albumin were eluted using 0.2% formic acid in 50% ACN and analyzed by SDS-PAGE 
(Figure 5.11).  
 
 
B 
 
 
Figure 5.11 Immunoprecipitation of albumin interactome from CSF using anti-albumin 
crosslinked Protein G beads. (A) Anti-albumin crosslinked Protein G beads were incubated with 250 
μL pooled and control CSF from 6 individuals and albumin-interactome eluted using 0.2% formic acid in 
50% ACN. Lane 1, standard marker proteins. Lane 2 and 3 are 250 μL of straight unprocessed AD and 
control CSF. Lane 4 and 5 are elutes from AD and control CSF samples respectively. (B) Aliquot of 
depleted CSF samples from AD (lane 2) and control (lane 3).The proteins with spot numbers labeled on the 
gel were identified by LC-MS/MS and are given in table 5.5  
    
iii
ii a, b
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Table 5.5 List of proteins identified from the 1D gel after immunoprecipitation of 
albumin-interactome from CSF 
 
 
Band 
# 
 
Protein 
 
Mr  
(kDa) 
 
Seq  
Covg 
(%) 
 
Mowse 
score 
 
Peptides matched 
 
 
 
 
 
 
i 
 
 
 
 
 
 
Albumin 
 
 
 
 
 
 
 
67 
 
 
 
 
 
 
30 
 
 
 
 
 
 
971 
 
LVTDLTK, AEFAEVSK, YLYEIAR, 
DDNPNLPR, FQNALLVR, TYETTLEK, 
QTALVELVK, TPVSDRVTK, 
LDELRDDEGK,KQTALVELVK, 
LVNEVTEFAK, FKDLGEENFK, 
AVMDDFAAFVEK, RHPDYSVVLLLR, 
DVFLGMFLYEYAR, 
KVPQVSTPTLVEVSR, 
HPYFYAPELLFFAK, 
RHPYFYAPELLFFAK,  
  
 
ii a 
 
PGDS2  
 
21 
 
17 
 
130 
 
TMLLQPAGSLGSYSYR, 
AQGFTEDTIVFLPQTDK 
 
 
 
ii b 
 
 
 
 
CA II 
 
 
 
29 
 
 
 
32 
 
 
 
262 
 
VVDVLDSIK, SADFTNFDPR, 
QSPVDIDTHTAK, 
AVQQPDGLAVLGIFLK, 
ILNNGHAFNVEFDDSQDK, 
YDPSLKPLSVSYDQATSLR 
 
 
 
iii 
 
 
 
TTR 
 
 
 
 
15 
 
 
 
68 
 
 
 
458 
 
GSPAINVAVHVFR, 
KAADDTWEPFASGK, 
AADDTWEPFASGK, 
TSESGELHGLTTEEEFVEGIYKVEIDTK, 
YTIAALLSPYSYSTTAVVTNPKE 
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5.4 Discussion 
 
The CSF proteome holds great promise as a source of biomarkers for diseases like 
Alzheimer’s disease that affect the brain. Despite the potential, it is challenging to 
analyze such complex proteomes because of the dynamic range of protein concentrations 
that exists in the CSF. As seen in figure 5.1, albumin and immunoglobulins dominate the 
CSF proteome and this makes the detection of low abundant proteins very difficult. Thus, 
reduction of sample complexity is essential when analyzing CSF. One way to circumvent 
this dynamic range problem is to deplete the high abundant proteins using commercially 
available depletion kits based on affinity methods using specific antibodies against 
albumin and immunoglobulins. However, serum proteome studies indicate that such 
affinity depletion methods result in concomitant removal of small low molecular weight 
proteins along with albumin and immunoglobulins [213]. The hypothesis of this study is 
that the high abundance protein, albumin in CSF, acts as a “molecular sponge” and soaks 
up small low molecular weight proteins. Selective enrichment of these low molecular 
weight proteins interacting with the high abundance proteins using immunoprecipitation 
will enable un-biased analysis of this fraction of the proteome, and comparison of the 
albumin-interactome between AD and control subjects is likely to provide useful 
biomarkers for the disease.        
 
5.4a Efficacy of Microcon cut-off filters 
 
A crude isolation of the albumin-interactome was carried out using cut-off filters after 
fractionating the complex CSF. A key point is the efficacy of the Microcon filters that 
needs to be tested to confirm its ability to effectively separate a complex proteome such 
as the CSF. To test the efficacy of the filters, a volume equal to 200 ng of each standard 
marker proteins was added to a 30 kDa cut-off filter and centrifuged. The flow through 
(below 30 kDa) and the retentate (above 30 kDa) were collected and subjected to 1D gel 
electrophoresis (Figure 5.2). The efficiency of cut-off filters in filtering the proteins is 
dependent on the molecular weight of the proteins. Our data indicate that the cut-off 
filters separated the proteins based upon their molecular weight quite effectively. 
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The Microcon cut-off filters have been used earlier for sample preparation and trypsin 
digestion in proteomic analysis using standard proteins [217]. Our studies indicated that 
the Microcon filters can be used for fractionation of proteins based upon their molecular 
weight facilitating isolation of the albumin-interactome. Almost 80-90% of proteins less 
than the cut-off value were filtered through the cut-off filters but with increasing 
molecular weight the recovery was less.  
 
5.4b Crude isolation of CSF albumin-interactome using Microcon cut-off filters  
 
Cut-off filters were used to isolate albumin-interactome after fractionation of CSF 
proteome based upon molecular weight. Using two filters- 100 and 50 kDa- three 
fractions were obtained. The fraction between 100 and 50 kDa (containing albumin) was 
disrupted for non-specific interactions that can exist between proteins and filtered 
through a second 50 kDa filter. The filtrate was subjected to 2-DE. Nine unique proteins 
were identified along with their various isoforms as a result of post-translational 
modifications.  
 
It should be noted here that the molecular weight of the proteins identified in this study 
were all less than 50 kDa. However, the proteins were initially from the fraction between 
100 and 50 kDa and were denatured by the addition of DTT in ACN. Given that the cut-
off filters passed approximately 90% of the proteins effectively (as seen from our 
efficacy study), the presence of these proteins in the between fraction indicated that they 
are either interacting with other proteins in the CSF or among themselves. Since the 
combined molecular weight is greater than their actual individual molecular weights they 
are hence retained in the fraction between 100 and 50 kDa. The addition of a solution of 
DTT in ACN disrupted this interaction and proteins smaller than 50 kDa were filtered 
through the second 50 kDa cut-off filter. To test our hypothesis that albumin acts a 
protein scaffold and interacts with other small proteins, immunoprecipitation using anti-
albumin antibody coupled Protein G sepharose beads was carried out. Albumin along 
with other proteins that might be interacting with albumin was immunoprecipitated under 
non-denaturing condition. 
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 This offers advantages:  
(1) it is a rapid procedure to isolate/enrich the albumin interactome;  
(2) the purity of proteins is high; and  
(3) it allows for the identification of proteins interacting with albumin.  
 
• Altered proteins in AD CSF 
 
2-DE experiments on CSF fractions indicated the presence of eight proteins with 
molecular weight less than 50 kDa in the fraction between 100 and 50 kDa (after 
fractionation using cut-off filters). Out of these eight proteins, four unique proteins and 
their various isoforms were significantly altered in the CSF from AD subjects (Table 
5.3). These proteins included PGDS2, transthyretin, PEBP and RBP. To test the 
hypothesis that the proteins might be interacting with albumin, immunoprecipitation of 
the albumin-interactome was carried out using anti- albumin antibody crosslinked Protein 
G beads. 
 
5.4c Immunoprecipitation of albumin-interactome 
 
A more precise isolation of the albumin-interactome was carried out using 
immunoprecipitation of albumin. A series of immunoprecipitation experiments were 
performed to optimize the various conditions for successful isolation of the albumin-
interactome from the CSF. These experiments included optimization of the ratio of anti-
albumin antibody and protein G beads for a given volume of CSF, determination and 
optimization of the necessary incubation times to ensure strong antigen-antibody 
interaction, the number and volume of wash steps to eliminate the CSF proteins non-
specifically interacting with the beads itself, and optimization of the number of elution 
steps required to elute the bound protein fraction.  
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• Evaluation of elution buffer 
 
In immunoprecipitation, elution conditions are intended to break the ionic, hydrophobic 
and hydrogen bonds that hold the antigen to the antibody. Ideally, elution should release 
only the protein bound to the antibody attached to Protein G beads and not the antibody 
itself. Three different elution buffers- 0.01% SDS, 20% ACN and 0.2% formic acid in 
50% ACN were evaluated for their effectiveness in stripping the proteins from the 
Protein G beads. SDS and ACN both eluted about the same amount of proteins from the 
beads. Elution buffer containing 0.2% formic acid in 50% ACN gave more proteins than 
the other two solvents. All three buffers, however, stripped the anti-albumin antibody 
attached to the protein G beads (Figure 5.6, Table 5.4). In order to prevent the elution of 
the anti-albumin antibody itself, the antibody in further experiments was covalently 
crosslinked to Protein G beads using dimethylpimelimidate (DMP). 
 
• Optimization of immunoprecipitation of albumin-interactome  
 
The immunoprecipitation protocol involves a multitude of steps to isolate the target 
protein from a complex mixture of proteins like CSF. Various parameters were 
investigated to obtain an optimized protocol that can selectively isolate the albumin-
interactome from CSF. From our elution buffer evaluation study, formic acid in ACN 
buffer stripped proteins from the beads better than SDS and 20% ACN; however it was 
also able to elute out anti-albumin antibodies (not crosslinked to Protein G in our elution 
buffer evaluation study). The elution of antibodies could, however, be prevented by 
covalently crosslinking the antibody to Protein G beads. Hence, for all further studies, the 
antibodies were chemically crosslinked to Protein G beads and 0.2% formic acid in 50% 
ACN was used as the elution buffer. The optimized immunoprecipitation protocol (given 
in experimental section) was repeated at least two times to verify the reproducibility and 
to establish standard operation procedures. A high reproducibility was achieved and the 
protein elution profiles were almost identical. Our immunoprecipitation results clearly 
supported our hypothesis that the proteins PGDS2, transthyretin and carbonic anhydrase 
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II were all interacting with albumin. The levels of these proteins were altered in CSF 
from AD patients.      
 
Prostaglandin D synthase (PGDS2) was originally known as β trace and was discovered 
by Clausen in 1961 in human CSF [218]. PGDS2 is a sialic acid (SA) containing 
glycoprotein with a molecular weight of 27 kDa [219]. PGDS2 is produced by 
leptomeninges and the choroid plexus of the brain [220-222]. In addition to the enzymatic 
function in the synthesis of prostaglandin D, PGDS2 is also believed to be involved in the 
transport of various lipophilic moieties including thyroid hormone and retinoic acid in 
CSF [219, 223-225]. There is increasing evidence that isoforms of proteins are 
differentially altered in AD, hence it becomes imperative to study the differentially 
expressed levels of post-translational modifications in AD biomarker discovery to 
understand the neuropathology [226]. Several studies have investigated post-translational 
modifications (PTM) of PGDS2 in CSF of patients with neurological diseases. Hiraoka et 
al. have studied the microheterogeneity of PGDS2 in the CSF of patients with various 
neurological diseases like Amyotrophic lateral sclerosis (ALS), Alzheimer’s disease 
(AD) and Parkinson’s disease (PD) using capillary isoelectricfocusing [227]. Since 
PGDS2 has two oligosaccharide chains and each chain has two SA groups, the protein 
has in total four SA groups. This allows for the possibility of 8 different isoforms for the 
protein. Various studies have identified four isoforms of PGDS2 in human CSF [227, 
228]. Studies investigating these different isoforms of PGDS2 will help to provide more 
insight about PGDS2 function in CSF. Currently, PGDS2 is used as a marker to detect 
the presence of CSF in nasal secretions from patients suffering from rhinorrhea [229]. 
PGDS2 was also reported as a marker for N-glycosylation defects in the brain [230].                     
  
 Earlier work indicated that the acidic isoforms of PGDS2 were decreased in the CSF of 
patients suffering from neurological diseases [231, 232]. From our 2-DE study, 8 protein 
spots (with different pIs but almost the same molecular weight) were identified as 
PGDS2. The measurement of total PGDS2 in spot intensity in AD and control gels using 
PD Quest software indicated that the protein level was only slightly increased in AD (by 
10%) when compared to levels in control samples. However, the three most acidic 
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isoforms were significantly up-regulated in AD, and one isoform at pI of approximately 7 
was present exclusively in the AD sample. One basic isoform of PGDS2 was down-
regulated significantly in AD. Since the various isoforms of PGDS2 have similar 
molecular weight but different pI, the most likely PTM of PGDS2 is glycosylation. 
Glycosylation of a protein changes its pI to be more acidic due to the addition of a 
carbohydrate moiety. Since the acidic isoforms of PGDS2 was found to be up-regulated 
in AD, our data suggests that there is increased glycosylation of PGDS2 in AD. Altered 
glycosylation of tau, cholinesterases and transferrin in AD have already been described, 
suggesting that aberrant glycosylation changes occur in AD [233-235]. Hashimoto et al. 
reported that sialylation of amyloid precursor protein (APP) increased the secretion of 
neurotoxic metabolites like amyloid beta peptide (Aβ) [236]. It was reported that 
hyperglycosylation of tau protein caused an increase in phosphorylation of tau resulting 
in hyperphosphorylated tau in the AD brain [233]. The differential expression levels of 
PGDS2 in CSF of AD patients further validated the impaired glycosylation in AD.  
 
Since glycosylation plays a pivotal role in various cellular processes like signaling and 
protein folding, and is synergistic with phosphorylation events, it is most likely that 
alteration in glycosylation can induce signaling cascades that mediate neurodegeneration 
[237]. Watanabe et al. reported that serum albumin could bring about the synthesis of 
prostaglandin D2 from prostaglandin E (i.e. the function of PGDS2) in platelets [238]. 
This indicates a PGDS2-like activity of albumin in platelets. Hence, either, PGDS2 and 
albumin have a common substrate (PGE2) that might be responsible for the interaction of 
PGDS2 with albumin observed in the immunoprecipitation study and could explain the 
presence of PGDS2 in the albumin-interactome fraction or albumin is associated with 
PGDS2 and this combination can carry out prostaglandin E conversion to PGD2. PGDS2 
was also reported to be present in human atherosclerotic plaques [239]. Since PGDS2 is a 
protein that is made up of mainly β sheets [240], it is possible that due to aberrant 
glycosylation of the protein, it aggregates in the brain of AD patients as well; however, 
more work is required to prove this speculation. 
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Two isoforms of transthyretin were identified in 2-DE gel and the more basic isoform 
was down-regulated three-fold in CSF from AD subjects. Transthyretin was also 
identified as one of the proteins present in the albumin-interactome. Transthyretin, 
formerly known as prealbumin, is a homotetrameric protein with a molecular weight of 
approximately 55 kDa. TTR is synthesized and released into the CSF by the choriod 
plexus [241]. A small amount of TTR synthesized in the liver also exists as a 
homotetramer in serum and constitutes about 0.5% of serum proteins [242]. Serum TTR 
cannot cross the blood brain barrier and hence TTR present in CSF is exclusively from 
the choroid plexus. TTR in CSF is predominantly in the monomeric form, but in the 
choriod plexus is a tetramer [231, 243].  
 
Transthyretin was identified in the neurofibrillary tangles as well as in amyloid plaques in 
the brain of AD patients [244]. It was reported that the lower the levels of TTR in CSF, 
the more demented were the patients [52]. The monomeric form of TTR in the CSF was 
found to sequester amyloid β protein (Aβ), which is responsible for the formation of 
amyloid plaques in the brain of AD patients [245]. TTR forms soluble complexes with 
Aβ and inhibits its aggregation. However, TTR itself is capable of forming amyloid 
fibrils that are associated with diseases such as familial amyliod cardiomyopathy (FAC), 
senile systemic amyloidosis (SSA) and familial amyloiotic polyneuropathy (FAP) [246, 
247].  
 
Transthyretin is a β-sheet rich protein and any event triggering misconformation can 
result in the stacking-up of these β sheets to form aggregates. Various PTMs of 
transthyretin have been detected in CSF and include sulfonation, cysteinylation and 
glutathione conjugation [248-250]. The isoforms that were detected in the 2-DE gels, in 
this study, were all of about the same molecular weight but had different isoelectric 
points. This suggested that the two isoforms were a result of either sulfonation or 
phosphorylation. The more basic isoform (with greater pI) was found to be down-
regulated significantly by approximately three-fold in the CSF of AD patients. The down-
regulation of TTR is in agreement with other published work [52]. The decrease in TTR 
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isoform could cause Aβ to be more susceptible for aggregation. More investigations are 
required to identify the PTM in TTR.  
 
Transthyretin was identified to be a component of the albumin-interactome through the 
described immunoprecipitation technique. One possible explanation for the presence of 
TTR in the albumin-interactome is the common substrates that both TTR and albumin 
share. TTR in CSF functions as a carrier protein mainly for thyroxin (T4) and vitamin A 
(retinol through the association with retinol binding protein-RBP) [251, 252]. The thyroid 
hormone and retinol are essential for normal development of brain [253, 254]. It was 
reported that TTR has high affinity for T4 while albumin has a low affinity but high 
capacity for T4 [255]. Albumin is the most abundant protein in CSF and being a known 
transport protein, it is quite possible that albumin is carrying with it other small proteins 
like TTR that have a common substrate such as T4 to lock onto. Our data show that 
retinol binding protein (RBP) was up-regulated by approximately 1.5 fold in the CSF of 
AD subjects. This is in agreement with results published earlier on the increased level of 
one isoform of RBP in the CSF from AD patients [226, 256, 257].                                
 
Two isoforms of phosphotidyl ethanolamine binding protein (PEBP) were identified in 
the 2-DE gel and both isoforms were significantly down-regulated by 2-fold in the CSF 
from AD subjects compared to control. In humans, PEBP is also known as 
neuropolypeptide h3 and contains the hippocampal cholinergic neurostimulating peptide 
(HCNP). Decreased levels of PEBP have been reported earlier in the hippocampus of 
brain from Tg2576 (mouse model of AD) [258]. It was also reported that PEBP 
immunoreactivities were found on amyloid plaques of both Tg2576 and AD brain 
sections [258]. The HCNP peptide is involved in the differentiation of neurons in the 
hippocampus where the protein also enhances the synthesis of choline acetyl transferase 
[259]. PEBP was not identified as a part of the albumin-interactome. 
 
Other proteins like SOD1, cystatin C, β-2 microglobulin and carbonic anhydrase II (CA 
II) were identified in the cut-off filter study. However, only CA II was observed in the 
immunoprecipitated albumin-interactome fraction. This observation suggested that 
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proteins other than CA II are not interacting with albumin but might be interacting with 
other proteins including themselves and thus have molecular weights greater than their 
actual individual molecular weights and hence be retained in the fraction between 100 
and 50 kDa. The other possibility is that the proteins are present in such low levels that 
they are not detected on the 1-D gel carried out after immunoprecipitation.  
 
Most of the altered proteins detected in the CSF from AD subjects, in our study, are rich 
in β-sheets, and some have already been identified in the amyloid plaques and NFTs. Any 
event triggering misconformation could result in aggregation of these proteins. The 
proteins also exhibit different isoforms, and differential expression of the isoforms 
indicate the importance of elucidation of PTMs. Studies related to levels of each isoform 
are important for biomarker discovery instead of total protein content. The observation 
that levels of certain proteins are altered in CSF from AD subjects is of considerable 
interest but must be interpreted cautiously. For example, one interpretation is that protein 
deficiency triggers one or more cascades of molecular events that cause 
neurodegeneration. On the other hand, reduced levels of protein isoforms in a 
neurodegenerative disorder like AD may represent an expected secondary consequence of 
neuronal cell loss. 
 
5.5 Conclusion 
 
Measurements of changes in the expression of multiple proteins and their isoforms 
provide a powerful strategy for understanding pathophysiological processes of diseases. 
Owing to its proximity to brain, CSF is an ideal target to identify biomarkers for diseases 
like AD that mainly affect the brain. However, the challenge in analyzing the CSF 
proteome by 2-DE is the huge dynamic range of the proteins. The current trend in 
biomarker discovery is to deplete albumin from the CSF sample; however, it should be 
realized that this could lead to removal of small proteins and peptides that might be 
interacting with albumin. The present study involves analysis and identification of the 
albumin-interactome that constitute the albumin-interacting proteins and comparison of 
this albumin-interactome between AD and control subjects to help in identification of 
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biomarkers for the disease. To test our hypothesis that albumin acts as a protein scaffold 
and “soaks-up” other small proteins, a crude isolation of the albumin-interactome was 
carried out using cut-off filters. The presence of proteins whose molecular weight is less 
than 50 kDa, in the fraction between 100 and 50 kDa that predominantly contains 
albumin, indicates that the highly abundant carrier protein albumin can sequester low 
molecular weight proteins in CSF. To reaffirm the observation that these low molecular 
weight proteins in the fraction between 100 and 50 kDa were indeed interacting with the 
carrier protein albumin, immunoprecipitation of the albumin-interactome using albumin 
as the “bait” protein was carried out, and the albumin-interactome studied using 1-D gel 
electrophoresis.   
 
Using this selective enrichment of the albumin-interactome, 21 protein spots were 
identified that comprised 9 unique proteins and their post-translational modifications. 
This is the first study to our knowledge that has successfully isolated albumin-
interactome from the CSF and compared these fractions of CSF proteome between AD 
and control subjects for differences.   
 
Various isoforms of prostaglandin D2 synthase, transthyretin, carbonic anhydrase II, β 2 
microglobulin, phosphatidyl ethanolamine binding protein, retinol binding protein, 
neuropolypeptide h3, SOD 1 and cystatin C were identified in the albumin containing 
fraction from cut-off filter study by 2-DE. Of these 9 proteins PGDS2, TTR and CA II 
were identified in the albumin-interactome after immunoprecipitation, using albumin as 
the bait protein. Our 2-DE results indicate alteration in the levels of various isoforms of 
proteins in the CSF from AD subjects. In particular, the acidic isoform of PGDS2 was 
up-regulated in the CSF from AD subjects. Other proteins that were altered in the CSF 
from AD subjects included the basic isoform of TTR, two isoforms of PEBP and one 
isoform of RBP. The observation that various isoforms of proteins were altered in the 
CSF from AD patients supports the glycosylation defects present in AD.  
     
In conclusion, the data presented herein demonstrate that albumin indeed interacts with 
small low molecular weight proteins in CSF. The levels of these small proteins 
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constituting the albumin-interactome are significantly altered in the CSF from AD 
subjects. The ability to detect these proteins in the CSF was the key finding of this work. 
The alterations in levels of the isoforms of proteins like PGDS2 support the concept that 
glycosylation defects are implicated in Alzheimer’s disease. Furthermore, the data 
implicate the acidic isoform of PGDS2 as a potential biomarker of AD.  
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CHAPTER SIX 
 
 
CONCLUSION 
 
 
Proteomics is a rapidly expanding field of research that has carved a niche of its own in 
life sciences. At its core, proteomics is all about separation and identification--the process 
of taking a sample of interest, separating out all of the proteins within, and then 
identifying them. As one can imagine there exists an array of proteomics tools to help 
accomplish this formidable task of protein analysis. Specifically, two-dimensional gel 
electrophoresis and mass spectrometry- two milestone technologic breakthroughs 
facilitated the ability to simultaneously look at multitude of proteins. Tremendous 
improvements in both methodologies are providing improved strategies to speed 
biological discovery. Though many chromatographic techniques are being introduced, 
two-dimensional gel electrophoresis has been the method of choice for the analysis of 
proteomes for nearly 35 years mainly because of its enormous resolving power and 
ability to simultaneously separate thousands of proteins. A number of modifications to 
the 2-DE methodology have been introduced and improvements in key components of the 
technology such as use of immobilized pH gradient gels and fluorescent staining have 
greatly improved reproducibility and sensitivity. 
 
The sensitivity of stains that are used to detect proteins after their separation by 2-DE, has 
been one factor influencing the amount of information that can be extracted from the 2-
DE gels. The development of a fluorescent ruthenium complex (RuMS) for staining 
proteins separated by gel electrophoresis with high sensitivity, broad linear dynamic 
range and that is compatible with mass spectrometry for subsequent identification of 
proteins (as described in chapter three of this dissertation) is quite valuable in this 
context. With the low detection limit of 1 ng of protein and cost-effective potential 
available with this in-house synthesized RuMS staining solution, it is not difficult to see 
why the development of this staining solution is a very practical and worthwhile avenue 
to pursue. Knowledge of exact composition of the stain will prove to be very beneficial in 
being able to reproducibly synthesize the stain and exploit its potential to the fullest. One 
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can envision using different ratios of the commercially available different ruthenium 
complexes- RuMS, RuDS and RuBPS to probe and obtain the exact composition of the 
in-house RuMS staining solution that is a value added information.  
 
Proteomics has diverse applications in various fields like medicine, toxicology, pharmacy 
and many others. The incredible potential of proteomics to discover new disease 
biomarkers and toxicity signatures were explored as described in this dissertation. The 
emerging field of toxicoproteomics integrates two disciplinary areas of toxicology and 
differential protein analysis and allows for better understanding of protein expression 
during toxicity and environmental stress for the advancement of public health. Proteomic 
techniques were applied to study the in vitro effect of malathion, an organophosphate 
insecticide on protein expression using human neuroblastoma cells. Our studies indicated 
that out of 122 human neuroblastoma proteins identified, 21 proteins were significantly 
altered after treatment with malathion. Results suggest significant down-regulation of key 
calcium modulators and chaperones in the malathion-treated cells. A model was proposed 
based on the altered proteins that malathion induces oxidative stress leading to possible 
misfolding of protein that can potentially accumulate and cause cytotoxicity in 
neuroblastoma cell cultures. The identification of differential protein expression in 
neuroblastoma cells after treatment with malathion is an important finding in regard to 
the OP toxicity, since there has been limited knowledge in this area. Though 
neuroblastoma cells are the preferred model to study in vitro OP toxicity, studies 
involving primary cell lines and animal models will provide more precise information on 
the implication of OPs on humans. One can also envision a similar kind of investigation 
performed on the liver proteome of OP exposed animals to identify protein targets of OP 
toxicity. The near-term payoffs of this type of work are two-fold. One is the 
understanding of mechanisms of toxicity and the other is the identification of biomarkers 
of exposure. While investigations presented here offered a basic foundation for 
understanding OP toxicity at the protein level, a closer examination involving analysis of 
sub-proteome will surely provide a greater appreciation of the underlying mechanisms of 
OP toxicity.  
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A major benefit of proteomic technology is its use in the development of biomarkers for 
diseases. Proteomic techniques can be applied to study innumerable human diseases 
ranging from cancer to infectious diseases. Alzheimer's disease (AD) affects more than 
4.5 million Americans. There is no cure for Alzheimer's disease yet and the primary goal 
of biomarker research is to detect and diagnose the disease before symptoms surface. 
Proteomics is most suited for mining biomarkers and tools allow comparing protein 
profiles of normal and diseased body fluids such as blood, CSF and urine. A proteomic 
analysis of CSF albumin-interactome was undertaken to identify and compare the protein 
constituents of this fraction of the CSF proteome between AD and normal subjects. The 
novel immunoprecipitation-based proteomics approach to AD biomarker discovery 
proved successful in isolating and identifying the otherwise difficult-to-analyze albumin- 
interacting proteins and their isoforms. The immunoprecipitation method to analyze 
interactomes in CSF is both feasible and effective. With increased efforts to diagnose and 
treat AD by early intervention and even towards prevention, it is evident that biomarkers 
will gain significance as tools to aid research and ultimately clinical practice. Our results 
indicated presence of small proteins including prostaglandin D2 synthase (PGDS2) and 
transthyretin to be components of CSF albumin-interactome. A key finding is the 
alteration in levels of different isoforms of these proteins constituting the albumin-
interactome in CSF from AD subjects and their potential to serve as biomarkers for AD. 
One can envision a careful evaluation of relative abundance of the different isoforms of 
the albumin-interactome proteins in CSF from AD, mild congnitive impairment and no 
cognitive impairment subjects be carried out to help generate a fingerprint model that can 
successfully delineate the various stages. A clear understanding of the post-translational 
modifications involved in these proteins will provide insight into the etiology of the 
disease. The methodology developed herein can also be applied to serum proteome that 
will enable non-invasive diagnosis of the disease. Though, this is a challenging endeavor, 
given the potential of various proteomics technologies, it should be possible to identify a 
sufficient number of biomarkers to revolutionize early detection. 
 
Application of two vital proteomics methodologies namely 2-DE and mass spectrometry 
along with the in-house developed staining solution described in this dissertation clearly 
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demonstrates the power of the technology to analyze complex proteomes like whole cell 
lysate and cerebrospinal fluid. With the potential that proteomics carries with it, it will 
not be too far in the future that mass spectrometry-based proteomic technologies will play 
key role in clinical diagnosis of diseases. With development of miniature mass 
spectrometers, field application of the technology is a promising area of pursuit that will 
enable detection of for example, toxic chemicals during warfare. Questions like how the 
technology can be implemented and what costs are involved in doing so, to accomplish 
the above-said vision, must be considered. The versatility of various proteomics 
methodologies is endless and the alliance of various separation techniques with mass 
spectrometry has the potential to improve quality of life.   
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Appendix A. List of proteins identified on 2-DE gels by MALDI-TOF mass 
spectrometry 
 
 
Spot 
number 
 
Protein 
 
Swiss-
Prot 
 
Mr (kDa) 
 
pI 
% 
Sequence 
coverage 
# of 
peptides 
matched 
 
 
2 
 
Calmodulin 
 
 
P62158 
 
16.7 
 
4.09 
 
18 
 
7 
 
3 
 
Parvalbumin α 
 
 
P20472 
 
11.9 
 
4.98 
 
46 
 
5 
 
4 
 
Ubiquitin like 
protein SMT 3A 
 
 
P55854 
 
0.89 
 
5.57 
 
20 
 
3 
 
 
6 
 
Enhancer of 
rudimentary 
homolog 
 
 
P84090 
 
 
12.2 
 
 
5.62 
 
 
23 
 
 
3 
 
 
7 
 
Putative S100 
Ca2+ binding 
protein  
 
 
 
Q9UDP3 
 
 
11.7 
 
 
6.28 
 
 
28 
 
 
3 
 
8 
 
 
Parvalbumin α 
 
P20472 
 
11.9 
 
4.98 
 
56 
 
5 
 
9 
 
Calgizzarin 
 
 
P31949 
 
11.7 
 
6.56 
 
40 
 
5 
 
 
14 
 
Retinoic acid 
binding protein 
 
 
P29762 
 
15.4 
 
5.31 
 
41 
 
8 
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15 
 
Serum amyloid A 
protein precursor 
 
 
 
P02735 
 
 
11.6 
 
 
5.89 
 
 
25 
 
 
3 
 
17 
 
Tubulin specific 
chaperone A 
 
 
O75347 
 
12.7 
 
5.25 
 
19 
 
4 
 
18 
 
Profilin II 
 
 
P35080 
 
14.9 
 
6.78 
 
30 
 
4 
 
 
19 
 
Ubiquitin 
conjugating 
enzyme E2N 
 
 
 
P61088 
 
 
17.1 
 
 
6.13 
 
 
25 
 
 
4 
 
20 
 
 
Cyclophilin A 
 
P05092 
 
17.8 
 
7.82 
 
20 
 
5 
 
25 
 
 
60s ribosomal 
protein L13a 
 
 
P40429 
 
 
23.4 
 
10.94 
 
21 
 
6 
 
26 
 
Histone H4 
 
 
P62805 
 
11.2 
 
11.36 
 
47 
 
6 
 
27 
 
 
Glucagon 
precursor 
 
 
P01275 
 
18.6 
 
5.62 
 
28 
 
4 
 
28 
 
Peroxiredoxin 2 
 
 
P32119 
 
21.8 
 
5.66 
 
32 
 
6 
 
29 
 
Retinal binding 
protein 
 
 
O43924 
 
17.4 
 
5.57 
 
16 
 
3 
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31 
 
Stathmin I 
 
 
P16949 
 
17.1 
 
5.77 
 
47 
 
9 
 
39 
 
hn RNP  
A2/B1 
 
 
P22626 
 
37.4 
 
8.97 
 
18 
 
6 
 
 
41 
 
 
Ras related 
protein Rab 37 
 
Q96AX2 
 
24.6 
 
5.96 
 
15 
 
3 
 
43 
 
HSP 27 
 
 
P04792 
 
22.7 
 
5.98 
 
21 
 
4 
 
45 
 
Peroxiredoxin 1 
 
 
Q06830 
 
22.1 
 
8.27 
 
39 
 
10 
 
46 
 
 
Peroxiredoxin 1 
 
Q06830 
 
22.1 
 
8.27 
 
34 
 
9 
 
 
47 
 
Orphan nuclear 
receptor 
steroidogenic 
factor 1 
 
 
Q9UCY6 
 
 
22.2 
 
 
 
9.35 
 
 
25 
 
 
6 
 
49 
 
HSP 27 
 
P04792 
 
22.7 
 
5.98 
 
13 
 
4 
 
50 
 
Tropomyosin α 1 
chain 
 
P09493 
 
32.7 
 
4.69 
 
13 
 
6 
 
51 
 
Cathepsin D 
precursor 
 
P07339 
 
26.6 
 
5.56 
 
12 
 
6 
 
 
53 
 
Glutathione S 
transferase A4 
 
 
O15217 
 
25.7 
 
7.89 
 
13 
 
4 
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55 
 
Ras related 
protein Rab 3A 
 
 
P20336 
 
24.9 
 
4.85 
 
18 
 
3 
 
56 
 
HSP 27 
 
 
P04792 
 
22.7 
 
5.98 
 
13 
 
4 
 
57 
 
Proteosome 
subunit β type 3 
 
 
P49720 
 
22.9 
 
6.14 
 
16 
 
4 
 
58 
 
Mn SOD 
 
 
P04179 
 
22.2 
 
6.86 
 
18 
 
4 
 
60 
 
Peroxiredoxin 6 
 
 
P30041 
 
24.9 
 
6.02 
 
36 
 
9 
 
63 
 
ARC34 
 
 
O43513 
 
 
27.2 
 
5.5 
 
13 
 
4 
 
65 
 
Tropomyosin α 4 
 
P07226 
 
28.5 
 
4.67 
 
21 
 
6 
 
66 
 
Tropomyosin α 4 
 
 
P07226 
 
28.5 
 
4.67 
 
23 
 
6 
 
67 
 
Prohibitin 
 
 
P35232 
 
29.8 
 
5.57 
 
38 
 
10 
 
 
68 
 
NG,NG, 
dimethylarginine 
dimethylamino 
hydrolase 2 
 
 
 
O95865 
 
 
29.6 
 
 
5.66 
 
 
26 
 
 
8 
 
69 
 
ERp 28 
 
 
P30040 
 
25.8 
 
6.08 
 
26 
 
8 
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70 
 
Eukaryotic 
translation 
initiation factor 
4H 
 
 
Q15056 
 
 
27.3 
 
 
6.67 
 
 
18 
 
 
4 
 
 
72 
 
F actin capping 
protein α 1 
subunit 
 
 
 
P52907 
 
 
32.9 
 
 
5.45 
 
 
24 
 
 
6 
 
73 
 
Corticotropin 
Lipotropin 
 
 
P01189 
 
26.6 
 
6.54 
 
17 
 
5 
 
74 
 
L-lactate 
dehydrogenase A 
chain 
 
 
P00338 
 
36.5 
 
8.46 
 
8 
 
4 
 
76 
 
Vimentin 
 
 
P08670 
 
53.5 
 
5.06 
 
26 
 
16 
 
77 
 
Vimentin 
 
 
P08670 
 
53.5 
 
5.06 
 
22 
 
12 
 
78 
 
Vimentin 
 
 
P08670 
 
53.5 
 
5.06 
 
19 
 
11 
 
79 
 
N-myc interactor 
 
 
Q13287 
 
35.1 
 
5.24 
 
20 
 
6 
 
80 
 
 
Actin β 
 
P02570 
 
41.7 
 
5.29 
 
21 
 
9 
 
81 
 
α enolase 
 
 
P06733 
 
47 
 
6.99 
 
23 
 
9 
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82 
 
Actin α 
 (cardiac) 
 
 
P04270 
 
41.7 
 
5.23 
 
 
9 
 
 
4 
 
83 
 
Actin β 1 
 
 
P60709 
 
41.6 
 
5.29 
 
 
28 
 
11 
 
84 
 
Actin γ  
 
 
P02571 
 
41.6 
 
5.31 
 
31 
 
12 
 
85 
 
Actin β  
 
 
P60709 
 
41.6 
 
5.29 
 
 
24 
 
10 
 
87 
 
SERCA3 
 
 
Q93084 
 
113.9 
 
5.42 
 
6 
 
9 
 
88 
 
Vimentin 
 
 
P08670 
 
53.5 
 
5.06 
 
22 
 
14 
 
89 
 
Vimentin 
 
 
P08670 
 
53.5 
 
5.06 
 
28 
 
17 
 
91 
 
 
β Tubulin 5 
 
P04350 
 
49.5 
 
4.81 
 
8 
 
6 
 
92 
 
 
α enolase 
 
P06733 
 
47.0 
 
6.99 
 
23 
 
9 
 
97 
 
α tubulin 6 
 
Q9BQE3 
 
49.8 
 
4.96 
 
23 
 
7 
 
100 
 
hnRNP H 
 
P31943 
 
49.2 
 
5.89 
 
16 
 
5 
 
 
101 
 
6 phospho    
gluconate 
dehydrogenase 
 
 
 
P52209 
 
 
53.0 
 
 
6.88 
 
 
11 
 
 
4 
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102 
 
Fascin 
 
 
Q16658 
 
54.4 
 
6.81 
 
19 
 
9 
 
103 
 
T complex protein 
1 β subunit 
 
 
 
P78371 
 
 
57.4 
 
 
6.01 
 
 
14 
 
 
7 
 
105 
 
 
α tubulin 6 
 
 
Q9BQE3 
 
49.8 
 
4.96 
 
19 
 
6 
 
106 
 
Tubulin β 4 chain 
 
 
Q13509 
 
50.4 
 
4.83 
 
12 
 
5 
 
107 
 
T complex protein 
1 ε 
 
 
P48643 
 
59.6 
 
5.45 
 
19 
 
12 
 
109 
 
Glucose regulated 
protein 
 
 
 
P11021 
 
 
70.4 
 
 
5.01 
 
 
23 
 
 
14 
 
110 
 
GRP75 
 
 
P38646 
 
68.7 
 
5.44 
 
29 
 
20 
 
114 
 
HSP 90 α 
 
 
P07900 
 
84.5 
 
4.94 
 
13 
 
12 
 
115 
 
HSP 90 β 
 
 
P08238 
 
83.1 
 
4.97 
 
13 
 
10 
 
116 
 
 
Pyruvate kinase 
M1 isozyme 
 
P14618 
 
57.8 
 
7.95 
 
10 
 
5 
 
117 
 
 
UMP synthase  
 
P11172 
 
 
 
52.2 
 
6.81 
 
13 
 
7 
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118 
 
 
Actin β 1 
  
 
P60709 
 
41.6 
 
5.29 
 
 
25 
 
10 
 
119 
 
 
Aldehyde 
dehydrogenase 
 
 
P48448 
 
42.7 
 
5.92 
 
9 
 
4 
 
120 
 
 
Lysyl hydroxylase 
2 
 
 
O00469 
 
842 
 
6.06 
 
6 
 
5 
 
121 
 
 
hnRNP K isoform 
a 
 
 
P61978 
 
50.9 
 
5.39 
 
17 
 
9 
 
122 
 
 
Vimentin 
 
P08670 
 
53.5 
 
5.06 
 
19 
 
 
11 
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Appendix B. List of proteins identified on 2-DE gels by LC-MS/MS 
 
 
Spot 
number 
 
Protein 
 
Swiss-
Prot 
 
 
Mr (kDa) 
 
pI 
 
% 
Sequence 
coverage 
 
 
# of 
peptides 
matched 
 
1 
 
Calmodulin 
 
 
P62158 
 
16.7 
 
4.09 
 
45 
 
7 
 
5 
 
 
Myotropin 
 
P58546 
 
12.8 
 
5.27 
 
14 
 
2 
 
10 
 
 
Ubiquitin 
 
P62988 
 
0.85 
 
6.56 
 
7 
 
5 
 
 
11 
 
Thioredoxin (ALT 
derived factor) 
 
 
P10599 
 
11.6 
 
4.82 
 
31 
 
5 
 
12 
 
Galectin 1 
 
 
P09382 
 
14.5 
 
5.34 
 
 
23 
 
3 
 
13 
 
 
Galectin 1 
 
P09382 
 
14.5 
 
5.34 
 
 
17 
 
2 
 
16 
 
Retinol binding 
protein 
 
 
P09455 
 
15.7 
 
4.99 
 
40 
 
5 
 
21 
 
 
Cyclophilin A 
 
P62937 
 
17.8 
 
7.82 
 
39 
 
6 
 
22 
 
 
Cyclophilin A 
 
P62937 
 
17.8 
 
7.82 
 
10 
 
5 
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23 
 
Cyclophilin A 
 
 
P62937 
 
17.8 
 
7.82 
 
39 
 
7 
 
24 
 
Profilin I 
 
 
P07737 
 
14.9 
 
8.47 
 
51 
 
9 
 
30 
 
 
Stathmin I 
 
P16949 
 
 
17.1 
 
5.77 
 
24 
 
3 
 
32 
 
 
Cofilin 1 
 
 
P23528 
 
18.5 
 
8.22 
 
19 
 
3 
 
33 
 
DJ 1 protein 
 
 
Q99497 
 
19.8 
 
6.33 
 
31 
 
6 
 
34 
 
ATP synthase δ 
 
 
P30049 
 
15 
 
4.53 
 
16 
 
3 
 
35 
 
Glyoxalase 1 
 
 
Q04760 
 
20.5 
 
5.25 
 
27 
 
4 
 
36 
 
Peroxiredoxin 2 
 
 
P32119 
 
21.8 
 
5.66 
 
36 
 
10 
 
37 
 
NM 23-H1 
 
 
P15531 
 
17.1 
 
5.83 
 
32 
 
6 
 
38 
 
Neuropolypeptide 
h3 
 
 
P30086 
 
20.9 
 
7.43 
 
35 
 
6 
 
40 
 
Rho GDI 
 
P52565 
 
23.2 
 
5.03 
 
7 
 
2 
 
42 
 
Glutathione S 
transferase A4 
 
 
O15217 
 
25.7 
 
7.89 
 
20 
 
4 
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44 
 
DJ 1 protein 
 
 
Q99497 
 
19.8 
 
6.33 
 
21 
 
5 
 
48 
 
 
HSP 27 
 
P04792 
 
22.7 
 
5.98 
 
25 
 
4 
 
52 
 
UCH L1 
 
 
P09936 
 
24.8 
 
5.33 
 
34 
 
7 
 
54 
 
UCH L1 
 
 
P09936 
 
24.8 
 
5.33 
 
24 
 
4 
 
59 
 
Mn SOD 
 
 
P04179 
 
22.2 
 
6.86 
 
13 
 
 
3 
 
61 
 
 
Chain A of TIM 
 
P60174 
 
26.5 
 
6.51 
 
23 
 
4 
 
62 
 
 
TIM 
 
P60174 
 
26.5 
 
6.51 
 
29 
 
5 
 
64 
 
Tropomyosin 3 
 
 
P06753 
 
32.8 
 
4.68 
 
26 
 
5 
 
71 
 
Tubulin β 1 
 
 
P07437 
 
49.7 
 
4.75 
 
7 
 
3 
 
 
75 
 
Glyceraldehyde 3 
PO4 
Dehydrogenase 
 
 
P00354 
 
 
36.1 
 
 
 
8.26 
 
 
11 
 
 
3 
 
86 
 
Calreticulin 
 
 
P27797 
 
46.4 
 
4.29 
 
5 
 
2 
 
90 
 
Vimentin 
 
 
P08670 
 
53.5 
 
5.06 
 
32 
 
9 
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93 
 
α enolase 
 
 
P06733 
 
47 
 
6.99 
 
31 
 
10 
 
94 
 
α enolase 
 
 
P06733 
 
47 
 
6.99 
 
21 
 
6 
 
95 
 
MT HSP 75 
 
 
Q12931 
 
80 
 
8.05 
 
14 
 
8 
 
96 
 
Tubulin α 6 
 
 
Q9BQE3 
 
49.8 
 
4.96 
 
13 
 
8 
 
98 
 
Protein disulfide 
isomerase 
 
 
P30101 
 
56.6 
 
6.10 
 
40 
 
24 
 
99 
 
Protein disulfide 
isomerase 
 
 
P30101 
 
56.6 
 
6.10 
 
29 
 
17 
 
104 
 
HSP 70/90 
organizing protein 
 
 
 
P31948 
 
 
62.6 
 
 
6.40 
 
 
18 
 
 
9 
 
108 
 
HSP 60 
 
 
P10809 
 
57.9 
 
5.24 
 
33 
 
6 
 
111 
 
 
Lamin A 
 
P02545 
 
74.1 
 
 
6.57 
 
16 
 
 
4 
 
112 
 
 
HSP 60 
 
 
P10809 
 
57.9 
 
5.24 
 
21 
 
7 
 
113 
 
 
HSP 60 
 
 
P10809 
 
57.9 
 
5.24 
 
19 
 
6 
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